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Summary 
 
Solid organ transplantation is now an established and effective treatment option for end-stage 
organ failure. Whilst early outcomes have improved significantly over recent decades, longer-
term outcomes have changed little. Despite advances in immunosuppression, most 
transplanted organs suffer an inevitable decline in function attributed to chronic rejection. It is 
evident that the alloimmune response remains incompletely characterised. Crucially, despite 
description several decades ago, the precise contribution that the direct (recognition of intact 
allogeneic MHC) and indirect (recognition of self-MHC restricted allopeptide) pathways make 
to allograft rejection remains incompletely understood. In this thesis, murine models of 
heterotopic cardiac transplantation have been utilised to analyse these pathways. The key 
findings of this work are as follows: 
 
1) If able to evade NK cell killing, passenger donor CD4 T cells can make cognate, direct-
pathway, interactions with recipient B cells. This interaction results in augmentation of 
all arms of the alloimmune response and acceleration of allograft rejection. 
 
2) Direct-pathway CD4 T cell allorecognition is restricted to the immediate post 
transplantation period. Donor APCs are the major source of MHC class II for direct-
pathway priming, and these are cleared rapidly by both innate and adaptive responses 
of the recipient, effectively limiting the longevity of direct allorecognition. 
 
3) The duration of indirect-pathway responses against different alloantigens is variable, 
limited by availability of donor antigen. Expression of donor MHC class II is restricted 
to APCs and possibly endothelium (where expression is transient) limiting the duration 
of indirect-pathway allorecognition against MHC class II alloantigen. Indirect-pathway 
CD4 T cell responses targeted against parenchymal alloantigen are long-lived, and can 
provide help for generating alloantibody against  different MHC alloantigens.  
 
4) In response to continual presentation of target epitope indirect-pathway CD4 T cell 
responses against parenchymal expressed alloantigen are long-lived. The continual 
division of these cells results in greatly increased numbers of alloantigen-specific CD4 T 
cells in the chronic phase of the response, but despite this, memory responses are 
impaired. 
 
5) Generating indirect-pathway regulatory T cells specific for parenchymal expressed 
alloantigen appears to be the most effective strategy to ameliorating chronic rejection.  
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1 
 
1 Introduction 
  
2 
 
1.1 Historical overview of transplantation 
 
Transplantation is considered one of the greatest achievements in medicine over the past 
hundred years. The concept of replacing diseased or damaged tissues and organs can however, 
be traced back to the 3rd century. Several paintings depict sainted physicians Cosmos and 
Damien attempting to transplant an entire leg1. 
 
Figure 1.1 Master of Los Balbases, ca. 1495 
The earliest recorded solid organ transplant took place in Vienna in 1902. Emerich Ullman 
performed a technically successful kidney transplant between two dogs2. This was followed in 
1906 by the first two human kidney transplants – using pig and goat donor organs, performed 
by Jaboulay. Both patients died soon after transplantation with little, if any, graft function. 
Despite these, and other, early failed attempts the technical challenges of organ 
transplantation were being overcome, largely due to the pioneering suturing techniques 
developed by Alexis Carrel; the first surgeon awarded a Nobel prize3.  
In spite of these technical achievements it was widely recognised that ‘biological factors’ 
resulted in rapid failure of transplanted tissues leading some to suggest transplantation as not 
only futile but also that ‘human experimentation was unwarranted and unethical’1. 
During World War II research into tissue compatibility became a priority to improve the 
treatment of aviator burn victims. To this end, Peter Medawar, a zoologist, was assigned the 
task of exploring skin allografts with plastic surgeon Thomas Gibson4. They observed that 
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allografts always failed, but importantly, that second grafts from the same donor failed more 
quickly; the so called ‘second-set phenomenon’. Medawar and Gibson reported a detailed 
series of experiments using rabbit skin grafts verifying this observation, concluding that ‘the 
mechanism by means of which foreign skin is eliminated belongs in broad outline to the 
category of actively acquired immune reactions’. This observation was one of the first 
demonstrations of the immunological basis of rejection4, 5. Further advances in our 
understanding of the immunological basis of transplant rejection was provided by the work of 
Snell and colleagues, who proposed the importance of cell surface histocompatibility 
molecules to allograft rejection6. 
Following the war, Medawar directed his efforts towards conceiving strategies to modulate 
the recipient’s immune response to the graft, famously coining the phrase ‘acquired 
immunologic tolerance’ to describe his vision7. He demonstrated in mice that intrauterine 
exposure to a donor strains cells resulted in a state of chimerism and permitted acceptance of 
subsequent donor strain skin grafts, but not third party grafts7. 
The next landmark was the first successful renal transplant performed by Merrill and Murray 
on December 23rd 1954 at Peter Bent Brigham Hospital in Boston, between identical twins8. 
Although performing the transplant between identical twins bypassed the immunological 
barrier, its publicised success renewed enthusiasm for transplantation around the world1. 
The next goal was to transplant across the genetic histocompatibility barrier. It was recognised 
that replicating Medawar’s state of chimerism with neonatal treatment in humans was 
impossible. However, it was discovered that chimerism could be achieved in mice by 
irradiation and subsequent inoculation with bone marrow cells. Furthermore, this strategy 
permitted acceptance of skin allografts from the donor strain9. 
In 1958 Murrays team adopted this strategy in human renal transplantation, subjecting 
recipients to total body irradiation to ‘weaken’ the immune system with or without donor 
bone marrow treatment. Only one of the twelve patients subject to this treatment (in this case 
without bone marrow) survived beyond a month, but this patient had good graft function for 
over 20 years10. This was the first time the genetic barrier to transplantation had been 
breached. Similar results were subsequently replicated in France11, 12. These successes 
questioned the requirement for true immunological tolerance and instead, emphasis shifted 
towards strategies aimed at prolonging graft survival without necessarily achieving tolerance. 
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This encouraged a search for a drug-based alternative to irradiation for suppressing recipient 
immunity. The first such chemical to be used was the anti-proliferative 6-mercaptopurine (6-
MP), a drug being evaluated for use in oncology. It had been observed that 6-MP significantly 
reduced antibody responses in rabbits13. Subsequent experiments in dog kidney transplant 
recipients by Roy Calne revealed 6-MP to be effective at delaying allograft rejection albeit in 
experiments with only ‘several’ dogs with only one surviving beyond 3 weeks14. Early results of 
human transplant recipients treated with 6-MP, or its derivative azathioprine, were poor, with 
few surviving three months15, 16. This all changed in 1963 with Starzl reporting >70% 1 year 
survival when the corticosteroid prednisolone was added to azathioprine, a strategy rapidly 
adopted by transplant centres throughout the world17. 
The next major breakthrough in immunosuppression came in 1979 with introduction of 
cyclosporine, a calcineurin inhibitor, which, when combined with prednisolone substantially 
improved outcomes of kidney transplant recipients18, 19. The success of cyclosporine provided 
the opportunity and impetus for the development of clinical programmes for transplantation 
of other organs: liver, heart and lungs initially. In 1989 a related compound tacrolimus (FK506) 
was introduced as an even more potent immunosuppressant, and remains the agent of choice 
today20. 
In addition to the advances in immunosuppression there have been significant improvements 
in organ preservation, understanding of histocompatibility and organ matching, surgical 
technique and post-operative patient management, all of which have contributed to solid 
organ transplantation becoming a successful and established therapeutic option for end-stage 
organ failure. In the UK during the financial year 2013-14 a total of 4648 solid organ 
transplants were performed. However, 7005 patients remain active on the waiting list and the 
success of transplantation is currently limited by the availability of donor organs. 
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1.2 Chronic rejection 
 
The short-term patient and allograft outcomes currently achieved are very good, with UK 1-
year graft survival for kidney and liver transplantation now 94% and 92.6%, respectively 
(www.odt.nhs.uk). Despite significant improvements in short-term outcomes, longer term 
outcomes following transplantation have improved very little over the past two decades. Most 
allografts suffer a gradual deterioration in function that is loosely referred to as chronic 
rejection and is characterised by a progressive allograft vasculopathy (AV) that leads to 
ischaemic fibrosis and eventual graft failure21. This process is considered the major factor 
limiting long-term allograft survival; within 5 years following transplantation, chronic rejection 
affects up to 80% of lung allografts, 20% of kidney and 40-50% of heart allografts22. It is 
notable that rates of chronic rejection differ between organs. Several possible explanations for 
this have been proposed. Organs differ in the amount of lymphoid tissue contained within 
them and it is conceivable that the load of donor lymphoid cells may influence the 
development of alloimmune responses in the recipient. Organs also differ in their susceptibility 
to duration of cold ischaemia – perhaps related to susceptibility to damage through 
ischaemia/reperfusion injury – for example the heart bowel are particularly sensitive with cold 
ischaemia times of only several hours tolerated whilst the kidney can withstand cold ischaemic 
periods in excess of 24 hours23. It has also been observed that the liver appears somewhat 
resistant to alloimmunity, and that a liver allograft is often immunoprotective for other 
allografts transplanted simultaneously, although the basis of this has not been fully 
elucidated24. 
Understanding the pathogenesis of chronic rejection, together with the basis of differences 
between the organs, and developing novel therapies for ameliorating the, currently inevitable, 
progressive decline in organ function is the goal of current transplant immunological research. 
1.2.1 Allograft vasculopathy 
 
Allograft vasculopathy is a vascular disease unique to transplantation that was first described 
in dog cardiac allografts in the 1960s25. It is a diffuse, circumferential lesion of arteries. The 
initiating lesion is endothelial injury and dysfunction which drives an exaggerated repair 
response characterised by fibroelastic intimal proliferation. This leads to accumulation of 
smooth muscle cells, macrophages, fibroblasts and extracellular matrix within the intima that 
does not breach the internal elastic lamina. These lesions result in luminal stenosis and 
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subsequent ischaemic damage to distal parenchyma, with cell death and replacement fibrosis 
resulting in graft dysfunction26-29. These lesions contrast with atherosclerosis which is 
characterised by eccentric calcified fibrous plaques30. 
Although thought of as primarily an immunological lesion driven by the alloimmune response, 
a number of non-alloimmune factors have also been demonstrated to be important in AV 
pathogenesis. Thus AV is considered a multifactorial process resulting from the cumulative 
damaging effects of alloimmune and non-specific insults on vascular endothelial cells26, 27. 
Traditional risk factors for endothelial injury such as hyperlipidaemia, hypertension, cigarette 
smoke and diabetes have all been shown to accelerate AV. Similarly, non-alloimmune 
transplant-associated factors have also been identified as risk factors for endothelial injury and 
subsequent development of AV, such as the catecholamine storm accompanying brain death, 
ischaemia-reperfusion injury and cytomegalovirus infection26, 27, 31. 
Clearly the adaptive alloimmune response plays a central role in the pathogenesis of AV, since 
the number and duration of episodes of acute rejection experienced, and the degree of donor-
recipient mismatch have both been shown to be independent risk factors for the development 
of AV32. Furthermore, AV only affects donor vessels, leaving the recipients vasculature in-tact. 
Donor specific antibody (DSA), T cells and NK cells have all been implicated to have central 
roles in driving the alloimmune endothelial injury and dysfunction leading to the development 
of the fibroelastic vascular lesions28, 29. 
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1.3 The alloimmune response 
 
Knowledge that variability in allograft rejection was genetically controlled resulted in discovery 
of the Major Histocompatibility Complex (MHC) (Human Leukocyte Antigens (HLA) in humans, 
and H-2 in mice)33, 34. Donor MHC molecules are the principal target of the recipients 
alloimmune response against an allograft. 
1.3.1 Major Histocompatibility Complex 
 
The MHC is a 4x106 base pair region of DNA on chromosome 6 in humans (17 in mice) which 
encodes for approximately 200 genes involved with the processing and presentation of 
peptide antigens on the cell surface. The MHC is pivotal to the generation of an antigen 
specific adaptive immune response against non-self. Cell surface MHC molecules loaded with 
antigenic peptides form the ligand of the T cell receptor (TCR), which is restricted to the 
recognition of self MHC molecules35. Encoded within the MHC are two subsets of HLA (H-2 in 
mice) molecules, both members of the immunoglobulin superfamily 36. 
1.3.1.1 MHC Class I 
Within the MHC class I locus are three classical molecules: HLA A, B, and C (H-2D, H-2K and H-
2L in mice). These are heterodimeric glycoproteins, comprising a heavy α chain (with α1, α2 
and α3 domains) non-covalently linked to a constant light chain: β2-microglobulin encoded by 
a non-polymorphic gene separate from the MHC locus37. The molecules bind peptides 8-11 
amino-acids in length derived from intracellular proteins generated by the proteasome, for 
presentation to cytotoxic CD8 T cells38. Class I molecules are expressed on all nucleated 
mammalian cells39. Exogenous proteins internalised via the lysosomal system have also been 
found to be presented by class I molecules, a process which has been termed ‘cross-priming’40.  
1.3.1.2 MHC Class II 
Within the MHC class II locus are three pairs of molecules: HLA-DR, DP and DQ (there are only 
two mouse equivalents – H-2 I-A and I-E). These are similarly non-covalently linked 
heterodimeric glycoproteins, comprising an α-chain (with α1 and α2 domains) and a β-chain 
(with β1 and β2 domains). The peptide binding groove of class II molecules is open-ended, 
accommodating typically longer peptides – 12-19 amino-acids in length. The peptides 
presented are exogenously derived via the endosome/lysosome system, and are presented to 
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helper CD4 T cells41. MHC class II molecules are only expressed constitutively on professional 
antigen presenting cells (APC), such as dendritic cells (DC), macrophages and B cells. 
 
The HLA system is the most polymorphic gene system in the human genome, with each 
individual expressing only a small number of alleles. MHC molecules are co-dominantly 
expressed so that each individual expresses six class I molecules and six class II molecules (one 
haplotype inherited from each parent). Early studies in transplantation identified the need to 
match donor and recipients based upon these cell surface glycoproteins, recognising that 
differences between donor and recipient at these polymorphic loci was the predominant 
driving force behind the alloimmune response33, 34, 42. 
Although clear that matching of MHC molecules is important, several studies identified that 
other antigenic determinants were important in transplantation – the so-called minor 
histocompatibility antigens. These were discovered in humans after a female received bone 
marrow from her brother, and the grafted cells were recognised as non-self, despite being a 
complete HLA match43. Further work in mice has confirmed the existence of minor 
histocompatibility antigens, such as the H-Y male complex of genes, but has demonstrated that 
the response to peptides derived from minor histocompatibility antigens is significantly weaker 
than to peptides derived from MHC molecules, suggesting a dominant role of the MHC in 
allograft rejection44, 45. 
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1.4 Pathways of Allorecognition 
 
The alloimmune response to a transplant is fundamentally different from the adaptive 
response against conventional antigens, posing the recipients immune system with a unique 
challenge. Two populations of APCs are available for recognition: those of donor origin carried 
with the allograft; and those of recipient origin. Both populations can be recognised by 
recipient T cells. This results in two distinct pathways by which allorecognition can occur 
(Figure 1.2). In the direct-pathway, recipient CD4 T cells recognise intact allogeneic MHC-
peptide complexes expressed on donor APCs. By contrast, in the indirect-pathway, recipient 
APCs internalise and process a variety of donor antigen, subsequently presenting them as self-
MHC restricted peptides to recipient CD4 T cells46. More recently, a third pathway of 
allorecognition has been proposed, the ‘semi-direct’ pathway in which it is proposed that 
recipient APCs can acquire intact donor MHC from donor cells, but the physiological 
significance of this pathway has yet to be elucidated47. 
 
 
Figure 1.2 Direct and Indirect allorecognition 
a) Direct allorecognition – recipient CD4 T cells experience intact MHC on donor antigen presenting cells 
(APCs) to recipient CD4 T cells. b) Indirect allorecognition – donor alloantigen is internalised, processed 
and presented as self-MHC restricted peptides by recipient APCs to recipient CD4 T cells. 
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Because donor APCs are thought to be rapidly eliminated after transplantation, direct-pathway 
responses are generally considered to be limited to the early period following transplantation. 
In contrast, the reliance on self-restricted recognition of recipient APCs theoretically enables 
indirect-pathway responses to continue indefinitely. It is thus stated, often axiomatically, that 
the direct-pathway is responsible for acute rejection, and the indirect for chronic rejection. 
However, this distinction has not been definitively confirmed48. 
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1.5 Direct Allorecognition 
 
Direct-pathway recognition of intact donor MHC presented by donor APCs was initially 
believed to be the predominant driving force behind allograft rejection due its observed 
strength. A very strong mixed lymphocyte reaction occurs when mixing donor and recipient 
cells, due to a high precursor frequency of recipient T cells able to recognise intact allogeneic 
MHC-peptide complexes – up to 1 in 10 (compared to as few as 1 in 10,000 recognising 
conventional antigens)49-51. Direct allorecognition creates a paradox when considering the 
stringent requirements for discriminating against non-self, imposed by self-MHC restriction35 
and there have been several theories proposed to explain the high precursor frequency of T 
cells with direct allospecificity. The idea of ‘altered-self’ was initially proposed as an 
explanation of how direct allorecognition occurs52. Consider a TCR which is specific for an 
antigenic peptide (X) in the context of self-MHC (A). The theory proposes that there is a high 
probability that there exists an allogeneic peptide (Y) which when coupled to an allogeneic 
MHC (B) could be recognised by that same TCR, which is supported by the observation in some 
studies that a significant proportion of direct-pathway T cells have a memory phenotype, 
implying previous priming against foreign antigen53, 54. 
Two subsequent models were proposed to explain the high precursor frequency (Figure 1.3). 
The ‘high determinant density’ model proposes that alloreactive T cells recognise amino acid 
polymorphisms exposed on the donor MHC molecules as antigenic, and that the peptide 
bound is of secondary relevance55. Each donor cell will express a multitude of allogenic MHC-
peptide complexes, and the high density can overcome the relatively low avidity, allowing 
lower affinity TCR-MHC interactions to result in successful T cell activation. This has been 
supported by demonstrating that alloresponses can be inhibited by blocking TCR recognition 
sites on allo-MHC with targeted mutations suggesting they may be more important than the 
nature of the bound peptide56-58.  On the other hand, the ‘multiple binary complex’ model 
suggests that the bound peptide is in fact pivotal52. It is suggested that allogeneic MHC is 
similar enough to self-MHC for direct-pathway T cells to recognise the peptide as foreign. 
Homologous proteins may then be recognised as foreign either because different derived 
peptides are presented by the allogeneic-MHC, or because identical peptides adopt a distinct 
conformation due to differences in the peptide binding groove59-62. Consequently, each 
alloreactive T cell clone may recognise only one, or a few, allogeneic-MHC peptide complexes, 
but each allogeneic-MHC will be recognised by a large number of clones, responsive to 
different bound peptides. This is supported by crystallographic studies which have 
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demonstrated that bound peptide participates in a significant number of interactions with the 
direct-pathway TCR63-67. 
 
 
Figure 1.3 Theories of direct T cell alloreactivity 
a) Peptide dependent model: T cells recognise variations in endogenous peptides presented b) Peptide 
independent model: T cells recognise polymorphisms of donor MHC molecules. (Reproduced from Mol 
immunol, 2008; 45(3): 583-98) 
 
Further evidence supporting the importance of direct-pathway allorecognition to graft 
rejection was the observed immunogenicity of donor leukocytes carried with the allograft42, 68. 
To this end, Lechler and Batchelor demonstrated that indefinite survival of rat kidney allografts 
could be achieved by re-transplanting into a second host69, 70. Temporary ‘parking’ of the graft 
in a first immunosuppressed host led to the depletion of donor APCs before re-transplantation. 
This observation was reinforced when rapid rejection occurred after administration of donor 
APCs to the second recipient71. More recently Pietra et al. demonstrated that direct-pathway 
CD4 T cells were both necessary and sufficient to mediate allograft rejection in lymphocyte 
deficient Rag-/- animals which could reject MHC class I deficient, but not MHC class II deficient 
allografts when reconstituted with syngeneic CD4 T cells. Furthermore, allografts were 
rejected by MHC class II knock-out recipients, in which indirect allorecognition was not 
possible; thus highlighting the importance of donor APCs and the direct-pathway to rejection72.  
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1.5.1 The contribution of direct allorecognition to rejection 
 
These observations have resulted in many inferring that direct allorecognition is the 
predominantly pathway responsible for acute rejection44, 50, 73, 74.  
However, due to the likely rapid elimination of donor APCs by natural killer (NK) cells, of the 
innate immune system, within hours to days of transplantation, the precise contribution of 
direct allorecognition to rejection remains uncertain75, 76. In keeping with this, clinical studies 
have identified a decline in the frequency of T cells with direct-pathway anti-donor specificity 
with time after renal and cardiac transplantation77, 78. In these studies direct and indirect-
pathway CD4 T cells are identified in vitro, examining peripheral blood CD4 T cell response 
(proliferation and cytokine production) following exposure to intact irradiated donor PBMCs or 
donor cytoplasmic membrane protein pulsed recipient PBMC’s respectively. Although this 
would suggest direct-pathway responses are restricted to early following transplantation, 
there is evidence that direct-pathway CD4 T cells can cause pathological findings characteristic 
of chronic rejection in models in which a graft is not rejected acutely79-81. Although donor APCs 
have been eliminated, this does not preclude the priming of direct-pathway CD4 T cells by 
other donor cells within the graft82. The ability of donor endothelium, for example, to express 
MHC class II and provide adequate co-stimulation for naïve or previously primed direct-pathay 
CD4 T cells has not been definitively excluded83-86. Additionally, the recently described ‘semi-
direct’ pathway, could also provide a route through which direct-pathway CD4 T cells could 
theoretically continue to be activated indefinitely47. Thus, the assertion that the direct-
pathway is short lived and only capable of contributing to acute rejection is perhaps 
unfounded. 
1.5.2 Direct-pathway effector functions 
 
Once activated, direct-pathway CD4 T cells have been shown to reject an allograft both 
independently and in the presence of other adaptive immune cells72, 81, 87. These helper CD4 T 
cells may contribute to rejection by several mechanisms: stimulation of a delayed type 
hypersensitivity reaction; provision of help to cytotoxic CD8 T cells; provision of help to B cells 
for alloantibody production; and via a direct cytotoxic effector function. 
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1.5.2.1 Delayed type hypersensitivity reaction 
 
Donor APCs prime alloreactive T cells to produce a pro-inflammatory, type-1 cytokine pattern 
of activation88. These ‘Th1’ CD4 T cells, by secreting cytokines, activate other innate immune 
cells such as macrophages which can lead to a delayed-type hypersensitivity (DTH) response. 
This damages the allograft by release of pro-inflammatory soluble mediators of cytotoxicity 
such as reactive oxygen species and tumour necrosis factor-α.  The DTH response is not 
believed to be an acute effector mechanism and so may only contribute to chronic rejection89-
91. 
1.5.2.2 Help for cytotoxic CD8 T cells 
 
CD8 T cells conventionally receive non-cognate, linked help from CD4 T cells which 
simultaneously bind to an APC presenting the epitopes for both CD4 and CD8 T cell 
recognition, forming a three-cell cluster (Figure 1.4). It is proposed that CD4 T cell help 
‘licenses’ the APC to make more effective MHC class I-restricted CD8 T cell presentations92-94. 
Taylor et al. have demonstrated in vivo that direct-pathway CD4 T cells can provide effective 
non-cognate, linked-help for direct-pathway cytotoxic CD8 T cells87. (In order to exert 
cytotoxicity to the graft, the CD8 T cell must be able to recognise allogenic MHC Class I – i.e. 
direct-pathway CD8 recognition). They propose a three-cell cluster requiring a donor APC, a 
direct-pathway CD4 T cell and a direct-pathway CD8 T cell.  Once activated, the direct-pathway 
CD8 T cells can effect graft rejection upon recognition of target MHC class I alloantigen on 
endothelial cells or graft parenchymal cells, by either inducing apoptosis through cross linking 
Fas, or by releasing perforin that creates pores in the cell membrane, allowing granzymes to 
enter95. However, because donor APCs are thought to be short-lived, it follows that this linked 
help to CD8 T cells is restricted to early following transplantation. Nevertheless, it has been 
shown that direct CD8 cytotoxicity can be primed even when CD4 T cell recognition is 
restricted to the indirect-pathway, suggesting that the provision of CD4 T cell help for 
generating CD8 T cell alloimmunity is more complex than for CD8 T cell responses against 
conventional antigen96.  
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Figure 1.4 Direct-pathway CD4 T-cell activation of direct-pathway CD8 T-cell cytotoxicity 
Intact donor MHC class II expressed by donor APCs is recognised by direct-pathway CD4 T cells. This 
licences the APC to prime direct-pathway CD8 T cells recognising intact donor MHC class I also expressed 
by the donor APC 
 
1.5.2.3 Help for B cell production of alloantibody 
 
B cell activation and generation of antibody responses against conventional antigen requires 
CD4 T cell help to be delivered in a cognate manner to the B cell directly, requiring the B cell to 
process and present its antigen in the context of MHC class II on its surface97.  It would be 
predicted, therefore, that as a recipient B cell will present peptide in a self-MHC restricted 
fashion, only indirect-pathway CD4 T cells would be able to provide cognate help for an 
alloantibody response. Nevertheless, the ability of direct-pathway CD4 T cells to provide help 
for alloantibody generation has been long debated.  
In 1996, two conflicting studies were published regarding the provision of help by direct-
pathway CD4 T cells for alloantibody production. Kelly et al. demonstrated that inhibition of 
direct allorecognition, by blocking MHC class II alloantigen, abrogated alloantibody production, 
and proposed that a similar three-cell cluster for non-cognate, linked-help by direct-pathway 
CD4 T cells for B cells may exist as for CD8 T cells98.  In contrast, Steele et al. demonstrated that 
MHC class II knock-out recipients, which restricts CD4 T-cell allorecognition to the direct-
pathway, did not develop a class-switched alloantibody response suggesting a necessary role 
for recipient antigen processing99. These studies have been reconciled by a more recent 
publication. The ability of direct-pathway CD4 T-cells to provide help to B-cells for alloantibody 
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production has been put into doubt by work using elegant transgenic models which overcome 
previous criticisms including the use of non-vascularised allografts and abnormal expression of 
donor and recipient MHC class II. In vascularised graft models in which only T-cells with direct-
pathway alloreactivity are present (with normal recipient MHC class II expression), it has been 
demonstrated that direct-pathway CD4 T-cells are unable to provide help for class-switched 
alloantibody responses, even when memory responses have developed, or the longevity of 
direct responses is prolonged by depletion of recipient NK cells100. Thus it appears unlikely that 
direct-pathway CD4 T cells contribute to alloantibody generation. 
1.5.2.4 Direct, direct-pathway CD4 T cell cytotoxicity 
 
The finding that a CD4 T cell reconstituted Rag-/- recipient can reject a cardiac allograft acutely 
implies that CD4 T cells can exert direct cytotoxicity against an allograft in vivo72. In support, 
three separate publications have demonstrated that monoclonal populations of direct-
pathway CD4 T cells can independently, acutely reject skin grafts81, 101, 102. The possibility that 
this is due to an acute DTH response remains but seems unlikely considering the time course 
of the observed rejection. The precise effector mechanism employed by these ‘cytotoxic’ CD4 
T cells is still debated. Some reports suggest cytotoxicity is dependent on FAS ligand 
expression103-106, others suggest it is dependent upon perforin expression106-108, whilst another 
suggests it is dependent on neither72, 109. Regarding vascularised cardiac allograft rejection, the 
role of direct-pathway CD4 T cells remains unclear. Evidence from Gill suggests that CD4 T cells 
can acutely reject a cardiac allograft acting alone, and that this is abrogated by using MHC class 
II deplete donors, implying an essential role for direct-pathway CD4 T cells72, 110. In contrast, 
Sayegh has demonstrated the ability of a transgenic population of direct-pathway CD4 T cells 
to reject skin but not cardiac allografts in the absence of other lymphocyte populations102.  In 
this study though, a monoclonal response was being observed which may not be 
representative of the polyclonal response typical of direct-pathway allorecognition. These data 
suggest that direct CD4 cytotoxicity may not play a significant role in vascularised allograft 
rejection. 
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1.6 Indirect allorecognition 
 
The observation that donor-leukocyte depleted allografts could be rejected with a delayed 
time course led to the hypothesis that, similar to conventional antigen recognition, alloantigen 
could be internalised, processed and presented by recipient APCs in a self-MHC restricted 
manner70, 71, 111, 112. There are several pathways by which donor antigen can be acquired: i) 
recipient APCs trafficking to the graft could internalise donor antigen, migrate to secondary 
lymphoid organs (SLO’s) and activate recipient CD4 T cells83; ii) soluble antigen shed from the 
graft could be carried to the SLO’s in the lymphatic or blood circulation113; or iii) passenger 
donor leukocytes trafficking to the SLO’s could be endocytosed and processed by resident 
APCs71, 114. 
Evidence has accumulated supporting an important role for the indirect-pathway in allograft 
rejection. Bradley et al. demonstrated that in an MHC class I mismatched rat cardiac allograft 
model, rejection was dependent on recipient CD4 T cells that could only recognise alloantigen 
in a self-MHC restricted manner115.  Fabre’s group subsequently demonstrated prolonged 
survival of rat kidney allografts after interfering with indirect presentation by administering a 
monoclonal antibody against MHC class II, opsonising recipient APCs116. They also 
demonstrated accelerated graft rejection if they immunised with peptides derived from an 
allogeneic MHC class I hypervariable region prior to transplantation (only able to prime 
indirect-pathway CD4 T cells)117. This was similarly observed by Sayegh et al. who also 
demonstrated that donor-specific hypo-responsiveness could be induced by intra-thymic 
injection of allogeneic MHC-derived peptides118, 119. 
With the advent of transgenic and gene ‘knock-out’ technology came more definitive evidence 
of the importance of the indirect-pathway. Auchincloss used MHC class II knockout mice as 
donors, precluding the ability of donor APCs priming CD4 T cells directly120. Skin grafts from 
these donors into MHC class I disparate recipients were rejected rapidly in wild-type 
recipients, confirming that indirect-pathway CD4 T cells alone could drive rejection121.  Further 
evidence has stemmed from TCR-transgenic mice, in which exclusive self-MHC restricted 
alloantigen recognition is guaranteed. Several TCR-transgenic models exist, whereby 
monoclonal populations of T cells express a TCR recognising peptides derived from minor 
antigen122-124, MHC class I125, 126 and MHC class II127 presented indirectly. In all of these models, 
indirect-pathway CD4 T cells have been demonstrated to effect allograft rejection. Unlike the 
poly-specific direct-pathway response, this work suggests that indirect alloresponses can be 
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mediated by a limited number of T cell clones directed to a single or a few dominant 
determinants within the polymorphic regions on alloantigen128-131. It has been demonstrated 
that over the course of an alloresponse, new allogeneic epitopes may become dominant 
determinants, termed epitope spreading, which may contribute to the establishment of 
chronic rejection132-135.  
1.6.1 `The contribution of indirect allorecognition to rejection 
 
The importance of the indirect-pathway to allograft rejection has become increasingly 
appreciated75, 96, 135-140. The hypothesis that it contributes only to chronic rejection stemmed 
from the observation that depleting donor APCs delayed acute rejection but did not prevent 
the development of chronic rejection141. The number of indirect-pathway CD4 T cells appears 
to increase with time after transplantation, likely due to the continuous presence of 
alloantigen for self-MHC restricted presentation142. There is also strong association between 
the presence of indirect-pathway T cells at late time points after human transplantation, and 
development of chronic rejection; further reinforcing the association between indirect-
pathway allorecognition and chronic rejection130, 143-147. For example, a study by Baker et al. 
observed high frequencies of CD4 T cells responding to the indirect-pathway late after living 
donor renal transplantation, with significantly higher responsiveness in those with evidence of 
chronic allograft nephropathy, whilst at the same time observing direct-pathway hypo-
responsiveness, implicating indirect-pathway responses in chronic rejection148. Further 
evidence of the contribution made by the indirect-pathway to human chronic rejection is 
provided by the correlation between donor specific antibodies and chronic rejection, since as 
discussed in Section 1.5.2, alloreactive B cells can only receive help from indirect-pathway CD4 
T cells. Chronic antibody mediated rejection is a well-defined pathological entity, and is a 
marker of indirect-pathway alloreactivity149-151. Pathogenicity of alloantibodies is directly 
evidenced by deposition of the complement product C4d on allograft endothelium. 
However, in addition to a role in chronic rejection, there is growing evidence that indirect-
pathway allorecognition could be important early after transplantation81; for example, 
Auchincloss’ demonstration of acute skin allograft rejection in the absence of direct -pathway 
allorecognition121. More recently, Brennan et al. described an elegant TCR-transgenic model in 
which directly and indirect-pathway CD4 T cells could be simultaneously tracked. Surprisingly, 
this work suggested that priming of the indirect-pathway is favoured, even early after 
transplantation142. The indirect-pathway cells also predominated within the effector T cell 
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population and perhaps more importantly, within the population with ‘memory-like’ 
phenotype, supporting a role for this pathway in acute rejection.  
That depletion of passenger APCs prolongs allograft survival is often quoted in support of a 
primary role for direct allorecognition in acute rejection69. Gould and Auchincloss though, 
suggest alternative interpretations, in keeping with a concurrent importance to indirect-
pathway allorecognition: i) donor APCs could function predominantly as vehicles to transport 
alloantigen to SLO’s for indirect-pathway processing, rather than as antigen for direct-pathway 
allorecognition and/or ii) depletion of donor APCs, with their high expression levels of MHC 
class II, could reduce the availability of antigenic determinants for indirect-pathway 
processing44.  
1.6.2 Indirect-pathway effector functions 
 
There is now convincing evidence that the indirect-pathway alone can reject both skin96, 121-124, 
152 and vascularised allografts125, 126, 153. Similar to the direct-pathway, indirect-pathway primed 
CD4 T cells have been demonstrated to preferentially differentiate into a pro-inflammatory 
type-1 cytokine-secreting phenotype and therefore can provide help to B cells and CD8 T 
cells154.  
1.6.2.1 Direct indirect-pathway CD4 T cell cytotoxicity 
 
Despite not being able to directly interact with graft cells, there is increasing evidence that 
graft damage can be caused by indirect-pathway CD4 T cells73, 125, 155.  
One possible mechanism is the development of chronic rejection driven by indirect CD4 T cells 
initiating a DTH reaction within the graft – although this is not believed to be effective at 
rejecting vascularised allografts156 . Several transgenic murine models have been reported in 
which monoclonal CD4 T cell populations restricted to the indirect-pathway have acutely 
rejected skin grafts, and reject cardiac allografts with a prolonged time course157-159.  As a 
result, alternative hypotheses for how indirect-pathway CD4 T cells can independently effect 
graft rejection have been proposed. Skin grafts are known to be vascularised by recipient 
endothelial cells, and these are capable of presenting self-MHC restricted graft antigens that 
can act as ligands for indirect-pathway primed effector cells160. It has also been speculated that 
the process of recipient endothelialisation can occur in vascularised allografts although the 
extent and significance are unclear73, 161.  A further mechanism postulates that graft damage 
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can be effected by indirectly primed T cells that have translocated into a graft and recognise 
their ligands on graft infiltrating recipient APCs, leading to bystander killing of graft cells in a 
manner analogous to DTH83, 162-164 (Figure 1.5). 
 
Figure 1.5 Postulated mechanisms by which graft damage can be effected by primed indirect-pathway 
CD4 T-cells 
 a) Recipient endothelialisation of allografts, with subsequent processing of donor antigen and 
presentation in the context of recipient MHC, and b) graft infiltrating recipient APCs processing and 
presenting donor antigens, both provide a potential target to indirect-pathway CD4 T cells. (Reproduced 
from Am J Transplantation 2003; 3:525-533) 
 
1.6.2.2 Help for B cell production of alloantibody 
 
In the case of T-dependent antigens, B cells, in most circumstances, require a cognate 
interaction with antigen specific CD4 T-cells in order to differentiate into antibody-secreting 
plasma cells (Figure 1.6)97. Because indirect-pathway CD4 T-cells are self-MHC restricted, 
unlike direct-pathway CD4 T-cells, they alone possess the ability to provide cognate help to B 
cells for alloantibody production87, 99, 100, 140, 165. B cells recognise intact alloantigen which is 
subsequently internalised, processed and presented as self-MHC restricted peptide to indirect-
pathway CD4 T cells in order to receive the necessary help to drive humoural alloimmunity.  
Pettigrew et al. demonstrated that although immunisation with allogeneic MHC derived 
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peptides could prime an indirect CD4 T-cell response, a destructive humoral response could 
only be elicited with the transfer of additional intact allogeneic MHC molecules, suggesting the 
requirement for B cell ligation of intact antigen in order to receive help from indirect-pathway 
CD4 T cells140. 
 
 Figure 1.6 Indirect-pathway CD4 T-cell activation of humoral alloimmunity. 
A B cell specific for alloantigen binds to, and internalises its target alloantigen, which is processed and 
presented in a self-MHC restricted manner to indirect-pathway CD4 T cells, which in turn provide help to 
the B cell for continued maturation of the alloantibody response. 
 
1.6.2.3 Help for CD8 T cell cytotoxicity 
 
Indirect-pathway CD8 T cells recognising allogeneic peptides restricted to self MHC can 
theoretically be activated by indirect CD4 T cells by a classical 3-cell cluster with a recipient 
APC160. Benichou confirmed the ability of self-MHC restricted indirect CD8 T cells to effect 
acute rejection of a single MHC class I mismatched skin graft after immunisation with peptides 
derived from the allogeneic MHC class I166. This was confirmed by Heeger who demonstrated 
that a transgenic population of CD8 T cells recognising allogeneic antigen by the indirect-
pathway could contribute to the rejection of skin grafts, but only when recipient endothelial 
cells could present the antigen160, 167. This suggests that, certainly for skin grafts, indirect-
pathway CD8 T cells may play a role in rejection due to graft revascularisation. However, a 
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question still remains as to how relevant this population of CD8 T cells is in clinical 
transplantation of vascularised organs due to the uncertainty surrounding whether the ligand 
for these cells is present in these grafts.  Heeger et al demonstrated in one model of cardiac 
transplantation, that indirect-pathway CD8 T cells were merely non-pathogenic bystanders due 
to the absence of a cognate antigen on the allograft (due to endothelium being predominantly 
of donor origin)168. Even priming these CD8 T cells had no impact on the kinetics of rejection. 
Direct-pathway alloreactive CD8 T cells, by contrast, are able to bind to graft cells and effect 
graft rejection. The ability of indirect-pathway CD4 T cells to prime these cells was first 
suggested by Lee et al. who demonstrated that murine skin grafts could be rejected by CD8 T 
cell cytotoxicity in a model in which CD4 T cell recognition was restricted to the indirect-
pathway96, 121.They demonstrated that direct-pathway CD8 T cells were recognising intact 
donor MHC class I on donor cells, and that the helper CD4 T cells were recognising self-
restricted alloantigen on recipient APCs by the indirect-pathway proposing a 4-cell cluster 
model with unlinked CD4 T cell help for the direct-pathway CD8 T cells. This model has faced 
criticism as, devoid of physical linkage, it seems to be inherently unstable and potentially 
uncontrolled, raising the potential for bystander CD8 T cell activation by self-MHC restricted 
CD4 T cells presented with unrelated peptides (Figure 1.7). 
 
 
Figure 1.7 Four-cell cluster model of indirect-pathway CD4 T-cell help for CD8 T cell allo-cytotoxicity 
Indirect-pathway CD4 T cell recognising allopeptide presented by a recipient APC provide ‘unlinked’ help 
to a direct CD8 T cell that recognises intact alloantigen on the surface of a donor APC. 
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One reconciliatory theory postulates that physical linkage of the 4 cells could be achieved if the 
recipient APC was a B cell. The B cell receptor could recognise its epitope on the donor APC, 
simultaneously presenting processed antigen in a self-MHC class II restricted fashion to an 
indirect-pathway CD4 T cell. The donor APC could also provide the epitope for a direct-
pathway CD8 T cell, thus bringing the two T cells in close proximity, allowing for more 
controlled unlinked help to be provided, thus preventing non-specific CD8 T cell activation96. 
This debate has led to the proposition of an alternative explanation - a third pathway of 
allorecognition, termed the ‘semi-direct’ pathway, which may reconcile the above findings47. 
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1.7 The ‘semi-direct’ pathway of allorecognition? 
 
The observation that DCs are able to acquire intact MHC molecules from other cells in vitro 
and in vivo, ‘cross-dressing’, has led to the suggestion that allogeneic MHC molecules acquired 
by recipient APCs could permit on-going presentation of antigen to direct-pathway T cells – a 
process now described as the semi-direct-pathway47, 169-171. This model would then permit the 
recipient APC to simultaneously present processed alloantigen in the context of self MHC class 
II to an indirect-pathway CD4 T cell, and intact allogeneic MHC class I to a direct-pathway CD8 
T cell, thus reconciling the requirement for linked-help in a three-cell cluster (Figure 1.8)172. 
 
Figure 1.8 Semi-direct-pathway of direct-pathway CD8 T cell activation 
Recipient APCs acquire intact donor MHC class I and present this intact on their surface, co-localising 
intact donor MHC class I and recipient MHC class II to a single APC, enabling the provision of linked-help 
from indirect-pathway CD4 T cells for generating cytotoxic CD8 T cell alloimmunity. 
 
Lechler’s group have provided convincing evidence for the intercellular transfer of MHC 
molecules, demonstrating that transfer can occur both by cell-to-cell contact through capture 
of membrane fragments - trogocytosis, and through exosome transfer173. They have 
additionally demonstrated the ability of these acquired MHC molecules to activate T cells, 
confirming the functional ability of the acquired molecules. Although most evidence for this 
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process is based on in vitro studies, there is increasing in vivo evidence for the existence of 
MHC transfer. Lechler’s group has shown acquisition of MHC upon adoptive transfer of DCs 
lacking both MHC class I and II molecules174. This was followed by Brown et al. demonstrating 
APCs expressing both donor and recipient MHC class II molecules after cardiac and kidney 
transplantation in their murine model175. Previous work from our laboratory has also provided 
evidence supporting the potential for the semi-direct-pathway to have clinical relevance176. 
Following in vitro co-culture of BALB/c and C57BL/6 DCs, some C57BL/6 DCs were 
demonstrated to present acquired BALB/c MHC class I H-2Dd both as processed allopeptide 
and intact unprocessed antigen. Transfer of these DCs into recipients of BALB/c cardiac 
allografts provoked direct-pathway CD8 T cell cytotoxicity that was dependent on indirect-
pathway recipient CD4 T cells. 
The relevance of this trogocytosis of alloantigen is, however, still unclear, because to be 
functionally important presentation of intact donor alloantigen by recipient APCs must be 
more effective for triggering cytotoxic alloimmunity than conventional encounter on donor 
APCs, and this has not been shown. Thus, despite increasing evidence supporting MHC transfer 
in vivo, the role of the semi-direct-pathway in the alloimmune response remains uncertain165, 
177, 178. 
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1.8 NK cell allorecognition 
 
Natural killer (NK) cells are effector cells of the innate immune system and have the ability to 
kill virus-infected or tumour cells without prior antigen priming, secrete cytokines, and 
regulate both innate and adaptive immune responses179. Despite not expressing clonal antigen 
receptors, NK cells are able to discriminate between cells of self and non-self. NK cells express 
a range of germ-line encoded inhibitory and stimulatory receptors found to be encoded within 
the NK gene complex (NKC)179, 180. Inhibitory killer cell immunoglobulin-like receptors (KIR) bind 
to classical MHC class I molecules, preventing the lysis of autologous cells in humans, leading 
to the concept of ‘missing-self’ activating NK cells181, 182. (The Ly49 receptor family are 
functional homologues in mice183). Additionally, NK cells also express a series of stimulatory 
receptors such as the evolutionary conserved CD94, NKG2 and NKR-P1 groups that bind to 
molecules associated with infection or cellular distress. Activation of NK cells has been 
demonstrated to require more than just absence of self MHC class I, but instead the balance of 
signals through inhibitory and stimulatory receptors regulate NK cell activation184. 
 
1.8.1 The role of NK cells in allograft rejection 
 
Early studies suggested that NK cells may not have a role in solid organ rejection since adaptive 
immune deficient SCID and Rag-/- mice were unable to reject allografts185. However, it is 
simplistic to argue that this is evidence for absence of NK alloreactivity, since it is recognised 
that NK cell effects can require adaptive immunity, for example antibody production to drive 
antibody-dependent cell-mediated cytotoxicity. In keeping with this, more recently it was 
observed that if NK cells in Rag-/- mice were activated by administration of IL-15 they were able 
to acutely reject skin allografts, highlighting that the role of NK cells in transplantation is more 
complex than initially recognised186. 
 
1.8.1.1 NK cells as effectors in allograft rejection 
 
A variety of mechanisms are thought to contribute to NK cell activation – all of which are 
present following transplantation: i) detection of missing, or altered-self MHC molecules; ii) 
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engagement of the Fc portion of IgG antibodies as opsonins; iii) detection of altered molecules 
on stressed cells; or iv) an inflammatory environment with  cytokines such as IL-12, IL-15 and 
IFNγ187, 188. NK cells have been demonstrated to be potent effector cells that can mediate 
rejection of both bone-marrow and xenogeneic solid organ allografts189-191. Furthermore, NK 
cell infiltration into allogeneic allografts is frequently observed in models of both acute and 
chronic rejection, suggesting that NK cells have a role in mediating allograft injury192, 193. For 
example, advanced AV lesions developed in cardiac allografts transplanted from parental to F1 
hybrid mice, a transplant system known to lack specific anti-donor T cell reactivity but retain 
anti-donor NK cell responses. NK cell depletion significantly abrogated the development of 
these lesions, suggesting that NK cells activated by missing-self MHC class I on donor 
endothelium can contribute to the development of AV28. In support, NK cells have been 
observed as infiltrates in AV lesions in human transplant recipients194.  
NK cells have several effector mechanisms all of which have been observed in experimental 
transplant models, and by which they could mediate allograft injury. NK cells can produce pro-
inflammatory cytokines such as IFNγ and TNFα that can induce DTH or cause direct tissue 
damage; NK cells can produce granzymes which induce target cell cytolysis; NK cells express 
Fas ligand which would enable them to induce Fas mediated killing; and NK cells produce 
chemokines such as monokine-induced by gamma-interferon that recruit activated T cells190, 
195-197.  
In human clinical transplantation, evidence for a role of NK cell alloimmunity in allograft 
rejection was provided by a study examining the impact of KIR-ligand matching between donor 
and recipients198. In a cohort of patients with minimal HLA mismatch (to minimise the impact 
of adaptive alloimmunity), KIR-ligand mismatch (recipient NK cells lacking receptors 
recognising donor MHC class I as ‘self’) was identified as an independent predictor of poor 
graft outcome suggesting NK cell alloreactivity to play an important role in allograft rejection. 
More convincing evidence for a role of NK cells in allograft rejection has subsequently been 
provided with microarray analyses reproducibly demonstrating NK cell gene transcripts to be 
upregulated in renal transplant biopsies in the context of antibody mediated rejection, 
implicating NK cells as effectors199-201. 
Thus, there is compelling evidence that NK cells can contribute to allograft injury and rejection, 
acting in conjunction with adaptive alloimmune responses. 
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1.8.1.2 NK cells in the maintenance of tolerance 
 
There is however, a growing body of evidence suggesting that NK cells can also contribute to 
the induction of allograft tolerance.  In a murine study of cardiac transplantation, depletion of 
NK cell subsets resulted in significantly accelerated rejection kinetics suggesting a role for NK 
cells in suppressing immune responses202. Similar findings have also been observed in bone-
marrow transplantation, whereby NK cells have been demonstrated to regulate the 
development of graft-versus-host disease (GVHD)203, 204. In both of these studies, regulation of 
GVHD development was found to be due to NK cell deletion of alloreactive donor T cells. 
Several mechanisms have been proposed for how NK cells regulate alloreactive T cells. There is 
some evidence that antigenically stimulated and activated T cells upregulate ligands for the 
stimulatory NK cell receptor NKG2D which target them for direct NK cell cytolysis205. Activated 
T cells are also known to upregulate expression of the death receptor Fas, the ligand of which 
(Fas ligand) is expressed on activated NK cells. In support of this as a potential regulatory 
mechanism, NK cells were unable to prevent GVHD and control the expansion of T cells from 
Fas-deficient donors203. A more recent suggestion has been the possibility that regulatory 
subsets of NK cells produce regulatory cytokines such as IL-10 and regulate T cells through this 
mechanism206. 
An alternative mechanism of NK cell mediated tolerance identified in solid organ 
transplantation involves deletion of donor DCs. In a skin transplant model, rejection ensued in 
recipients deplete of NK cells207. NK cells were responsible for rapid deletion of passenger 
donor DCs which limited their survival and dissemination within the recipient. This was found 
to alter the location and extent of T cell priming, dampening the adaptive alloimmune 
response and promoting a tolerogenic environment208. 
 
Taken together, it is clear that NK cells have the potential to influence outcomes following 
transplantation. However, current understanding of NK cells and their impact on alloimmunity 
is incomplete, hindering development of approaches to harness or control their behaviour.   
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1.9 Regulatory immune cells 
 
It is now widely accepted that there exist regulatory populations of leukocytes able to promote 
tolerogenic immune responses. Harnessing these cells in clinical transplantation to prolong 
allograft survival has become the focus of much on-going research209. The drive for introducing 
regulatory cellular immunotherapy to transplantation is to remove the requirement for 
lifelong treatment with immunosuppressive drugs and their complications such as toxicity, 
infection and malignancy, as well as ameliorating the inevitable development of chronic 
rejection. Several populations of regulatory immune cells have been discovered. 
 
1.9.1 Regulatory T cells 
 
The existence of a population of immune cells with suppressor properties was first 
demonstrated in 1971 by Gershon and Kondo210. Their experiments suggested a role for 
thymocytes in generating tolerance, and that tolerance could be transferred to other hosts by 
transfer of spleen cells. Adoptively transferrable suppression of transplant rejection became a 
consistent finding, but the cells responsible were not yet characterised and some scepticism 
remained211. Subsequently Hall et al. provided strong evidence in a rat cardiac allograft model, 
that CD25+ CD4 T cells were responsible for mediating transplant tolerance212, 213. This was 
extended to demonstrate that transferred tolerance was ‘infectious’ in that transferred 
regulatory T cells could recruit non-regulatory CD4 T cells in a recipient to become 
regulatory214. Subsequent work demonstrated that these cells could also control autoimmunity 
and GVHD215. The next major step forward was discovery of the master transcription factor for 
regulatory CD4 T cells: Forkhead box P3 (FOXP3) in 2003, deficiency of which results in the 
severe autoimmune disease scurfy in mice, or immunodysfunction polyendocrynopathy and 
enteropathy, x-lined syndrome in humans216-218.  
Further work has confirmed that regulatory CD4 T cells (Treg) can be reliably defined by 
expression of high levels of CD25 (the IL-2 receptor α-chain) and the transcription factor 
FOXP3, and that these cells play a role in limiting immune responses such as those observed in 
autoimmunity such as type 1 diabetes and chronic inflammatory conditions such as 
inflammatory bowel disease, inhibit GVHD and prevent or delay allograft rejection in animal 
models178, 219. Two populations of Treg have been characterised.  Natural Treg (nTreg), 
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represent 5-10% of the peripheral CD4 T cell population (natural, nTreg) and are selected in 
the thymus to maintain peripheral tolerance against self-antigen. Induced Treg (iTreg) develop 
in response to antigenic encounters in a tolerogenic environment in the periphery (induced, 
iTreg)209, 220. It has been proposed that nTreg, which are positively selected with a moderate to 
high affinity for self-antigens in the thymus have a role in regulating against autoimmunty, 
whilst iTreg derived from naïve T cells selected with higher affinity for non-self antigen have a 
role in suppressing responses against foreign antigens211. 
Four modes of action have been proposed for how Treg exert their suppression (Figure 1.9): 
suppression by secretion of inhibitory cytokines such as IL-10, TGF-β and IL-35; suppression by 
cytolysis through granzyme and perforin dependent mechanisms; suppression by metabolic 
disruption such as through consumption of local IL-2; and suppression by modulation of 
dendritic-cell (DC) maturation or function that then disrupts subsequent CD4 T cell 
activation221. No clear consensus of the single most important mechanism has been 
determined178.  
 
 
Figure 1.9 Suppressor mechanisms of regulatory T cells 
Proposed mechanisms of Treg suppression. Reproduced from Vignali et al. Nature Immunology 2008
221
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There is now an extensive body of evidence that Treg have the ability to significantly prolong 
allograft survival following transplantation in animal models209, 215, 222, 223. This has involved 
development of techniques to isolate, induce and expand Treg in vitro. Furthermore, there is 
suggestion that particularly effective donor-specific tolerance can be established by 
administration of allospecific Treg, as compared to polyclonal Treg165, 224.  
The success in animal models has led to the beginnings of clinical translation of Treg therapy.  
Success with human Treg was first suggested by demonstration that ex-vivo expanded human 
Treg were effective at abrogating rejection in humanised mouse models224, 225. Several studies 
have now been performed in the setting of bone marrow transplantation, where Treg therapy 
has been shown to be safe with some efficacy in preventing development of GVHD209, 226, 227.  
In solid organ transplantation, very limited experience with Treg therapy has been reported so 
far. However, a multicentre phase I/IIa clinical trial funded by the European Union FP7 
programme, the ONE study, is currently investigating the safety and production feasibility of 
regulatory cellular therapy, including several types of Treg, in living donor kidney transplant 
recipients209, 215, 228. The goal of developing cellular immunotherapy is to permit induction of 
long-lived donor-specific tolerance without the requirement for long-term chemical 
immunosuppression. The results of the ONE study are eagerly awaited. 
 
1.9.2 Tolerogenic dendritic cells 
 
Dendritic cells, as professional APC’s, have an essential role in driving adaptive responses 
against foreign antigens. Nevertheless, their importance to the maintenance of central and 
peripheral tolerance has been increasingly appreciated229, 230. Tolerogenic DC’s are immature, 
maturation resistant or alternatively activated DC’s that express surface MHC molecules, have 
a low ratio of co-stimulatory to inhibitory signals, and an impaired ability to synthesise T helper 
1 cell cytokines (such as IL-12)229. Tolerogenic DC’s can be reproducibly generated in vitro 
through exposure to various anti-inflammatory and immunosuppressive agents, raising the 
potential for their use clinically in transplantation229. Tolerogenic DC’s maintain peripheral 
tolerance using several mechanisms including: T cell deletion; inducing T cell anergy; inducing 
Treg; and by expressing immunoregulatory factors such as IL-10 and TGF-β230.  
Experimental administration of tolerogenic DC’s in transplantation models has been 
undertaken with DC’s of both donor and recipient origin, with prolonged allograft survival 
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demonstrated (reviewed in 229). These cells differ in their ability to cognately interact with 
direct and indirect-pathway CD4 T cells. Recipient-derived tolerogenic DC’s pulsed with donor 
antigen will only be able to interact with indirect-pathway T cells. By contrast, donor-derived 
tolerogenic DC’s will only interact with direct-pathway T cells. It may be predicted therefore, 
that donor-derived tolerogenic DC’s may not be effective at abrogating chronic rejection, 
however, this is not found to be the case229. 
Administration of in vitro generated donor-derived myeloid and plasmacytoid tolerogenic DC’s 
7 days prior to transplantation has been demonstrated to significantly prolong the survival of 
murine cardiac allografts, effects which can be enhanced by administering co-stimulatory 
blockade agents simultaneously230-232. Notably, in addition to significantly decreasing anti-
donor direct-pathway responses, indirect-pathway responses are also impaired. After 
administration of donor-derived tolerogenic DC’s, donor antigen is found to be presented by 
recipient DC’s – suggesting that the tolerogenic DC’s are acting as a source of donor antigen, 
that can be presented to indirect-pathway T cells, leading to their down-regulation, and 
contributing to the observed prolonged allograft survival233, 234. A recent study by Wang et al. 
has characterised this further, identifying that following administration of donor-derived 
tolerogenic DC’s there was preferential deletion of indirect-pathway CD4 T cells which was 
dependent upon recipient DC’s235. Wang et al. additionally identified that, surprisingly, the 
observed reduction in direct-pathway responsiveness was also dependent on the presence of 
recipient DC’s highlighting that the interaction between the tolerogenic DCs and host cells is 
more complex than simply binding to direct-pathway CD4 t cells in the recipient. 
Another strategy to target both direct and indirect-pathway CD4 T cells has been the use of 
semi-allogeneic DC’s that co-express donor and recipient MHC molecules, typically by 
administering F1 (donor x recipient) DCs. These semi-allogeneic tolerogenic DC’s appear 
particularly effective at regulating indirect-pathway responses, possibly by Treg induction, and 
have been shown to lead to indefinite survival of allografts236, 237. These cells could also interact 
with T cells in a semi-direct manner. 
Although tolerogenic DC’s offer some promise as a therapy, there remains the potential that 
these cells could revert to an immunogenic phenotype upon administration, with the inherent 
risk of sensitising the recipient and accelerating graft rejection. 
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1.9.3 Regulatory B cells 
 
Regulatory B cells (Breg) are a more recently described population of immune cells with 
immunoregulatory function. Definitive characterisation of these cells has remained challenging 
because they are a rare subset of B cells and lack characteristic phenotypic or molecular 
markers analogous to those that define Treg such as FOXP3238. 
The suggestion that B cells may have an immunomodulatory role was first suggested upon 
observation that certain autoimmune models worsened upon B cell depletion239. The 
relevance to transplantation was similarly suggested when depletion of B cells at the time of 
kidney transplantation was surprisingly demonstrated to enhance acute T cell mediated 
rejection240. Two further studies suggesting a role for B cells in transplantation tolerance were 
published in 2010. Sagoo et al. observed that immunosuppression-free kidney transplant 
recipients are characterised by increased numbers of B cells, despite lacking donor-specific 
antibodies and demonstrated donor-specific T cell hypo-responsiveness in vitro, alluding to an 
immunoregulatory role for B cells in transplantation241.  In the second, Newell et al. examined 
gene expression profiles and lymphocyte subsets of tolerant renal transplant recipients (off 
immunosuppression for greater than a year with stable renal function). Tolerant recipients had 
increased expression of multiple B cell differentiation markers and had elevated numbers of 
naïve and transitional B cells, again suggesting a central role for B cells in regulating 
alloimmunity242. More recent, functional, examination of B cells from similarly tolerant 
recipients has revealed a much higher percentage of IL-10 producing B cells, and quantity of IL-
10 produced by B cells of tolerant recipients, and an impaired ability to differentiate into 
plasma cells243. 
It has been proposed that Breg may influence effector T cell responses either directly through 
antigen presentation and co-stimulation, or indirectly by cytokine production – particularly IL-
10243. It is thought that interaction with Breg results in an increase in Treg development244. 
Although cognate interaction with Breg can only occur with indirect-pathway T cells, due to B 
cell presentation of antigens in the context of self-MHC, this pathway is particularly associated 
with chronic rejection and remains an important target of tolerogenic therapies. 
Because of its apparent crucial role in mediating Breg suppression, IL-10 production is largely 
used as a marker for Breg identification. To date, a number of Breg subsets with overlapping 
phenotypes and functions have been identified in various mouse models245. As such, unlike for 
Treg and tolerogenic DC’s, it has not yet been clarified how Breg can be reproducibly 
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generated in vitro for therapeutic use. A recent study from Rothsteins group has suggested 
that ligation of T cell immunoglobulin and mucin-domain-containing protein 1 (TIM-1) induces 
Breg expansion and regulatory activity246. Prolonged islet graft survival was observed in a 
murine model using a stimulatory anti-TIM-1 monoclonal antibody to induce Breg in vivo and 
following transfer of TIM-1+ B cells246. 
The potential for Breg as an immunomodulatory therapy in transplantation has yet to be fully 
elucidated and currently there are no clinical studies with Breg as a cellular therapy, but this 
remains an active area of research209. 
 
 
1.9.4 Regulatory macrophages 
 
Macrophages are cells of the innate immune system that respond to local inflammatory 
signals. Regulatory macrophages (Mreg) have been described as a population of macrophages 
that limit inflammatory responses and prevent prolonged activation of classical 
macrophages247. Mreg can be induced by stimulation with M-CSF and IFNγ and these cells have 
been shown to prolong survival of cardiac allografts in murine models, through inhibiting T cell 
proliferation through iNOS dependent mechanisms and through contact-dependent deletion 
of activated T cells248. Importantly, human Mregs have been successfully used as a cellular 
therapy in kidney transplantation. They proved to be safe and well tolerated and promising 
clinical outcomes were observed249, 250. Mreg are also being examined as part of the ONE 
study. 
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1.10 Limitations of murine models 
 
Rodent models have been essential to the study of transplantation immunology, and have 
provided the opportunity to gain significant understanding of the process of allograft rejection 
and to discover novel therapeutic interventions. Several transplant models exist, the most 
frequently utilised being skin transplantation, heterotopic cardiac transplantation and kidney 
transplantation251, 252. In this thesis the heterotopic cardiac transplant model has been used. 
This has been the most widely utilised vascularised transplant model since its development in 
1973 by Corry et al.253. There are several advantages of this model. It represents an 
immediately vascularised allograft, and allograft function is easily assessed by palpation of the 
recipient abdomen, with a defined endpoint for rejection – cessation of palpable beat. Unlike 
other vascularised transplant models, the recipient does not succumb to allograft rejection 
permitting examination of immunological responses even after the allograft has been rejected. 
Furthermore, the model has proven to be reproducible. However, there are shortcomings. The 
allograft does not contribute to cardiac output and is not truly physiological since blood only 
flows through the right side of the heart. The absence of functional contraction against an 
afterload results in progressive atrophy of the myocardium. This abnormal blood flow has 
been described as resulting in epicardial and endocardial inflammation due to chronic 
ischaemia. There are also anatomical differences between murine and human hearts. For 
example, coronary arteries are predominantly epicardial in humans, but are intramural in 
mice251, 252.  
Mice are the mainstay of in vivo immunological experimentation and have been instrumental 
to our understanding of the human immune system in health and disease. However, it must be 
borne in mind that there are significant differences between mice and humans in immune 
system development, activation and response to challenge254. Some examples with relevance 
to this thesis include: i) mice and humans differ in T cell co-stimulatory molecule expression - 
for example, 100% of murine T cells express CD28 whilst this is much lower in humans. This 
different pattern of co-stimulatory molecule expression is of relevance when considering 
extrapolation of experiments utilising co-stimulatory blockade agents. ii) Activated human CD4 
T cells express MHC class II and may have a role in antigen processing and presentation which 
is not the case in mice. This may introduce some differences in characteristics of murine and 
human indirect-pathway CD4 T cell activity. iii) There is considerable evidence that human 
endothelial cells constitutively express MHC class II and can activate memory CD4 T cells. This 
is not the case in mice. This may result in significant differences in alloresponses against 
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vascularised allografts between humans and mice – with implications for both direct and 
indirect-pathway CD4 T cell responses since an on-going source of intact MHC class II is present 
in humans, but not in mice254.  
It should also be remembered that in human clinical transplantation recipients typically 
receive, at least initially, triple agent immunosuppression with corticosteroid, a calciuneurin 
inhibitor and an anti-proliferative agent such as azathioprine or mycophenolate mofetil. As is 
the case in most murine transplant immunology research, such immunosuppression has not 
been administered in the models reported in this thesis.  
It is important to be aware of these potential limitations when considering extrapolating data 
from studies such as these in mice, to humans. 
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1.11 Aims and Objectives 
 
The CD4 T cell alloimmune response is characterised by its unique ability to recognise 
alloantigen via two distinct pathways, the direct and indirect, which are thought to differ 
markedly in their respective duration and the mechanisms by which each contributes to 
allograft rejection. These differences however, remain largely unproven. In this thesis I aim to 
definitively examine the duration of the direct and indirect-pathways of allorecognition and 
understand the factors responsible for driving and limiting their longevity using a murine 
model of heterotopic cardiac transplantation. 
Cellular immunotherapies are becoming an attractive treatment option in transplantation for 
attaining donor specific tolerance. Of these, regulatory T cell therapy has been studied in 
greatest detail, and clinical translation is not too distant. The second aim of this work is to 
examine if possessing a more detailed understanding of the alloimmune pathways will be 
useful to guide development of regulatory T cell therapy. 
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2 Methods 
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2.1 Animal work 
2.1.1 Mouse strains and Animal Husbandry  
 
C57BL/6 (H-2b), BALB/c (H-2d) and CB6F1 (C57BL/6 X BALB/c F1 – H-2bd) mice were purchased 
from Charles River Laboratories (Margate, United Kingdom). Bm12 mice - B6(C)-H2-
Ab1bm12/KhEgJ (H-2bm12)255, T cell receptor-deficient C57BL/6 mice - B6.129P2-
Tcrbtm1MomTcrdtm1Mom/J (H-2b, TCRKO/Tcrbd-/-)256 and mice expressing the diphtheria toxin 
receptor gene (DTR) under the CD11c promoter on a C57BL/6 - B6.FVB-Tg (H-2b – B6.DTR)257 
and BALB/c -  C.FVB-Tg (H-2d – BALB/c.DTR)257 background were purchased from Jackson 
Laboratories (Bar Harbor, ME). Subsequently, BALB/c.DTR mice were crossed with C57BL/6 to 
obtain CB6F1 (H-2bd) mice expressing the DTR gene. Similarly, Tcrbd-/- mice were backcrossed 
onto a bm12 background to obtain the bm12.TCRKO strain. 
C57BL/6 Rag2−/− (H-2b, RAG2KO) mice, lacking B and T cells were kindly gifted by Prof. T. 
Rabbitts (Laboratory of Molecular Biology, Cambridge, U.K.). Rag2IL2rg258 (Rag2-/- mice with an 
additional IL-2 receptor γ chain knockout were kindly gifted by Dr Francesco Colucci (University 
of Cambridge, UK). These additionally lack NK cells.  
C57BL/6 mice that lack expression of I-Ab, but express the I-Eα gene (ABOIE) and express I-E on 
the surface of their APCs were gifted by Prof C. Benoist (Joslin Diabetes Center, Boston, MA)259. 
C57BL/6-Tg(Kd)RPb  mice (B6.Kd)162 that additionally express the H-2Kd gene were gifted by Dr 
R.P. Bucy (University of Alabama, Birmingham, AL). 
Bm12.Kd.IE mice were created in-house by first crossing bm12 x B6.Kd selecting from the 
offspring for those expressing I-Abm12 and H-2Kd but not I-Ab on PCR (bm12.Kd). These were 
then crossed with ABOIE animals and off-spring selected for expression of: I-Abm12, I-E and H-
2Kd. Bm12.IE mice were the F1 offspring of bm12 x ABOIE. 
Bm12.Kd.IE mice expressing the DTR gene under the CD11c promoter were created in-house 
by first crossing B6.FVB-Tg mice with ABOIE mice. The F1 generation mice expressing DTR were 
back-crossed to ABOIE, with I-E+ DTR+ offspring selected (lacking I-Ab). These were then crossed 
with bm12.Kd mice and expression of DTR confirmed by PCR. 
TCR transgenic animals (Table 2.1): Rag2-/- TEa mice (H-2b, TEa) ), specific for I-Ab restricted I-
Ed52-68 peptide were gifted by Prof A. Rudensky (University of Washington, Seattle, WA)
260; 
Rag1-/- TCR75 mice (H-2b, TCR75), specific for I-Ab restricted H-2Kd54-68 peptide were gifted by 
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Prof P. Bucy (University of Alabama, Birmingham, AL)125; Rag2-/- ABM mice (H-2b, ABM), I-Abm12 
restricted were gifted by Dr T. Crompton (Imperial College, London, UK)261; and Rag1-/- Marilyn 
mice (H-2b, Mar) specific for I-Ab restricted dby608-622 peptide were gifted by Dr Di Scott 
(Imperial College, London, UK)123 .  
 
Table 2-1 Summary of T cell receptor transgenic strains 
 
A summary of animals used in this work is presented in Table 2.2. Mice weighed between 18-
22g at the time of their use for in vitro experiments and transplants. 
Genotyping and phenotyping of the mouse colonies was kindly performed by Mrs Margaret 
Negus, Mrs Jackie Higgins and Mrs Sylvia Rehakova. All animals were maintained in specific-
pathogen free facilities and fed standard rodent diets at Central Biomedical Services (CBS), 
University of Cambridge. Animals were cared for and all experimental procedures performed 
were approved by the United Kingdom Home Office under the Animal (Scientific Procedures) 
Act 1986. 
  
Transgenic 
CD4 T-cell 
TCR variable 
segments 
Epitope 
ABM261 Vα2, Vβ8 Recognition of intact I-Abm12 presenting undefined peptide 
TCR75162 Vα1.1, Vβ8.3 Recognition of peptide 54-68 (QEGPEYWEEQTQRAK) derived from class I 
H-2Kd in the context of class II MHC I-Ab 
TEa260 Vα2, Vβ6 Recognition of peptide 52-68 (ASFEAQGALANIAVDKA) derived from the 
class II I-Edα chain in the context of class II I-Ab 
Mar123 Vα1.1, Vβ6 Recognition of peptide 608-622 (NAGFNSNRANSSRSS) from H-Y minor 
histocompatibility antigen dby in the context of class II MHC I-Ab 
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Strain Description MHC I MHC II 
CD8 T 
cells 
CD4 T 
cells 
B 
cells 
C57BL/6 H-2b wild-type Kb Db Lnull I-Ab I-Enull + + + 
BALB/c H-2d wild-type Kd Dd Ld I-Ad I-Ed + + + 
CB6F1 H-2b x H-2d F1 cross K
bd Dbd Ld I-Abd       I-Ed + + + 
Tcrbd-/- TCR deficient C57BL/6 Kb Db Lnull I-Ab I-Enull - - + 
RAG2-/- 
B and T cell deficient 
C57BL/6 
Kb Db Lnull I-Ab I-Enull - - - 
Rag2IL2rg 
B, T and NK cell deficient 
C57BL/6 
Kb Db Lnull I-Ab I-Enull - - - 
B6.C-2bm12/ 
KhEg bm12) 
C57BL/6 mutant expressing 
I-Abm12 
Kb Db Lnull 
I-Abm12 I-
Enull 
+ + + 
B6.Kd 
C57BL/6 with Kd transgene Kbd Db 
Lnull 
I-Ab I-Enull + + + 
Bm12.Kd 
Bm12 with Kd transgene Kbd Db 
Lnull 
I-Abm12 I-
Enull 
+ + + 
ABOIE 
C57BL/6 with I-Ed transgene 
and I-Ab knockout 
Kb Db Lnull I-Anull I-Ed + + + 
Bm12.IE Bm12 x ABOIE F1 K
b Db Lnull I-Abm12 I-Ed + + + 
Bm12.Kd.IE 
Bm12.Kd x ABOIE F1 K
bd Db 
Lnull 
I-Abm12 I-Ed + + + 
Bm12.Kd.IE. 
DTR 
Bm12.Kd.IE expressing DTR 
under CD11c promoter 
Kbd Db 
Lnull 
I-Abm12 I-Ed + + + 
B6.DTR 
C57BL/6 expressing DTR 
under CD11c promoter 
Kb Db Lnull I-Ab I-Enull + + + 
BALB/c.DTR 
BALB/c expressing DTR 
under CD11c promoter 
Kd Dd Ld I-Ad I-Ed + + + 
Mar 
Rag2-/- TCR transgenic – 
recognising I-Ab restricted 
H-Y  
Kb Db Lnull I-Ab I-Enull - + - 
TEa 
Rag2-/- TCR transgenic – 
recognising I-Ab restricted I-
Ed  
Kb Db Lnull I-Ab I-Enull - + - 
TCR75 
Rag1-/- TCR transgenic – 
recognising I-Ab restricted Kd 
Kb Db Lnull I-Ab I-Enull - + - 
ABM 
Rag2-/- TCR transgenic – 
recognising I-Abm12 directly 
Kb Db Lnull I-Ab I-Enull - + - 
 
Table 2-2 Details of the murine strains used in this work 
‘+’ indicates presence and ‘-‘ absence of cell type 
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2.1.2 Murine heterotopic cardiac transplantation 
 
The technique used is based on that described originally by Corry and Russell in 1973 with 
some modifications262, 263. 
In this model the donor ascending aorta was anastomosed end-to-side to the recipient 
abdominal aorta and the donor pulmonary artery to the recipient inferior vena cava (IVC). The 
transplanted hearts function as aorto-caval shunts and do not contribute to the cardiac output 
of the recipient. Blood enters the donor ascending aorta retrogradely from the recipient 
abdominal aorta and is diverted into the coronary arteries by the closed, competent aortic 
valve. After the myocardium is perfused, venous blood drains into the right atrium through the 
coronary sinus and is pumped back through the donor pulmonary artery into the recipients IVC 
by the right ventricle (Figure 2.1). 
The procedure was carried out using an operating microscope (Carl Zeiss OPM11-FC or 
OPM16-CH, Germany) at magnifications of between 6x to 40x. Operating time was 
approximately 60 minutes and an operative mortality of less than 5%. 
 
 
Figure 2.1  Murine heterotopic cardiac transplant model. 
(from Hasegawa et al
263
) 
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2.1.3 Donor operation 
The donor was anaesthetised using a mixture of isoflurane and oxygen at 2 l/min administered 
via a nose cone. The animal was strapped to the operating board in the supine position using 
adhesive tape. 
The abdominal cavity was opened via a large midline incision and the abdominal viscera 
deflected to the left exposing the IVC. 100 IU of unfractionated Heparin (Leo Pharma A/S, 
Ballerup, Denmark) was injected into the IVC using a 1 ml syringe attached to a 25 gauge 
needle and the puncture gently closed with a cotton bud. After about 5 seconds the IVC and 
abdominal aorta were transected, exsanguinating the animal. 
The thoracic cavity was opened by dividing the diaphragm, cutting through the ribs along both 
sides of the thoracic spine up to the thoracic inlet and then across anteriorly to remove the 
entire anterolateral chest wall. The azygous vein, the superior vena cava (SVC) and IVC were 
ligated with silk ties and divided. 
The ascending aorta was divided proximal to the brachiocephalic artery. The main pulmonary 
artery was also divided just distal to its bifurcation. Fat and connective tissue between the 
aorta and pulmonary artery was carefully teased away at this stage. The pulmonary veins were 
ligated en-mass with a circular tie around the base of the heart. The donor heart was then 
detached from the posterior mediastinal structures by blunt dissection and placed in ice cold 
saline. 
2.1.4 Recipient operation 
 
The recipient mouse was weighed before being anaesthetised using a mixture of isoflurane 
and oxygen at 2 l/min. A subcutaneous injection of 0.1 ml Temgesic diluted in 0.5 ml 0.9% 
saline was given at the nape of the neck. The animal was taped to an operating table at 37oC in 
the supine position. 
A midline abdominal incision was made from the pubic symphysis to the xiphisternum and a 
self-retaining retractor was inserted to expose the abdominal cavity. The urinary bladder was 
emptied by gentle pressure using sterile cotton buds. 
Using cotton buds the intestines were gently deflected superiorly onto a piece of moistened 
sterile gauze on the anterior chest wall. They were covered with another strip of moist gauze. 
A small strip of connective tissue between the descending/left colon and the small bowel was 
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divided during this manoeuvre. The bladder and the internal genitalia were retracted 
downwards and covered with moist sterile gauze. Moisture was maintained throughout the 
procedure by periodic irrigation with warm saline. 
Using two cotton buds the abdominal aorta and IVC were dissected free from the 
retroperitoneal connective tissue overlying the psoas muscles on both sides. The lumbar veins 
running in the posterior midline from the IVC between the renal vessels and the bifurcation 
were exposed and ligated using 7-0 vicrylTM to obtain adequate length for the application of 
the vascular clamps later. 
The connective tissue overlying the great vessels was removed by a combination of blunt and 
sharp dissection. In the male, the gonadal vessels were dissected laterally at this point. 
Non crushing clamps were applied across the great vessels just distal to the renal vessels and 
proximal to the bifurcation of the great vessels. The IVC was emptied via a venotomy using a 
30G needle which was then used to make the arteriotomy, taking care not to damage the 
posterior wall. The arteriotomy was extended using micro-scissors to match the diameter of 
the donor aorta. The lumen was flushed with saline to remove any thrombi. 
The donor heart was placed into the recipients abdomen with the remnant of the ascending 
aorta lying to the left, the base cranially and the left atrium caudally. Two stay sutures were 
placed anchoring the cranial and caudal ends of the donor ascending and recipient descending 
aorta. The lower one was used to construct a continuous end to side anastomosis in a counter-
clockwise direction. This was done using a 10-0 nylon BearTM surgical suture on a round bodied 
4mm (3/8) needle (Bear Medic Corp., Tokyo, Japan). The heart was turned over to the right 
side when suturing the second wall, and constantly kept cool under a swab soaked with ice 
cold saline. 
The venotomy was now extended to lie parallel but at a more caudal level in relation to the 
arteriotomy. The donor pulmonary artery was anastomosed to the recipient IVC in a similar 
manner using the same 10-0 sutures. The sutures were kept lax to prevent purse-stringing and 
constriction of the anastomosis. 
Cut pieces of the moistened haemostatic agent SurgicelTM were placed around both 
anastomoses. The distal clamp was removed first to check the competency of the PA – IVC 
anastomosis. Once satisfactory, the proximal clamp was gently removed a few seconds later 
while applying pressure on the descending aorta with a cotton bud. This was gradually 
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withdrawn allowing distal blood flow and perfusion of the heart, any transient bleeding being 
controlled by gentle pressure with cotton buds. 
Satisfactory perfusion was indicated by a bright red donor heart displaying strong and 
rhythmic contractions. Warm saline was infused into the peritoneal cavity and the viscera 
were replaced. The abdominal muscle and skin were closed in two layers of continuous 5-0 
vivrylTM sutures. 
The cold ischaemia time (i.e. the duration from placement of the heart in ice cold saline to the 
transfer to the abdominal cavity) was approximately 20 minutes. 
 
2.1.5 Recovery 
 
On completion of the procedure, the recipient was placed in an incubator at 28oC on soft dry 
bedding material. Recovery took about half-an-hour and the mice were checked for hind limb 
paralysis. If this was present they were killed immediately. Food and water were provided, and 
animals remained in the incubator overnight. 
Grafts were assessed by abdominal palpation and rejection defined as the complete cessation 
of a palpable contraction.  
 
2.1.6 Skin transplantation 
 
Sterile techniques were maintained throughout. Full thickness tail skin was obtained from 
sacrificed donor animals, cut to 1 cm2 and place in cold (4°C) saline. Recipient animal 
anaesthesia was induced and maintained with inhalational isoflurane, subcutaneous analgesia 
(Temgesic) was given and the animals placed prone on a heated (37°C) operating board. 
Forceps were used to lift the skin of the upper dorsum to allow a 1cm2 area of skin to be 
removed in a single cut and the donor skin was laid over the defect. The donor skin was 
sutured to the recipients back with eight simple 5/0 sutures.  The animal was placed in a 28°C 
incubator until recovery was complete. Rejection was defined as loss of skin graft at least two 
days post transplantation; loss of skin graft within 48 hours of grafting was defined as a 
technical failure.   
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2.1.7 Delivery of cells and antibodies 
2.1.7.1 Intravenous (i.v.) injection 
 
Where required, populations of lymphocytes or monoclonal antibodies were suspended in 
100-200 µl Hartmann’s solution (Animalcare Ltd, York, UK) and injected intravenously (i.v.) via 
the tail vein. Prior to injection, animals were placed in an incubator (37°C) for 10 minutes until 
veins were prominent.  
2.1.7.2 Intraperitoneal (i.p.) injection 
 
For some experiments, monoclonal antibodies or diphtheria toxin were suspended in 300 µl 
Hartmann’s solution and injected intraperitoneally (i.p.). 
 
2.1.8 Generation of bone-marrow chimeras 
2.1.8.1 C57BL/6 x B6.DTR chimeras 
 
To restrict expression of the DTR gene to haematopoietic lineage, C57BL/6 x B6.DTR bone-
marrow chimeric mice were generated. C57BL/6 mice were lethally irradiated (13 Gy in two 
divided doses 3 hours apart) using a Caesium-137 source and reconstituted i.v. with 2x107 
B6.DTR bone marrow cells intravenously. Chimerism and DTR expression were confirmed by 
flow cytometric analysis and PCR of peripheral blood lymphocytes respectively (Figure 2.2a,b) 
at least 4 weeks after reconstitution.  
2.1.8.2 Bm12.IE x Bm12.Kd.IE chimeras 
 
To restrict expression of MHC class I H-2Kd to haematopoietic lineage, bm12.IE x bm12.Kd.IE 
bone-marrow chimeric mice were generated. BM12.IE mice were lethally irradiated (13 Gy in 
two divided doses 3 hours apart) using a Caesium-137 source and reconstituted i.v. with 2x107 
bm12.Kd.IE bone marrow cells intravenously. Chimerism and haematopoietic H-2Kd expression 
were confirmed by flow cytometric analysis of peripheral blood lymphocytes (Figure 2.2c,d) at 
least 4 weeks after reconstitution.  
All chimeric animals were closely monitored and were sacrificed if severe signs of irradiation 
illness manifested. 
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Figure 2.2 Confirmation of bone marrow chimeric status prior to use in experiments 
(a) C57BL/6 x B6.DTR chimeric status was confirmed by demonstrating reconstitution of peripheral blood with 
lymphocyte populations 6 weeks following bone marrow transfer by flow cytometry. (b) Expression of the 
diphtheria toxin receptor was confirmed by PCR (performed by S Rehakova). (c) bm12.IE x bm12.Kd.IE chimeric 
status was confirmed by demonstrating peripheral blood reconstitution as above. (d) Acquisition of MHC class I H-
2K
d
 expression (expressed by bm12.Kd.IE bone marrow donors but not expressed by bm12.IE bone marrow 
recipients) was confirmed by flow cytometry of peripheral blood lymphocytes. 
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2.1.9 Leukocyte depletion and co-stimulation blockade 
 
2.1.9.1 Treatment protocol for depletion of dendritic cells (DC) 
 
Donor DC depletion 
Donor mice expressing the DTR gene under the CD11c promoter were injected i.p. with 
10ng/mg diphtheria toxin (Quadratech Diagnostics Ltd, Epsom, UK) daily for seven days prior 
to the procurement of their hearts. The extent of depletion of DCs was measured by flow 
cytometry using the donor spleen on the day of retrieval. 
Recipient DC depletion 
C57BL/6 x B6.DTR bone marrow chimeras (Section 2.1.8.1) were used as recipients when 
depleting recipient DCs with diphtheria toxin due to the systemic effects experienced in non-
chimeric diphtheria toxin sensitive mice257, 264. Mice were injected i.p. with 10g/mg diphtheria 
toxin (Quadratech Diagnostics Ltd, Epsom, UK) either i) daily for the seven days prior to 
transplantation and subsequently twice a week thereafter, or ii) daily for seven days, four 
weeks after transplantation and subsequently twice a week thereafter. The extent of DC 
depletion was measured by flow cytometry using splenocytes upon animal sacrifice. 
 
2.1.9.2 Treatment protocol for depletion of Natural Killer (NK) cells 
Donor and/or recipient mice were injected i.p. with 0.5 mg anti-NK1.1-depleting monoclonal 
antibody (mouse 1gG2a, clone PK13 – hybridoma) (ATCC-LGC Standards Parnership, 
Middlesex, UK) in 300 µl Hartmann’s solution on days -2, 0 and +2 in relation to cardiac 
transplantation and weekly thereafter. Depletion of NK cells was confirmed by flow cytometry 
using splenocytes upon animal sacrifice for harvest of experimental tissues. 
 
2.1.9.3 Treatment protocol for depletion of CD4 T cells 
Donor mice were injected i.p. with two doses of depleting anti-CD4 mAb (1.0mg each dose; 
2mg total) (YTS 191.1; European Collection of Animal Cell Cultures, Salisbury, UK) five and one 
day prior to procurement of their hearts. Depletion of CD4 T cells was confirmed by flow 
cytometry using peripheral blood lymphocytes (PBLs) the day before heart retrieval. In 
addition, depletion of CD4 T cells in the spleen and other tissues was confirmed by flow 
cytometry on the day of retrieval. 
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2.1.9.4  Treatment protocol for depletion of B cells 
Mice were injected i.p. with a single dose of 250μg depleting anti-murine CD20 mAb (18B12 
(pEAG2948/TOC262), IgG1 gifted by Cherie Butts at Biogen Idec Boston MA, US) seven days 
prior to requiring B cell depletion265. Depletion of B cells was confirmed by flow cytometry 
using peripheral blood lymphocytes and spleen of treated animals on the day of sacrifice. 
 
2.1.9.5 Treatment protocol for depletion of macrophages 
Mice were injected i.p. with 1mg of liposomal clodrinate (purchased from Prof van Rooijen: 
www.clodrinateliposomes.org266-269) seven and three days prior to transplantation. Efficacy of 
depletion was confirmed by flow cytometry using peripheral blood lymphocytes and spleens of 
treated animals on the day of sacrifice. 
 
2.1.9.6 Treatment protocol for co-stimulation blockade 
Mice were injected i.p. with 500μg anti-CD154 mAb (clone MR-1; BE0017-1; Bio X Cell West 
Lebanon, NH, US) on days -2, 0, 2 and 4 in relation to transplantation. 
 
2.1.10 Collection of blood 
 
Animals were pre-warmed at 37°C for 10 min to dilate tail veins. Approximately 20-30µl of 
blood was collected from the superficial tail vein of animals. When required, up to 1mL of 
blood could be obtained from animals at the time of sacrifice by direct cardiac puncture under 
terminal anaesthetic. In the case that peripheral blood lymphocytes were required, the tubes 
were pre-coated with heparin. 
 
To collect serum from non-heparinised blood, samples were stored overnight at 4oC to 
encourage clot formation. After one cycle of micro-centrifugation (14,000 revolutions per 
minute for 7 minutes), serum was aspirated and samples were aliquoted. All serum samples 
were heated at 56°C for 30 minutes in order to inactivate complement and stored at -20°C 
until analysed.  
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2.2 Cell Preparations and culture 
 
All cell preparation and culture procedures were performed in a Microflow SE laminar flow 
hood (BIOQUELL, Andover, Hampshire, UK) with Roswell Park Memorial Institute (RPMI) 1640 
tissue culture medium (GibcoTM, Invitrogen, Paisley, UK), containing heat inactivated 10% 
foetal calf serum (FCS) (Biowest Ltd, Ringmer, East Sussex, UK), 2mM L-glutamine, 100 IU/ml 
penicillin, 100μg/ml streptomycin and 2-ME (2-mercapto-ethanol) unless stated otherwise. 
Centrifugation was performed in a Howe 6K10 Centrifuge (Sigma Laboratory Centrifuges 
GmbH, Osterode am Harz, Germany) at 200g for 7 minutes at 4oC, unless otherwise stated. 
Cells were counted with a Neubauer chamber (Hawksley, Lancing, Sussex, UK). 
2.2.1 Cell preparations 
2.2.1.1 Single cell preparation from spleen 
 
Spleens were harvested from sacrificed mice, mashed and teased through a 40μm nylon cell 
strainer (Becton Dickinson, Franklin Lakes, NJ, USA) with the rubber end of a 1 mL syringe 
plunger. The cells were washed with medium, centrifuged and re-suspended as a single cell 
suspension in an appropriate volume of medium.   
 
2.2.1.2 Single cell preparation from bone marrow 
 
Tibias and femurs were dissected from sacrificed animals. The marrow was flushed out with 
HBBS, and teased through a 40µm nylon cell strainer, as above. 
 
2.2.1.3 Peripheral blood lymphocytes (PBLs) 
 
Heparinised blood was diluted five-fold with 0.17M ammonium chloride for 5 minutes at room 
temperature (RT) to lyse erythrocytes and then centrifuged at 3000 rpm for 5 minutes. 
Supernatant was subsequently aspirated by a fine pipette, and the cell pellet re-suspended 
with medium. 
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2.2.1.4 Cell isolation from heart tissue 
 
Hearts were cut in half and rinsed with HEPES buffered Dulbecco modified Eagle medium 
(DMEM) (Gibco®, Life technologies Ltd.) to remove all blood and blood clots. The tissue was 
dissected into 1-2mm pieces, transferred to a 5ml bijou and incubated in a 37°C water bath for 
30 minutes with sufficient Collagenase Digestion mix (1mg/ml Collagenase A [Roche, USA], 
1mg/ml DNAse1 [Roche, USA] and 2% FCS [Sigma] in DMEM) to cover the tissue. The resulting 
suspension was teased through a 40µm nylon strainer and incubated for a further 15 minutes. 
To stop the action of collagenase, the suspension was re-suspended in 50ml ice cold working 
medium containing 2-mercaptoethanol (2-ME) (10% FCS, 100IU/ml penicillin-streptomycin 
[Sigma-Aldrich Inc.], 2mM L-Glutamine [Sigma-Aldrich Inc.] and 0.05mM 2ME [Sigma-Aldrich 
Inc.] in DMEM) and centrifuged. Cells were washed with 50ml DMEM, and digested further 
with 3ml Trypsin/EDTA (Sigma-Aldrich Inc.) in a 37°C water bath for 10 minutes. The reaction 
was stopped with 50ml ice cold working medium, and the cells were passed through a 40µm 
nylon cell strainer to remove any remaining undigested tissue.  
 
2.2.1.5 Cell subset enrichment using magnetic cell sorting 
 
Single cell suspensions were re-suspended in MACS buffer (PBS + 0.5% BSA + 2mM EDTA 
+0.09% azide) and incubated at 4oC for 15 minutes with antibody coated magnetic microbeads 
(Miltenyi Biotec, Bergisch, Germany) at 10 μl per 107 cells as per the manufacturers 
instruction.  
Cells were washed, re-suspended in MACS buffer and the appropriate cell subset enriched by 
positive and negative selection using an AutoMACSTM (Mitenyi Biotec, Bergisch, Germany) 
separator. The cells were counted and re-suspended in culture medium. 
 
2.2.1.6 Carboxyfluorescein diacetate succinimidyl ester (CFSE) labelling of splenocytes 
 
Single cell suspensions of splenocytes were re-suspended in PBS + 5% FCS at a concentration of 
1 x107 cells per ml. A 10μl aliquot of CFSE [10mM] (Invitrogen, Paisley, UK) was diluted in an 
equal volume of PBS + 5% FCS. 2μl of this was added per 1 ml cell suspension and rapidly 
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mixed before incubation for 5 minutes at room temperature in the dark, with occasional 
agitation. At the end of this period the cells were washed thrice in 20ml of PBS + 5% FCS and 
reconstituted in an appropriate volume of 0.9% normal saline for adoptive transfer following 
counting270. 
 
2.2.2 Cell culture 
 
2.2.2.1 Murine bone marrow dendritic cell (BMDC) culture 
 
The method used was based on previously described protocols271, 272. Bone marrow was 
flushed with RPMI medium from the femurs and tibias, passed through a 40 μm nylon cell 
strainer and centrifuged at 300g for 7 minutes. The cells were re-suspended at a concentration 
of 1.5 x 106 cells/ml in full culture medium supplemented with murine granulocyte-
macrophage colony stimulating factor (GM-CSF) (Peprotech Ltd, UK) at 10 ng/ml and 
recombinant murine IL-4 (Peprotech Ltd, UK) at 10 ng/ml. The suspension was distributed into 
flat bottom 6 well cell culture plates (Corning Incorporated, NY, USA) at 3 ml/well. The plates 
were incubated in a 5% CO2-air mix at 37
oC in a SANYO MCO-17AI CO2 incubator (SANYO 
Electric Corp, Japan).  
 
On day 2, 3 ml of fresh GM-CSF and IL-4 supplemented culture medium was added to each 
well. On the 4th day, non-adherent cells were washed off and 3 ml of fresh GM-CSF and IL-4 
supplemented culture medium was added. On the 6th day a further 3 ml of the culture medium 
- without IL-4 - was added to each well. The DCs were removed from the plates with a cell 
scraper on day 8, re-suspended in medium and counted. 
 
2.2.2.2 Murine endothelial cell culture 
 
Ten to fourteen day-old neonatal hearts were obtained and cells isolated as described in 
Section 2.2.1.4. Cells were re-suspended in MACS buffer and incubated with biotinylated 
monoclonal antibodies against endothelial cell markers: CD31, CD105 and Isolectin B4. After 
incubation, endothelial cells were enriched using anti-biotin magnetic Microbeads using an 
autoMACS separator as described above. The resultant cells were cultured in tissue culture 
flasks (NuncTM, Thermo Scientific Ltd.), pre-coated with 1% Gelatin (Sigma-Aldrich Inc.) in PBS, 
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and cultured in growth medium (Hepes buffered DMEM with 10% FCS, 100IU/ml penicillin-
streptomycin, 2mM L-Glutamine) overnight. Non-adherent cells were washed away, and 
Endothelial Cell Growth Factor (E9640, Sigma-Aldrich Inc. St Louis, MO) added to the culture 
medium. Cells were passaged by incubation with Trypsin-EDTA Solution at 37°C, until cells 
were visibly detached under low power magnification. 
 
2.2.2.3 Murine regulatory CD4 T cell culture 
 
Ninety-six well, U-bottomed, cell culture plates (Corning Incorporated, NY, USA) were coated 
with anti-CD3 monoclonal antibody (Clone 145-2C11, BD Pharmingen, CA, USA) at 1μg/ml in 
bicarbonate buffer, incubating in a humidified chamber for 2 hours in a 5% CO2-air mix at 37
oC 
in a SANYO MCO-17AI CO2 incubator (SANYO Electric Corp, Japan). After incubation, the plates 
were washed 4 times with culture medium.  
CD4 T cells were positively selected with anti-CD4 MicroBeads using an autoMACS separator as 
described in above. 1.5x105 CD4 T cells were distributed into each well of the 96 well plate at a 
final volume of 200μl of full medium supplemented with IL-2 at a concentration of 2ng/ml (Life 
technologies, CA, USA), and TGF-β at a concentration of 5ng/ml (eBioscience, CA, USA). The 
plates were incubated in a humidified chamber for 5 days in a 5% CO2-air mix at 37
oC as above. 
After five days, regulatory T cell phenotype was confirmed by flow cytometry, staining for 
expression of CD25 and FOXP3 as detailed below. 
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2.3 Antibody quantification 
 
2.3.1 Determining circulating anti MHC class I antibody—H-2Kd by ELISA 
 
Serum samples were collected from experimental animals weekly and analysed for the 
presence of anti-H-2Kd IgG alloantibody by enzyme linked immunoabsorbent assay (ELISA).  
Ninety-six well ELISA plates (Immulon 4HBX; Thermo, Milford, MA) were coated with 
recombinant conformational H-2Kd (generated in house) at 5μg/ml in Na2CO3-NaHCO3 buffer 
(pH 9.6) and incubated overnight at 4oC. Non-specific binding sites were blocked with 1% 
Marvel dried skimmed milk powder (Premier International Foods, UK) in PBS (hereafter 
referred to as ‘Marvel’) at 200 µl/well for 2 hours at 37°C. After washing (x6 with 0.05% tween 
20 [Sigma, Poole, UK] in PBS throughout), samples were diluted 1:9 in Marvel and 50 µl/well 
added. Serial tripling dilutions were carried out down the remaining 8 rows of the plate, and 
the plate incubated at 37°C for 1 hour. After washing, 50 µl/well biotinylated Rabbit F(ab’)2 
anti-mouse IgG (STAR11B, AbD Serotec, Oxford, UK) at 1 µg/ml in Marvel was added and 
incubated at 37°C for 1 hour. After washing, 50 µl/well ExtrAvidin peroxidase conjugate 
(Sigma, Poole, UK) at 1 µg/ml in Marvel was added and incubated at room temperature (RT) 
for 1 hour. Plates were washed and 3,3’, 5,5’-tetramethylbenzidene (TMB) microwell 
peroxidise substrate (Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA) was added. 
Colour was developed for 5 minutes and the reaction stopped by the addition of 0.2 M H2SO4. 
Absorbance at 450nm was measured on a FLUOstar OPTIMA plate reader (BMG Labtech, 
Aylesbury, UK). For each sample, an absorbance versus dilution curve was plotted, and the 
area under the curve was calculated273. The AUC was then calculated as a percentage of the 
AUC of a standard of serial diluted pooled hyperimmune sera (sera pooled from C57BL/6 
recipients of BALB/c cardiac allografts collected at week 5 post-transplant. Pooled serum from 
naïve C57BL/6 mice was used as a negative control). AUC percentages were normalised 
between plates by using an identical positive control on each plate. 
 
2.3.2 Determining circulating anti MHC class II antibody— I-E by flow cytometry 
 
Serum samples were collected from experimental animals weekly and analysed for an I-E 
alloantibody responses, using flow cytometry. Samples were diluted 1:9 in FACS buffer (1 
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µg/ml BSA [Sigma, Poole, UK] + 10 µl/ml 10% Azide [Sigma, Poole, UK] in PBS), 50 µl/well 
added to a 96-well U-bottomed plate (BD, Franklin Lakes, NJ, USA) and serial tripling dilutions 
carried out down the remaining 8 rows of the plate. BMDCs were cultured from ABOIE animals 
(as in Section 2.2.2.1). Upon harvest, BMDCs were blocked with anti-mouse CD16/CD32 (clone 
2.4G2; BD Pharmingen, San Diego, CA, USA) at 5 µl/ml in FACS buffer for 30 minutes. The cells 
were washed and counted. BMDCs were then re-suspended at 1 x 107 cell/ml in FACS buffer 
and 50 µl transferred to each well of the plate, and incubated at 4°C for 30 minutes. The plate 
was washed twice by addition of 150 µl/well FACS buffer, centrifuged at 1200 rpm for 4 
minutes, the supernatant discarded and cells re-suspended. Bound alloantibody was detected 
with 50 µl FITC-conjugated anti-mouse IgG mAb (STAR 70; Serotec, Oxfordshire, UK) at 10 
µmg/ml in FACS buffer, and incubated for a further 30 minutes at 4°C. The plate was washed 
as above and the cells re-suspended. Cells contained within each well were then processed by 
flow cytometry, gating on the DC population and presenting as a histogram of FITC 
fluorescence. The geometric mean-channel fluorescence was obtained, and plotted against 
dilution, and the AUC was obtained and results analysed as above, against the same 
hyperimmune positive control.  This approach, rather than ELISA, was adopted due to the 
unavailability of conformational MHC class II I-E during these studies. 
 
2.3.3 Determining circulating antinuclear autoantibody by HEp-2 indirect 
immunofluorescence 
 
The presence of antinuclear autoantibodies (ANA) was determined by HEp-2 indirect 
immunofluorescence (The Binding Site, Birmingham, UK). HEp-2 binding has been used 
traditionally for detecting autoimmune responses in human patients, but mouse autoantibody 
also binds to the target nuclear antigens, and this technique has been validated for this 
purpose274. 
Serum samples were diluted 1 in 10 in PBS and incubated for 30 minutes on slides coated with 
HEp-2 cells. Bound autoantibody was then detected with FITC-conjugated goat anti-mouse IgG 
(STAR70; AbD Serotec, Oxford, UK). Monospecific positive and negative pre-diluted controls 
were used according to the manufacturers instruction. Pooled sera from naïve C57BL/6 
animals were used as an additional negative control. Serial two-fold dilutions (1 in 10 to 1 in 
2560) of sera from TCRKO mice injected i.v. with 5x106 purified bm12 CD4 T cells, which 
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develop augmented antinuclear antibody responses274, were used to generate a standard 
curve (Figure 2.3). 
For each sample, four random photomicrographs were taken and the intensity of staining 
determined by morphometric analysis using MetaMorph software (Molecular Devices, 
Downingtown, PA, USA). The fluorescence intensity was then determined relative to a 
standard curve of serially diluted pooled hyperimmune serum that was assigned an arbitrary 
value of 1000 fluorescence units for the 1 in 10 dilution, 500 units for the 1 in 20 dilution and 
so on274. 
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Figure 2.3 A representative example of a HEp-2 standard dilution curve 
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2.4 B cell H-2Kd ELISPOT 
 
96-well MultiScreen® Filter Plates (Merck Millipore) were coated with recombinant 
conformational H-2Kd (generated in house) at 5μg/ml in Na2CO3-NaHCO3 buffer (pH 9.6) at 4°C 
overnight. Excess binding sites on the plates were blocked with 0.5% BSA in PBS (Blocking 
buffer) at 37°C for 1 hour, followed by five washes with sterile PBS, and one wash with ELISPOT 
culture medium (10% FCS, 1% penicillin-streptomycin + 2mM L-Glutamine and 0.05mM 2-
mercaptoethanol [2ME; Sigma-Aldrich Inc] in RPMI culture medium [Gibco®, Life Technologies 
Ltd.]). 
Single cell suspensions from spleen and bone marrow were re-suspended in culture medium as 
described above and added to the plate in triplicates of 1 x 106, 1 x 105 and 1 x 104 cells per 
well. Precautions were taken to ensure sterility during this stage. The plates were incubated 
undisturbed for 20 hours at 37°C in 5% CO2 in a humidified chamber.  
Plates were washed ten times with 0.05% Tween in PBS. Bound antibodies were detected with 
biotinylated Rabbit F(ab’)2 anti-mouse IgG (STAR11B, AbD Serotec, Bio-Rad Laboratories Inc.) 
followed by ExtrAvidin Peroxidase conjugate (Sigma-Aldrich Inc.) diluted at 1:1000 
concentration in Blocking buffer. Each incubation was performed at 37°C for 2 hours and the 
plates washed six times after each step. 
For development of spots, 5mg of AEC (Sigma-Aldrich Inc.) dissolved in 2.5ml 
dimethylformamide (Sigma-Aldrich Inc.) was added to 10 ml 0.05 M Sodium acetate buffer 
(pH5.0). The solution was filtered through a 0.45µm filter (Sartorius Stedim Biotech) and mixed 
with Hydrogen peroxide solution (Sigma-Aldrich Inc.) (0.3%). Plates were incubated with the 
developing solution for 15-45 min in the dark at room temperature, until spots were visible in 
wells carrying the positive control with the naked eye. The plate was washed three times with 
distilled water and left to dry in the dark before being read on an AIDTM Elispot Reader 
version 3.5 (Autoimmun Dignostika, Strasberg, Germany). Data was expressed as mean 
number of responders per 106 cells. 
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2.5 CD8 ELISPOT 
 
96-well MultiScreen® Filter Plates (Merck Millipore) were coated with anti-IFNγ monoclonal 
antibody (Clone RA-6A2, BD Bioscience) at 10μg/ml in Na2CO3-NaHCO3 buffer (pH 9.6) at 4°C 
overnight. Excess binding sites on the plates were blocked with 0.5% BSA in PBS (Blocking 
buffer) at 37°C for 1 hour, followed by five washes with sterile PBS, and one wash with ELISPOT 
culture medium (10% FCS, 1% penicillin-streptomycin + 2mM L-Glutamine and 0.05mM 2-
mercaptoethanol [2ME; Sigma-Aldrich Inc] in RPMI culture medium [Gibco®, Life Technologies 
Ltd.]). 
CD8 T cells from the spleens of recipient mice were purified from single cell suspensions of 
splenocytes using anti-CD8a (Ly-2) coated magnetic microbeads (Miltenyi Biotec, Bergisch 
Gladbach, Germany) as per the manufacturer’s instructions. 2 x105 of these purified 
(responder) CD8 T cells were added to each well in triplicate. 8 x105 donor strain whole 
splenocytes (irradiated at 2000 rads) were also added to each well as stimulators. The plates 
were incubated undisturbed for 20 hours at 37°C in 5% CO2 in a humidified chamber.  
Plates were washed ten times with 0.05% Tween in PBS. Bound IFNγ was detected with a 
biotinylated anti-IFNγ monoclonal antibody (clone XMG1.2, BD Bioscience. [The recommended 
matched pair with the capture antibody]) at 40μg/ml, followed by ExtrAvidin Peroxidase 
conjugate (Sigma-Aldrich Inc.) diluted at 1:1000 concentration in Blocking buffer. Each 
incubation was performed at 37°C for 2 hours and the plates washed six times after each step. 
For development of spots, 5mg of AEC (Sigma-Aldrich Inc.) dissolved in 2.5ml 
dimethylformamide (Sigma-Aldrich Inc.) was added to 10 ml 0.05 M Sodium acetate buffer 
(pH5.0). The solution was filtered through a 0.45µm filter (Sartorius Stedim Biotech) and mixed 
with Hydrogen peroxide solution (Sigma-Aldrich Inc.) (0.3%). Plates were incubated with the 
developing solution for 15-45 min in the dark at room temperature, till spots were visible in 
wells carrying the positive control with the naked eye. The plate was washed three times with 
distilled water and left to dry in the dark before being read on an AIDTM Elispot Reader 
version 3.5 (Autoimmun Dignostika, Strasberg, Germany). Data was expressed as mean 
number of spot counts for the triplicate wells, per 106 responder CD8 T cells. 
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2.6 Flow cytometry 
 
All antibodies used in flow cytometry are detailed in Table 2.3.  Prior to analysis, cells were 
transferred to flow cytometry tubes (BD Falcon, Franklin Lakes, NJ, USA). Samples were 
analysed on a FACS CantoTM II using FACS Diva software (BD Biosciences, San Jose, CA). 
 
2.6.1 Surface antigen staining 
 
Flow cytometry was carried out using a minimum of 2-5 x 105 target cells per well in 96-well U-
bottomed plates (BD Falcon, Franklin Lakes, NJ, USA). Single cell suspensions in FACS buffer 
(100 μL/well of PBS with 0.1% BSA, 0.1% sodium azide) were added to the plates. The cells 
were blocked with anti-CD16/CD32 (FcRγ II/III, clone 2.4G2, BD Pharmingen, San Diego, CA) at 
a 1:200 dilution for 30 minutes to prevent non-specific antibody binding via cellular Fc 
receptors. All incubations with primary and secondary monoclonal antibodies were performed 
on ice and in the dark for 30 minutes, with two washes in FACS buffer between each step. Cell 
membrane of nonviable cells can trap fluorescent reagents, and therefore, 7-amino-
actinomycin D (7-AAD) was routinely added to label dead cells dead cells which were excluded 
from the analysis. Control cells stained with each fluorescent antibody separately were used as 
single stain compensation controls to calculate any spectral overlap and calibrate the 
compensation gating for each fluorochrome.  
 
2.6.2 Intracellular antigen staining 
 
Single cell suspensions in FACS buffer were obtained and Fc receptors blocked with anti-
CD16/CD32 as above at a 1:200 dilution for 30 minutes in 96 well U-bottomed plates on ice in 
the dark. Cells were then washed twice in PBS. 100μL fixable viability dye at 1/1000 
concentration in PBS, was added to each well to stain dead cells and was incubated for 30 
minutes (Fixable viability dye eFluor® 780, eBioscience, SanDiego, CA). Cells were washed 
twice in FACS buffer. Primary (and if necessary secondary) monoclonal antibodies against 
surface antigens were added and incubated for 30 minutes. Cells were washed twice in FACS 
buffer. Cells were fixed and permeabilised using the BD Cytofix/cytopermTM 
fixation/permeabilisation kit (BD biosciences, San Jose, CA) as per the manufacturers 
instructions. 100 ml of fixation/permeabilisation solution was added to thoroughly 
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resuspended cells and incubated for 20 minutes. Cells were then washed in BD Perm/WashTM 
solution from the kit. Monoclonal antibodies against intracellular antigens diluted in BD 
Perm/WashTM solution were added and cells incubated for 30 minutes. Cells were washed 
twice more with BD Perm/WashTM solution, and finally re-suspended in FACS buffer and 
analysed.  
 
2.6.3 TrucountTM cell quantification 
 
Single cell suspensions of splenocytes were re-suspended in a known volume of culture 
medium. An aliquot of defined volume was sampled for surface antigen staining as described 
above. Upon completion of staining, samples were transferred to TrucountTM tubes (BD 
Biosciences, San Jose, CA) containing a known number of fluorescent beads, and all events 
recorded. Gates were positioned around the bead and cell populations of interest, and cell 
number in the original sample calculated: 
 
 
2.6.4 Quantification of CFSE labelled CD4 T cell proliferation 
 
Proliferation of CFSE labelled CD4 T cells (Section 2.2.1.6) was quantified using FlowJo™ (Tree 
Star, Oregon) flow cytometry analysis software. Upon cell division, the relative fluorescence 
intensity of CFSE in the daughter population is approximately half that of the parent. 
Therefore, upon division, a series of peaks is generated on a FITC channel histogram (Figure 
2.4). FlowJo™ uses a non-linear curve-fitting algorithm to quantify proliferation and report a 
series of statistics. First, it models a Gaussian distribution at the highest fluorescence intensity 
peak (the parent population). By halving the fluorescence intensity, the daughter population 
distributions can be modelled, and this model is iterated until no further improvement in the 
model can be achieved to fit the data. Manual adjustments in defining the position of the 
parent peak can be made, and the results were taken for the position with the best quality of 
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fit to the data, as defined by the lowest Root Mean Square value. The statistic used to compare 
proliferation in this work is the ‘percent divided’ which represents the percentage of cells from 
the original sample that have undergone division270, 275.  In all experiments where CFSE labelled 
transgenic CD4 T cells were transferred to experimental animals, cells were also transferred to 
a naïve C57BL/6 mouse as a negative control to confirm that any proliferation was consequent 
upon exposure to alloantigen due to the challenge presented to the experimental mice. 
 
 
Figure 2.4  Representative histogram of T cell proliferation 
Live CD4 T cells of interest gated and histogram against FITC fluorescence plotted to show CFSE dilution. 
Each peak to the left of the parent population on the far right represents daughter population peaks. 
Extent of proliferation is then quantified on FlowJo
TM
 software. 
 
2.6.5 Staining with MHC class II tetramer to identify antigen specific CD4 T cells 
 
MHC class II I-Ab tetramers presenting peptide from the MHC class I H-2Kd [peptide 54-68 
(QEGPEYWEEQTQRAK)], MHC class II I-Ed [52-68 (ASFEAQGALANIAVDKA)] and control human 
CLIP (Class II-associated invariant chain peptide) [peptide 87-101 
(PVSKMRMATPLLMQA)]  conjugated to PE, were kindly gifted by the NIH Tetramer facility, 
Atlanta, GA. Whole spleen single cell suspensions in FACS buffer were obtained and Fc 
receptors blocked with anti-CD16/CD32 (FcRγ II/III, clone 2.4G2, BD Pharmingen, San Diego, 
CA) at a 1:200 dilution for 30 minutes in Falcon tubes. PE-conjugated tetramer was added at a 
concentration of 1:250 and cells incubated for 1 hour at 37oC. Subsequently the cells were 
washed and re-suspended in MACS buffer (PBS + 0.5% BSA + 2mM EDTA +0.09% azide). To 
enrich the tetramer bound cells, the single cell suspension was incubated with anti-PE 
magnetic MicroBeads (Miltenyi Biotec, Bergisch, Germany) as above. The PE labeled, and thus 
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tetramer bound cells, were extracted by positive selection using the program POSSEL on an 
AutoMACSTM (Miltenyi Biotech) separator. The enriched fraction was then washed and re-
suspended in FACS buffer. The cells were then stained with flurochrome-labeled monoclonal 
antibodies specific for cell surface antigens CD19, CD4, CD11b, CD11c and CD8, and 7-AAD for 
dead cell exclusion, and incubated for 30 minutes at 4oC as in Section 2.6.1. Cells were washed 
twice more in FACS buffer and analysed.  
 
2.6.6  Regulatory CD4 T cell suppression assay 
 
To examine the ability of regulatory T cells (Treg) to exhibit regulatory behaviour, suppression 
assays were performed as described by Collison et al.276. 
Naïve C57BL/6 CD4 T cells were positively selected with anti-CD4 MicroBeads using an 
autoMACS separator as described above, and labelled with CFSE (Section 2.2.1.6). 2.5x104 CFSE 
labelled CD4 T cells were distributed into each well of a 96 well plate at a final volume of 200μl 
of full medium supplemented with 1mM sodium pyruvate (Life technologies, CA, US), 5mM 
HEPES (Life technologies, CA, US) and 100mM non-essential amino acids (Life technologies, CA, 
US). CD3/CD28 CD4 T cell activating Dynabeads® were added to each well at a 1:1 ratio with 
the naïve CD4 T cells to induce proliferation (Figure 2.5) as per the manufacturers instruction 
(Life technologies, CA, US). Into column 12 of the 96 well plate 1.25x104 cultured Treg were 
added to each well (representing a 1 Treg to 2 naïve CD4 T cell ratio). A 2-fold serial dilution 
was performed along the plate (Figure 2.6). Positive (Naïve CD4 T cell + Dynabead® only) and 
negative (Naïve CD4 T cell only) control columns were used. Plates were incubated in a 
humidified chamber for 3 days in a 5% CO2-air mix at 37
oC in a SANYO MCO-17AI CO2 incubator 
(SANYO Electric Corp, Japan). Following incubation, cells were processed by flow cytometry 
and extent of naïve CD4 T cell proliferation quantified as described in Section 2.6.4. 
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Figure 2.5 Regulatory CD4 T cell suppression assay 
CD3/CD28 Dynabeads® (Life Technologies) activate naïve CD4 T cells and induce proliferation. The aim 
of this assay is to evaluate the efficacy of regulatory CD4 T cells in attenuating the induced polyclonal 
naïve CD4 T cell proliferation. This is assessed by quantification of proliferation on flow cytometry, since 
the naïve CD4 T cells are CFSE labelled. 
 
 
Figure 2.6 Regulatory T cell suppression assay plate diagram 
96 well plate plan for suppression assay, reproduced from Collison et al.
276
. Tconv refer to CFSE labelled 
naïve C57BL/6 CD4 T cells in this work. 
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Antibody Conjugate Clone Working dilution Source Catalogue number 
7AAD PerCP - 1/500 BD Pharmingen 51-68981E 
CD197 (CCR7) PerCP 4B12 1/250 BD Pharmingen 560812 
CD3 PE 145-2C11 1/100 BD Pharmingen 553083 
CD3 FITC 145-2C11 1/100 BD Pharmingen 553061 
CD4 APC GK 1.5 L3T4 1/500 BD Pharmingen 553051 
CD4 PE Cy7 RM4-5 1/2000 BD Pharmingen 552775 
CD4 BIO GK 1.5 1/500 BD Pharmingen 553728 
CD4 FITC GK1.5 1/100 BD Pharmingen 553729 
CD4 APC Cy7 GK1.5 1/100 BD Pharmingen 560181 
CD8 PE 53-6.7 1/100 BD Pharmingen 553032 
CD8 PerCP 53-6.7 1/100 BD Pharmingen 551162 
CD8 APC Cy7 53-6.7 1/200 BD Pharmingen 561092 
CD11b APC Cy7 MI/70 1/200 BD Pharmingen 557657 
CD11c FITC HL3 1/50 BD Pharmingen 557400 
CD11c PE HL3 1/50 BD Pharmingen 557401 
CD16/CD32            
Fc Block
TM
 
- 2.4G2 1/200 BD Pharmingen 553141 
CD19 APC ID3 1/250 BD Pharmingen 550992 
CD19 FITC 1D3 1/100 BD Pharmingen 553785 
CD19 PE 1D3 1/200 BD Pharmingen 553786 
CD19 PE Cy7 1D3 1/200 BD Pharmingen 552854 
CD25 PE PC61 1/100 BD Pharmingen 553866 
CD25 PercP PC61 1/200 BD Pharmingen 551071 
CD40 BIO HM40-3 1/100 BD Pharmingen 553721 
CD40 FITC HM40-3 1/50 BD Pharmingen 553723 
CD44 APC IM7 1/200 BD Pharmingen 561862 
CD44 FITC IM7 1/50 BD Pharmingen 553133 
CD45.1 APC Cy7 A20 1/200 BD Pharmingen 560579 
CD45.2 APC Cy7 104 1/200 BD Pharmingen 560694 
CD49b BIO DX-5 1/1000 BD Pharmingen 553856 
CD62L APC MEL-14 1/100 BD Pharmingen 561919 
CD69 APC H1.2F3 1/100 BD Pharmingen 560689 
CD69 FITC H1.2F3 1/50 BD Pharmingen 553236 
CD80 FITC B7-1 1/100 BD Pharmingen 553768 
CD86 BIO GL-1 1/50 BD Pharmingen 553690 
CD105 BIO MJ7/18 1/200 BioLegend 120403 
CXCR5 BIO APC 1/200 BD Pharmingen 560615 
Foxp3 PE MF23 1/100 BD Pharmingen 560408 
Isolectin B4 BIO B-1205 1/25 Vector W1208 
Kd PE SF1-1 1/100 BD Pharmingen 553566 
Ki 67 
Alexa Fluor 
647 
B56 1/100 BD Pharmingen 558615 
CD279 (PD1) APC J43 1/500 BD Pharmingen 562871 
APC Streptavidin 
conjugate 
Secondary - 1/1000 
Cantag 
Laboratories 
SA1005 
PECy7 Streptavidin 
conjugate 
Secondary - 1/1000 BD Pharmingen 557598 
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Thy 1.1 PE OX-7 1/1000 BD Pharmingen 554898 
Thy 1.1 Biotin OX-7 1/20,000 BD Pharmingen 554896 
Thy 1.1 PerCP OX-7 1/2000 BD Pharmingen 557266 
Thy 1.1 APC Cy7 OX-7 1/200 BD Pharmingen 561401 
Vα2 Biotin B20.1 1/1000 BD Pharmingen 553287 
Vα2 FITC B20.1 1/100 BD Pharmingen 553288 
Vβ6 PE RR4-7 1/200 BD Pharmingen 553194 
Vβ6 Biotin RR4-7 1/500 BD Pharmingen 553192 
Vβ8 PE OX-7 1/100 BD Pharmingen 553862 
Vβ8.3 PE 1B3.3 1/100 BD Pharmingen 553664 
Anti-mouse IgG Biotin - 1/100 Serotec Star 70 
Anti-mouse IgG FITC - 1/1000 Serotec Star 11b 
NK1.1 BIO PK136 1/2000 BD Pharmingen 553163 
I-E PE 14-4-45 1/250 BD Pharmingen 553544 
I-A
b
 FITC AF6-120.11 1/100 BD Pharmingen 553551 
YA-e Biotin YAe 1/50 Produced in lab - 
YA-e Biotin YAe 1/100 
LifeSpan 
Biociences 
LS-C106473 
Rat IgG2b Isotype 
control 
PE - 1/100 BD Pharmingen 556925 
Rat IgG1 Isotype 
control 
FITC - 1/100 BD Pharmingen 554684 
Rat IgG1 Isotype 
control 
APC - 1/100 BD Pharmingen 554686 
 
Table 2-3 Monoclonal antibodies used for flow cytometry staining in this thesis  
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2.7 Histology: Staining 
2.7.1 Paraffin sections and staining 
 
Tissue was placed in 10% formalin solution in PBS and paraffin-mounted. The paraffin sections 
were then stained with either haematoxylin and eosin (H&E) or elastin van Gieson (EVG) using 
Weigert’s method to delineate the internal elastic lamina (IEL), by the Department of 
Pathology, Papworth Hospital, Cambridge, UK.  
 
2.7.2 Frozen sections 
 
Tissue was embedded in OCT compound (VWR International, USA), flash frozen in liquid 
nitrogen, and stored at -80°C. Serial 7µm cryostat sections of the frozen tissue were placed 
onto Poly-l-lysine coated slides (Sigma-Aldrich Inc.) and fixed in chilled acetone for 10 minutes. 
Sections were air-dried for 30 minutes and stored at -80°C. 
 
2.7.3 Immunohistochemistry staining 
 
Immunohistochemistry was performed on cryostat sections using the avidin-biotin-peroxidase 
technique (Vector Laboratories Inc.) for detection of the complement by-product C4d. Sections 
were thawed and rehydrated in PBS, and tissue peroxidase activity was quenched by 
incubation with 0.3% H2O2 in PBS for 10 min. The sections were washed in excess PBS and 
incubated with Avidin D blocking solution (Vector Laboratories Inc.) for 15 minutes, re-washed, 
and then incubated with Biotin blocking solution (Vector Laboratories) for 15 minutes. Non-
specific binding sites were blocked by incubating sections with 5% Rabbit serum (Sigma) in PBS 
(blocking solution) for 20 minutes. Sections were incubated with primary antibody - purified 
anti-C4d (1D62, ABCAM) diluted in the blocking solution at room temperature for 30 minutes. 
Bound primary antibody was detected by incubation with biotinylated secondary antibody 
(anti-rat IgG [ABCAM]) for 30 min followed by incubation with ABC [avidin and biotinylated 
horseradish peroxidase (HRP) complex] solution (Vector Laboratories Inc.) for 30 minutes. All 
incubations were carried out in a humidified chamber and followed by two 5 minute washes in 
excess PBS.  
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For development, sections were incubated with 0.3mg/ml DAB with 0.03% hydrogen peroxide 
for 30-45s. The sections were subsequently counterstained with Harris’ haematoxylin (Sigma-
Aldrich Inc.) for 1s. Sections were dehydrated with increasing concentrations of ethanol, 
cleared in xylene, and mounted in DPX (Sigma-Aldrich Inc.). This technique was performed by 
Sylvia Rehakova 
 
2.7.4 Immunofluorescence staining 
 
Sections were incubated with 5% BSA (Sigma-Aldrich Inc.) and 4% goat serum (Sigma-Aldrich 
Inc.); or 5% Rabbit serum in PBS (In the case if C4d staining) for 1 hour at room temperature to 
block non-specific binding sites. Sections were incubated with primary antibodies conjugated 
to a fluorochrome; or antibodies conjugated to biotin, followed by incubation with 
fluorochrome-conjugate secondary antibody (Table 2.4). Antibodies were diluted in blocking 
solution and each incubation was carried out in a humidified chamber in the dark for 1 hour, 
followed by two washes in excess PBS for 10 minutes. Sections were counterstained with 20% 
Harris’ haematoxylin (Sigma-Aldrich Inc.) for 20 seconds, washed in excess distilled water and 
mounted in FluorSaveTM reagent (Calbiochem®, Merck-Millipore). 
Monoclonal antibodies used for immunofluorescence staining are detailed in Table 2.4. 
Antibody Conjugate Clone Working dilution Source Catalogue number 
Streptavidin Cy2 - 1:500 Jackson 016-220-684 
Goat anti-rat 
IgG 
Cy3 - 1:500 Jackson 112765-143 
B220 Purified RA3-6B2 1:200 BD Pharmingen 553084 
PNA FITC  1:100 Vector Labs Y0626 
GL-7 Biotin Gl-7 1:100 E Bioscience 13-5902-85 
IgG2 ακ 
isotype 
Biotin FC-1071 1:250 BD Pharmingen 553982 
IgM  κ1 isotype Biotin R4-22 1:250 BD Pharmingen 550342 
CD31 Purified MEC 13.3 1/250 BD Pharmingen 557355 
I-E FITC 14-4-45 1/50 BD Pharmingen 558846 
I-A
b
 FITC 
AF6-
120.11 
1/50 BD Pharmingen 553551 
C4d Purified 16D2 1/100 ABCam ab11863 
C4d secondary 
(anti-rat IgG) 
Biotin - 1/100 ABCam ab6673 
 
Table 2-4 Antibodies used for immunofluorescence staining in this work 
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2.8 Histology: Imaging and analysis 
 
2.8.1 Microscopic imaging 
 
Sections were viewed using an IX81 microscope with a 20X0, 70 UplanApo lense (Olympus, 
Japan). Images were photographed using an ORCA-ER digital camera (Hamamatsu Photonics, 
Japan) and acquired with CellR 2.6 software (Olympus Imaging Solutions, Germany). 
2.8.2 Quantification of chronic allograft vasculopathy (AV) 
 
Chronic allograft vasculopathy was assessed by morphometric analysis of EVG stained vessels 
using CellR digital imaging software (Olympus, Tokyo, Japan). Percentage cross-sectional area 
luminal stenosis was calculated as demonstrated in Figure 2.7 using the equation: 
Area within internal elastic lamina −  Area of lumen
Area within internal elastic lamina
×  100% 
All elastin-positive vessels in each section were evaluated, with an average of 10 vessels/ heart 
examined. The severity of vasculopathy, parenchymal damage and cellular infiltration were 
also qualitatively assessed by an experienced cardiothoracic histopathologist (Dr. Martin 
Goddard, Consultant Cardiothoracic Histopathologist, Papworth Hospital, Cambridge, UK) who 
was blinded to the study groups. 
 
Figure 2.7 Calculating luminal stenosis 
A representative light photomicrograph of an EVG stained paraffin section demonstrating the areas 
quantified for calculation of luminal stenosis (the area within internal elastic lamina and the luminal 
area). 
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2.8.3 Quantification of germinal centre activity 
 
To assess the degree of germinal centre (GC) formation within the spleens of allograft 
recipients, 7μm sections were stained with B220 and GL7 as described in Section 2.7.4. The 
percentage of follicles with GCs was derived by dividing the total number of B220+ follicles 
within a random section by the number of GL7+ GCs: 
Number of GL7  positive GCs
Number of B220 positive follicles
×  100% 
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2.9 Statistical analysis 
 
Statistical analysis of data was performed using GraphPad Prism (v 5.03; GraphPad Software 
Inc, CA, US.). The Kaplan-Meier method was used to plot graft survival, with the Log rank 
(Mantel-Cox) test used to compare groups. For other variables, data was analysed using the 
unpaired t-test, or the Mann-Whitney test for non-parametric data. Comparison of antibody 
levels over the course of an experiment was performed using two-way analysis of variance. p 
<0.05 was considered statistically significant.  
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3 Model to study direct and indirect 
allorecognition reveals a role for 
passenger lymphocytes in 
augmenting alloimmune responses 
following transplantation 
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3.1 Introduction 
3.1.1 Transgenic CD4 T cells 
 
The development of T cell receptor (TCR) transgenic mice has been a significant advance in 
immunology. Several CD4 TCR transgenic mice have been developed to permit detailed 
analysis of specific immunological pathways. These mice possess insertion of a transgene 
encoding a defined, antigen specific, rearranged TCR. The mice are then crossed onto a Rag-/- 
background to prevent endogenous TCR rearrangement, thus eliminating non-transgenic 
specificity CD4 T cell expression. This also prevents B cell and CD8 T cell development. Thus, 
the mice possess a monoclonal population of CD4 T cells of defined specificity. These mice, and 
their CD4 T cells, can be used to undertake detailed investigation of antigen specific responses, 
and have been widely used to study the alloimmune response following transplantation. 
Transgenic CD4 T cells can be adoptively transferred in a number large enough to permit 
detection and tracking by knowledge of their specific Vα and Vβ subunit expression, but small 
enough to behave in a physiological manner277. In this work, four TCR transgenic strains have 
been utilised: ABM, TCR75, TEa and Mar (Figure 3.1). 
 
 
Figure 3.1 Antigen specificity of T cell receptor transgenic strains 
a) ABM – direct-pathway, b) TCR75 – indirect-pathway: MHC class I H-2K
d
, c) TEa – indirect-pathway: 
MHC class II I-E and d) Mar – indirect-pathway: minor histocompatibility H-Y antigen. 
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3.1.1.1 ABM 
The ABM strain was generated by Palmer and colleagues from a TCR shown to be positively 
selected in C57BL/6 mice and negatively selected in bm12 mice. In the initial report describing 
their production, ABM mice were used to study TCR motifs which regulate positive selection261. 
This strain carries Vα2.1 and Vβ8.1 gene segments as transgenes, from the 3BBM74 CD4 T cell 
clone that recognises I-Abm12 by the direct-pathway, in a peptide degenerate fashion. 
 
3.1.1.2 TCR75 
The TCR75 transgenic strain was developed by Bucy and colleagues for detailed study of 
indirect-pathway CD4 T cell responses162. This strain carries the Vα1.1/Jα33 and Vβ8.3/Jβ1.4 
transgenes from the IκB7/5 CD4 T cell clone that reacts to amino acids 54-68 of the H-2Kd Class 
I MHC presented in the context of the Class II MHC I-Ab (Kd54-68/I-Ab epitope). An allelic 
polymorphism at the CD90 locus has also been introduced in this strain to distinguish its cells 
from those of other C57BL/6 strains by cell surface expression of the Thy1.1 antigen. 
 
3.1.1.3 TEa 
The TEa transgenic strain was developed by Rudensky and colleagues originally for the detailed 
study of positive and negative thymocyte selection260. This strain carries the Vα2.3Jα11 and 
Vβ6Dβ2Jβ2.6 transgenes from the p8.3 CD4 T cell clone that reacts to amino acids 52-68 of the 
I-E MHC class II α chain presented in the context of the Class II MHC I-Ab (I-Eα52-68/I-Ab 
epitope). 
 
3.1.1.4 Mar 
The Mar transgenic strain was developed by Di Santo and colleagues originally to investigate 
the role of γ chain-dependent cytokines in the homeostasis of antigen-specific CD4 T cells in 
vivo123. This strain carries the Vα1.1-Jα35 and Vβ6-Jβ2.3 transgenes from the Marylin CD4 T cell 
clone that reacts to amino acids 608-622 of the H-Y minor histocompatibility antigen dby 
presented in the context of the Class II MHC I-Ab (dby 608-622/I-Ab epitope). 
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3.1.2 Bm12 to C57BL/6 model of chronic rejection 
 
Experimental work in this thesis is based upon the bm12 to C57BL/6 model of chronic 
rejection. The bm12 strain was identified as a naturally occurring spontaneous mutant variant 
of C57BL/6 which differs by only three amino acids in the third hypervariable region of the 
peptide binding groove of the MHC class II I-Ab, creating the so-called I-Abm12 class II 
molecule278-280. The amino acid changes consist of codon 67 (isoleucine to phenylalanine), 
codon 70 (arginine to glutamine) and codon 71 (threonine to lysine) (Figure 3.2). As a 
consequence of the Eα gene being deleted in the H-2b haplotype, these two strains cannot 
produce functional MHC class II I-E molecules255. Thus, the bm12 strain possesses only a 
limited class II mismatch, but is identical at MHC class I and minor histocompatibility loci. 
 
Figure 3.2 I-A
bm12
 MHC class II is mismatched from I-A
b
 at just three amino acid loci 
Molecular ribbon diagram demonstrating the position and structural differences between the I-A
bm12
 
and I-A
b
 MHC class II molecules consequent upon the three amino acid disparity (highlighted red). 
Courtesy of Dr Dermot Mallon, Department of Surgery, University of Cambridge 
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3.1.2.1 Rejection in the bm12 to C57BL/6 model 
 
As a consequence of this limited antigenic mismatch, a much reduced proportion of recipient T 
cells are found to be reactive to bm12 allografts – a precursor frequency of ~2.5% compared to 
the 21% typical of complete MHC mismatches50. Despite this, bm12 skin grafts are acutely 
rejected by C57BL/6 recipients255, 279, 281 and cardiac allografts are rejected chronically with 
development of allograft vasculopathy (AV) and consequent parenchymal injury274, 281, 282. 
Rejection in this model appears to be dependent upon recipient T cells. Early work in this 
model demonstrated that AV could be observed following transplantation into RAG2KO 
recipients following reconstitution with recipient T cells (CD4 and CD8), in the absence of B 
cells283. Furthermore, they demonstrated that this was dependent upon IFNγ, since no 
rejection was observed when IFNγ knock-out T cells were transferred, and AV is markedly 
attenuated when bm12 allografts were transplanted into IFNγ knock-out recipients281. In 
keeping with these findings, AV is significantly diminished in CD8 T cell knock-out recipients 
suggesting that CD8 T cells play a role in allograft rejection through their cytotoxic activity and 
IFNγ secretion284. It is worth considering that donor and recipient strains share MHC class I loci, 
and so CD8 T cells cannot recognise allograft cells by the direct-pathway. Instead, they 
presumably recognise disparate I-Abm12 peptides presented in the context of shared MHC class 
I molecules (indirect-pathway CD8 T cell recognition) presented by donor APCs. 
Further examination of this model has highlighted that both direct and indirect-pathway CD4 T 
cells are important to allograft rejection, where CD4 T cells recognise intact I-Abm12 or self-
restricted processed I-Abm12 allopeptide respectively. The direct-pathway appears capable of 
driving allograft rejection since AV is observed when bm12 cardiac allografts are transplanted 
into H2-M C57BL/6 mice which express normal levels of MHC class II but possess a defect in 
peptide loading285. In these recipients, CD4 T cells can only recognise I-Abm12 by the direct-
pathway. However, the importance of indirect-pathway CD4 T cells is demonstrated by long-
term survival and absence of AV in bm12 cardiac allografts when transplanted into ABM.RAG-/- 
mice – possessing a monoclonal population of CD4 T cells recognising I-Abm12 by the direct-
pathway102. Further evidence was provided by demonstrating accelerated rejection in 
recipients previously primed with bm12 peptide274. It is not clear how indirect-pathway CD4 T 
cells themselves would mediate allograft injury since their epitope is not expressed by the 
allograft. It is more likely that indirect-pathway CD4 T cells drive cytotoxic CD8 T cell or 
humoral responses. 
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Although rejection has been seen to occur in the absence of B cells283, humoral immunity also 
appears to contribute, since rejection is significantly delayed in C57BL/6.μ-MT recipients which 
lack B cells274. Furthermore, endothelial IgG deposition in bm12 cardiac allografts has been 
confirmed102 and detailed histological examination of donor cardiac allografts reveals 
additional features characteristic of humoral alloimmunity such as vascular proliferation, 
fibrinoid necrosis and complement C4d deposition274. 
 
3.1.2.2 Antinuclear autoantibody development 
 
Despite the above evidence of humoral alloimmunity work from our laboratory, and others, 
has demonstrated that no anti-bm12 alloantibody develops following challenge274, 279. 
Considering the limited nature of the MHC class II mismatch, this likely reflects the absence of 
a conformational epitope for B cell allorecognition. However, high levels of antinuclear 
autoantibody were discovered in recipients, as detected by HEp-2 indirect 
immunofluorescence274. Different patterns of HEp-2 staining were observed for different 
recipients, suggesting that a range of autoantibody specificities are generated and that this 
differs between recipients. This work also implied an effector role for autoantibody in allograft 
rejection, as suggested by reduction in severity of AV when autoantibody responses were 
prevented, and by accelerated rejection in recipients primed for humoral autoimmunity.  
It is not immediately obvious why a bm12 cardiac allograft should drive the development of 
autoantibody. Eisenberg’s group has contributed significantly to our understanding of this. 
They observed that adoptive transfer of bm12 splenocytes resulted in development of 
antinuclear autoantibodies and an SLE like autoimmune phenotype286. They extended this 
finding to demonstrate that this was a Graft versus Host (GvH) cognate ‘direct-pathway’ 
interaction between the donor CD4 T cells and recipient B cells286, 287. They generated mixed 
C57BL/6 and bm12 bone marrow chimeras and demonstrated that upon transfer of bm12 
splenocytes only C57BL/6 B cells produced autoantibody, despite bm12 B cells being subject to 
potential bystander activation287. In C57BL/6 recipients they observed that the entire recipient 
B cell population becomes activated – as would be expected since all recipient B cells express 
allogeneic I-Ab, regardless of BCR specificity, and so should receive equal direct-pathway help, 
which should in theory lead to a polyclonal antibody response288. That only autoantibody is 
produced was postulated to be due to antigen availability at the time of B cell activation289. 
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Work from our laboratory has extended these findings to the cardiac transplant model. In a 
similar manner, when T cell depleted bm12 donors (bm12.TCRKO strain or T cell depletion with 
anti-CD4) were transplanted into C57BL/6 recipients, no autoantibody developed and reduced 
AV observed274. These findings suggest that passenger CD4 T cells carried with the cardiac 
allograft activate recipient B cells in a GvH manner by cognate direct-pathway recognition of 
recipient I-Ab, driving the development of autoantibody. This process can occur because 
murine CD4 T cells do not express MHC class II and therefore are not recognised as allogeneic 
by the recipient in this strain combination. 
One question arising from these observations is why does global GvH activation of recipient B 
cells only result in autoantibody generation? Eisenberg alluded to the concept that specificity 
of antibody generated in the context of GvH B cell activation is dependent upon antigen 
availability289. Recent work from our laboratory has sought to examine the hypothesis that 
plasma cell differentiation requires concurrent BCR ligation in addition to direct-pathway 
cognate donor CD4 T cell help. T cell deficient C57BL/6 mice (Tcrbd-/-) were adoptively 
transferred with bm12 CD4 T cells and immunised with ovalbumin. Control mice received 
bm12 CD4 T cells only. Whilst both groups developed autoantibody, only those immunised 
with ovalbumin developed IgG anti-ovalbumin antibody (Ines Harper, Department of Surgery, 
manuscript in preparation). This has also been observed with alloantigen challenge. These 
results suggest that although global B cell activation is observed, differentiation into antibody 
secreting plasma cells required concurrent ligation of the BCR, conforming to the 2-signal 
hypothesis of B cell activation290. 
 
3.1.2.3 How does autoantibody mediate allograft rejection and is autoantibody important 
in clinical transplantation? 
 
There has been increasing appreciation that autoantibodies may contribute to allograft injury 
and rejection in clinical transplantation291-293. Indeed the development of humoral 
autoimmunity has been reported for all solid organ allografts and there is increasing 
association with poorer allograft outcomes. For example, anti-vimentin autoantibody (a 
cytoskeletal protein found within the intima and media of coronary arteries) has been 
observed in some human cardiac transplant recipients and has been associated with 
accelerated AV development294, 295. Similarly, anti-endothelial cell autoantibody has been 
associated with higher rates of cellular rejection following renal transplantation296. 
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What remains unclear though is how autoimmunity develops in human transplant recipients. 
The prevailing view is that following transplantation the inflammatory milieu, perhaps 
exacerbated by ischaemia-reperfusion injury, and ongoing tissue remodelling, leads to 
exposure of cryptic self-antigens on graft endothelium, normally not available for immune 
recognition297, 298. This may also be a consequence of damaging innate and adaptive 
alloresponses299.  It has also been observed that intra-cellular proteins can be translocated to 
the cell-surface during apoptosis300. The exposure of cryptic autoantigens in the context of 
activated innate and adaptive alloresponses may be sufficient to trigger autoimmunity and 
activate auto-reactive CD4 T cells.  
Why the damaging effects of autoimmunity, both in human and experimental transplant 
recipients, appear restricted to the donor allograft remains incompletely understood. Target 
autoantigens are predominantly intracellular proteins that will be expressed by both donor 
and recipient, but transplant recipients do not appear to experience detectable systemic 
autoimmunity.  
It is proposed that exposed autoantigens on endothelium as a consequence of the processes 
described above may then permit endothelial autoantibody binding and subsequent initiation 
of downstream signalling, as has been reported for anti-HLA antibodies, activating the cells as 
a possible initiating lesion driving AV and thus mediate its progression directly301. It has also 
been observed that antibody molecules can be internalised by cell surface receptors, and this 
may permit an alternative route of access for autoantibody to autoantigens and possible 
activation of endothelial cells302. Alternatively, bound autoantibody may act indirectly and 
target endothelial cells for complement fixation and/or NK cell mediated antibody-dependent 
cellular cytotoxicity, acting as an opsonin for more efficient antigen processing and 
presentation to recipient alloreactive CD4 T cells, in turn enhancing humoral and cellular 
alloimmunity301, 303.  
 
3.1.2.4 Is there a role for donor CD4 T cells in human transplantation 
 
It is now widely recognised that populations of memory and naïve CD4 T cells reside in non-
lymphoid organs and tissues304-306. As a result it is likely that solid organ transplantation will 
deliver substantial numbers of donor lymphocytes to the recipient. Unlike the bm12 to 
C57BL/6 model, human transplant recipients are almost always significantly more mismatched 
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and so how long donor lymphocytes survive following transplantation is not clear. Although 
immunosuppression may prevent them from being rapidly cleared by adaptive responses, 
innate immune recognition by NK cells would be expected to lead to early clearance307. 
Nevertheless, it is clear from early human transplantation studies that circulating donor 
lymphocytes are often detectable in recipients, although in small numbers308. The impact of 
passenger donor lymphocytes is incompletely understood, although clinical manifestations 
have been described. In some patients donor CD4 T cells manifest as devastating acute GvH 
disease, which is an uncommon but fatal complication following solid organ transplantation309. 
Similarly, several cases of ‘passenger lymphocyte syndrome’ have been reported, whereby 
haemolysis in the recipient is triggered by donor B cell recognition of mismatched blood group 
antigens leading to antibody production310-312. It has been postulated that donor CD4 T cells 
provide help to these B cells since recipient CD4 T cells would be tolerant to these self-
antigens. 
Thus, the impact passenger lymphocytes have on the alloimmune response to a solid organ 
transplant, both in humans and mismatched experimental models, remains incompletely 
understood. 
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3.2 Aims 
 
The aims of the research described in this chapter are as follows: 
 
1. To develop and characterise a murine model of chronic rejection with which to further 
examine the direct and indirect-pathways of allorecognition using the described TCR 
transgenic CD4 T cells. 
 
2. Evaluate the impact of passenger donor CD4 T cells on adaptive alloimmunity in a 
model based on the bm12 to C57BL/6 but which possesses additional MHC class I and 
II mismatches*. 
 
 
 
 
 
 
 
 
 
 
 
 
 
* In addressing the second aim there was some overlap with the work of a colleague (I. Harper). 
Although some of the experiments have been performed in conjunction, all the data presented here is 
my own experimental work. A manuscript on both our findings is in preparation on which we are joint 
first authors.  
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3.3 Results 
 
3.3.1 The direct-pathway is short-lived, whilst longevity of the indirect-pathway is 
variable 
 
Longevity of direct and indirect allorecognition pathways was initially examined using four 
murine cardiac transplant models, each with a single major or minor histocompatibility antigen 
mismatch (Table 3.1). Heterotopic cardiac transplantation was utilised, since this is the 
standard vascularised allograft model used in transplant immunological research, having the 
advantage over other potential vascularised organs that allograft function can be easily 
assessed by abdominal palpation. Donor and recipient strains were selected to ensure that 
transferred monoclonal TCR transgenic CD4 T cell populations recognised their alloantigen 
either directly or indirectly. 
Donor Recipient Donor antigen mismatch Transgenic T cell 
recognising mismatch 
bm12 C57BL/6 Class II I-A
bm12 
ABM - directly 
ABOIE C57BL/6 Class II I-E
d
 TEa - indirectly 
B6.K
d
 C57BL/6 Class I H-2K
d 
TCR75 - indirectly 
C57BL/6 Male C57BL/6 Female H-Y Minor antigen Mar - indirectly 
 
Table 3-1 Donor and recipient mouse strains 
 
To examine longevity of the direct-pathway fluorescently labelled (CFSE) ABM CD4 T were 
adoptively transferred either on the day of transplant (early) or 28 days later (late). Since CFSE 
is equally distributed amongst daughter cells at division, each daughter cell possesses half the 
fluorescence of the parent and CFSE dilution can be used to quantify proliferation as described 
in Section 2.6.4. For this work, 4-6x106 TCR transgenic splenocytes were adoptively 
transferred. CD4 T cells represent 20-25% of splenocytes in these transgenic strains (Figure 
3.3). Whilst robust proliferation was observed at the early time-point, this was absent at the 
late time, suggesting priming of the direct-pathway is short-lived (Figure 3.4a). 
In a similar manner, priming of the indirect-pathway against donor MHC class I, MHC class II 
and minor histocompatibility antigen was examined. Indirect-pathway allorecognition of MHC 
class I derived peptide was found to be long-lived, being equally strong at the early and late 
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time-points. Indirect-pathway priming against minor histocompatibility, male H-Y, antigen was 
also long-lived, but there was significant attenuation at the late time point. In contrast, whilst 
indirect allorecognition of peptides derived from donor MHC class II occurred early, 
proliferation was absent at the late time point, suggesting, as for direct allorecognition, 
indirect-pathway priming against MHC class II is short-lived (Figure 3.4b-d). This variability in 
the longevity of indirect allorecognition has not been previously described. 
In this experiment transgenic CD4 T cells, except TCR75, were identified by staining for their 
TCR α or β subunits (ABM - Vβ8; TEa Vβ6; Mar Vα1.1). Since these subunits are expressed by 
endogenous CD4 T cells, by chance, a population of CFSE negative cells can be seen on the 
histograms. TCR75 CD4 T cells were more specifically identified by staining for a congenic 
marker: CD90.1/Thy 1.1, thus avoiding the endogenous populations.  
Since allogenicity of the four donor allografts is potentially different, this may have contributed 
to the variable proliferation observed since extent of CD4 T cell proliferation will not solely 
depend upon antigen availability, but other factors such as cytokine milieu. To control for this 
potentially confounding factor, it was necessary to confirm the longevity of indirect-pathway 
allorecognition in recipients of a single donor allograft expressing all of the above mismatched 
alloantigens. 
Furthermore, because B6.Kd and male C57BL/6 donors also express the recipient MHC class II, 
I-Ab, it would be possible for donor APCs to present alloantigen to the transgenic CD4 T cells 
via the direct-pathway, potentially complicating interpretation of the previous results.  
 
 
Figure 3.3 Proportion of CD4 T cells in TCR transgenic splenocytes 
Representative flow cytometry plot of TEa splenocytes gated on live lymphocytes. 
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Figure 3.4 Longevity of direct and indirect-pathway allorecognition in individual models 
Representative flow cytometry plots and bar chart summarising proliferation following adoptive transfer 
of 4-6x10
6
 CFSE labelled a) ABM  splenocytes into C57BL/6 recipients of bm12 hearts b) TCR75 
splenocytes into C57BL/6 recipients of B6.K
d
 hearts; c) TEa splenocytes into C57BL/6 recipients of ABOIE 
hearts and d) Mar splenocytes into female C57BL/6 recipients of male C57BL/6 hearts, 0 or 28 days 
following transplantation or naïve C57BL/6 control mice (all groups n=3). Animals were sacrificed 6 days 
later and splenocytes analysed by flow cytometry. Proliferation of transgenic CD4 T cells quantified 
using FlowJo software (Tree Star, Oregon). P values using the Mann Whitney test. 
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3.3.2 Developing a new donor strain: bm12.Kd.IE 
 
To overcome the shortfalls of the individual models presented above, a new donor strain was 
developed that allowed for simultaneous examination of the direct and three indirect-pathway 
targets. To achieve this, the donor strain was required to express the MHC class II: I-E and I-
Abm12, class I: H-2Kd and must NOT express MHC class II I-Ab to prevent any direct-pathway 
presentation to the indirect-pathway TCR transgenic CD4 T cells. This was achieved by crossing 
a bm12.Kd strain (I-Abm12, H-2Kd) with an ABOIE (I-Ed, I-Ab knock out) – both of which lack 
expression of I-Ab. The resulting F1 offspring, referred to henceforth as bm12.Kd.IE, possess the 
required complement of MHC molecules (Figure 3.5a). Expression of I-Abm12 and absence of I-
Ab was confirmed by PCR. Prior to experimental use, the expression of H-2Kd and I-E was 
confirmed by flow cytometry on peripheral blood mononuclear leukocytes (Figure 3.5b,c). 
When a male bm12.Kd.IE is transplanted into a female C57BL/6, indirect allorecognition of 
class I, class II and minor H-Y antigen can be examined simultaneously.  
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Figure 3.5 Characterisation of the bm12.Kd.IE donor strain 
A series of intercrosses were performed between bm12, B6.Kd and ABOIE strains to derive the 
bm12.Kd.IE strain. (a) Comparison of MHC complement in BM12.Kd.IE and C57BL/6 strains. (b) Flow 
cytometric demonstration of expression of MHC class I H-2K
d 
(left) and class II I-E antigens (right) on live 
peripheral blood mononuclear leukocytes from bm12.Kd.IE strain; these are not expressed on parent 
bm12 strain. (c) PCR genotyping of I-A loci of bm12, B6 and bm12.Kd.IE strains using different primer 
pairs specific for β chain of the I-A alpha-helix region. The bm12.Kd.IE strain expresses the I-A
bm12
, but 
not the I-A
b
, antigen. (PCR performed by S Rehakova) 
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3.3.3 Characterisation of the bm12.Kd.IE to C57BL/6 model 
 
3.3.3.1 Graft survival and histopathology 
 
Bm12.Kd.IE hearts demonstrate long-term survival in C57BL/6 recipients with a median 
survival time of >100 days (n=12). Serial graft histology was reviewed by a consultant 
cardiothoracic histopathologist (Dr Martin Goddard, Papworth Hospital, Cambridge, UK). At 
one week following transplantation an aggressively proliferating dense cellular infiltrate was 
identified. At this early time, minimal myocyte damage was observed and there was no 
evidence of vascular injury. By three weeks, the infiltrate had subsided with only a few residual 
inflammatory cells observed, suggesting there is an early ‘hit’ that resolves. There was 
evidence of early injury, with areas of myocyte drop-out, and early vascular changes, with 
endothelialitis seen in some intra-myocardial vessels. Florid endothelialitis was identified in 
some major coronary vessels. By week seven the grafts showed some areas of replacement 
fibrosis indicating chronic parenchymal injury. There were also larger areas of myocyte loss. 
The majority of intra-myocardial vessels demonstrate the presence of concentric proliferative 
vascular lesions of endothelial and smooth muscle origin, suggesting a vasculopathic process, 
with associated areas of injury, likely a consequence of chronic ischaemic injury.  This is in 
keeping with the macroscopic scarred appearance, although the majority continue to 
demonstrate rhythmical contraction. At day 100, although the majority continue to beat, there 
is a rhythm irregularity in many, and the hearts appear swollen and scarred. Microscopically, 
the replacement fibrosis, myocyte drop out and vasculopathy have significantly progressed, 
with some vessels occluded. These histological features are compatible with chronic antibody-
mediated damage149 (Figure 3.6). 
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Figure 3.6 Histological evaluation of donor bm12.Kd.IE cardiac allografts following transplantation 
Representative photomicrographs of paraffin sections of donor cardiac allografts at 1, 3, 7 and 15 weeks 
following transplantation. Left panels stained with Elastin van Gieson (EVG) demonstrating the 
progression of allograft vasculopathy. Right panels stained with haematoxylin and eosin (H+E) 
demonstrating the early inflammatory infiltrate (week 1) and subsequent progressive myocyte drop-out 
and replacement fibrosis. Magnification indicated on panels.  
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In comparison, syngeneic transplanted hearts continue to beat indefinitely. Microscopically, 
there is no evidence of an early inflammatory infiltrate, nor injury to either the myocardium or 
the intra-myocardial vasculature, supporting that the findings in the bm12.Kd.IE donor hearts 
to be attributed to the alloimmune response (Figure 3.7) 
 
Figure 3.7 Histological evaluation of syngeneic donor cardiac allografts 
Representative photomicrographs of paraffin sections of syngeneic donor cardiac allografts. No early 
inflammatory infiltrate is observed (left panel, haematoxylin and eosin) and there is no development of 
allograft vasculopathy by 100 days following transplantation (right panel, elastin van Gieson). 
Magnification indicated on panel. 
 
The extent of AV present in day 100 donor bm12.Kd.IE and syngeneic hearts was quantified 
morphometrically, measuring the mean luminal stenosis of intra-myocardial vessels (Section 
2.8.2). A substantial degree of AV was observed in allogeneic hearts. 
 
Figure 3.8 Allograft vasculopathy in donor bm12.Kd.IE cardiac allografts 
Allograft vasculopathy quantified by calculating luminal stenosis from elastin van Gieson stained paraffin 
sections of bm12.Kd.IE and syngeneic donor allografts 100 days following transplantation. n=7 in each 
group. P values using the Mann Whitney test.  
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3.3.3.2 Humoral alloimmune effector responses 
 
Having established that bm12.Kd.IE cardiac allografts provoke a chronic alloimmune response 
in C57BL/6 recipients, the effector arms of this response were next investigated. The disparate 
MHC possessed by the donor are: class I H2-Kd, and class II I-E and I-Abm12. Work from our 
laboratory, and previous studies, have highlighted that due to the similarity to I-Ab, and the 
absence of a conformational epitope for B cell recognition, C57BL/6 mice do not form anti-I-
Abm12 alloantibody274, 279. In contrast, long-lasting alloantibody responses were detected against 
both the MHC I H-2Kd and MHC II I-E (Figure 3.9). 
 
Figure 3.9 Alloantibody generation in recipients of bm12.Kd.IE cardiac allografts 
Alloantibody levels were quantified in weekly serum samples from C57BL/6 recipients of bm12.Kd.IE and 
syngeneic cardiac allografts. Anti-H-2K
d
 alloantibody (a) quantified by ELISA and anti-I-E alloantibody (b) 
quantified by flow cytometric labelling of I-E expressing ABOIE strain BMDCs. N=7 in all groups. P values 
using two-way ANOVA 
 
Our laboratory have previously demonstrated that in the bm12 to C57BL/6 model, donor CD4 
T cells are responsible for driving the development of autoantibody, through ‘graft-versus-
host’ mediated provision of ‘direct-pathway’ help to recipient B cells274. It was therefore 
anticipated that a bm12.Kd.IE donor heart may provoke a similar autoimmune humoral 
response. Indeed this was found to be the case, as significant long-lived autoantibody levels 
were detected in recipients of bm12.Kd.IE hearts by HEp-2 indirect immunofluorescence 
(Figure 3.10). 
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Figure 3.10 Autoantibody quantification using HEp-2 indirect immunofluorescence 
Antinuclear autoantibody levels were quantified in weekly serum samples from C57BL/6 recipients of 
bm12.Kd.IE and syngeneic cardiac allografts. Autoantibody was quantified using HEp-2 indirect 
immunofluorescence. Representative immunofluorescence photomicrographs shown. N=7 in all groups. 
P values using two-way ANOVA 
 
In keeping with the allo- and autoantibody responses detected, significant germinal centre 
(GC) activity was detected by immunofluorescence. Germinal centres were quantified by 
staining cryostat sections of recipient spleen 50 days following transplantation. The proportion 
of GCs was indicated by identifying the proportion of B220+ B cell follicles that also stained 
positive for GC activity as indicated by GL-7 staining (Section 2.8.3; Figure 3.11). 
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Figure 3.11 Germinal centre activity in cardiac allograft recipients 
Analysis of germinal centres in recipients of bm12.Kd.IE and syngeneic cardiac allografts 50 days 
following transplantation. (a) Germinal centres quantified in recipients of bm12.Kd.IE and syngeneic 
allografts (n=6, p value using Mann-Whitney test); (b) Representative haematoxylin and eosin stained 
paraffin section of recipient spleen demonstrating follicles; (c) Representative immunofluorescence 
cryostat sections of recipient spleen stained with B220 (B cell), and GL-7 (germinal centre B cells) at 40X 
magnification for syngeneic donors (top panels) and bm12.Kd.IE donors (lower panels).  
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Further examination of the alloantibody response was undertaken by performing an ELISPOT 
to detect the presence of anti-H-2Kd antibody secreting cells, both in the spleen, but also in the 
bone marrow (although this did not reach statistical significance), where long-lived plasma 
cells reside. Detection of antibody secreting cells was identified in both locations, suggesting 
productive GC output with deposition of long-lived plasma cells in the recipient bone marrow. 
 
Figure 3.12 H-2K
d
 ELISPOT 
Quantification of H-2K
d
 antibody secreting cells in spleen (a) and bone marrow (b) of C57BL/6 recipients 
of bm12.Kd.IE cardiac allografts 50 days following transplantation by ELISPOT (n=5). Representative 
images of well shown. P values using Mann-Whitney test. (Positive control C57BL/6 recipients of BALB/c 
cardiac allografts at 7 days following transplantation; negative control naïve C57BL/6) 
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In keeping with the detection of long-lived humoural responses, histological examination of 
the hearts, described above, is suggestive of chronic antibody mediated damage. To further 
confirm a role for antibody in mediating AV, grafts were stained for the complement by-
product C4d, which is a well-established clinical marker of antibody-mediated rejection, and 
C4d staining is recommended by current International Society for Heart and Lung 
Transplantation guidelines for the diagnosis of antibody mediated rejection149. Endothelial C4d 
deposits could be readily identified, along with diffuse parenchymal staining for C4d, which has 
been described as a generic feature of ischaemic death, a consequence of the vasculopathic 
process in these hearts (Figure 3.13). 
 
Figure 3.13 Immunofluorescence and immunohistochemical staining for C4d complement deposition 
Representative photomicrographs of immunohistochemistry (left panels) and immunofluorescence 
(right panels) staining for complement by-product C4d of cryostat sections of donor bm12.Kd.IE cardiac 
allografts harvested 50 days following transplantation (n=7). As negative and positive controls, 
representative images from syngeneic heart grafts and BALB/c heart allografts that provoked strong 
humoral alloimmunity in T cell deplete TCRKO recipients reconstituted with TCR75 CD4 T cells 
respectively (sections courtesy of M Chhabra). All panels x40 magnification.  
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3.3.3.3 Cell-mediated alloimmune responses 
 
To investigate the presence of a cytotoxic CD8 T cell-mediated arm to the alloimmune 
response in this model, a CD8 IFNγ ELISPOT was performed. Whilst a robust CD8 T cell 
alloresponse was detected 7 days following transplantation, by day 12 only minimal reactivity 
was seen. This may reflect the histological finding of an intense inflammatory infiltrate at 1 
week, which almost completely resolves by week 3 following transplantation.  
 
Figure 3.14 CD8 T cell IFNγ  ELISPOT 
Quantification of cytotoxic CD8 T cell alloimmunity in C57BL/6 recipients of bm12.Kd.IE cardiac allografts 
7 and 12 days following transplantation using IFNγ ELISPOT assay (n=5). Irradiated bm12.Kd.IE 
splenocytes were used as stimulators. Responses compared to those observed in C57BL/6 recipients of a 
BALB/c cardiac allograft (positive) and naïve C57BL/6 (negative). Representative images of wells 
presented. P values using Mann-Whitney test 
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3.3.4 Innate immune reactivity 
 
Having characterised the adaptive alloimmune response, I was interested to understand the 
contribution of the innate immune response to allograft rejection. To examine this, RAG2KO 
mice, which lack adaptive immunity due to deletion of the recombination-activating 2 gene 
(Rag), preventing maturation of T and B cells, were utilised as recipients. First, bm12.Kd.IE B 
cells were adoptively transferred i.v. into RAG2KO recipients. B cells, rather than CD4 T cells, 
were chosen due to their expression of the full allogeneic MHC repertoire. Murine CD4 T cells 
are thought not to express MHC class II254, and would therefore not express the allogeneic I-E 
or I-Abm12. Fully allogeneic BALB/c and syngeneic C57BL/6 B cells were transferred as positive 
and negative controls respectively. Mice were bled weekly for 7 weeks. Similar levels of 
circulating bm12.Kd.IE and C57BL/6, but not BALB/c, B cells were identified over this period. 
Similarly, bm12.Kd.IE B cells were present in RAG2KO recipient splenocytes following sacrifice 
on day 50 (Figure 3.15). These results suggest that bm12.Kd.IE cells evade innate immune 
surveillance, perhaps a consequence of the shared expression of MHC I Kb and Db.  
 
Figure 3.15 Bm12.Kd.IE cells evade innate immune recognition 
Percentage of CD19 positive cells within the live lymphocyte gate on (a) weekly bleeds and (b) in 
splenocytes at 50 days, following adoptive transfer of 1x10
6
 MACS purified B cells i.v. into RAG2KO 
recipients (n=3 in each group). Despite the small percentages of B cells attained, very distinct 
populations were observed. P values using Mann Whitney test. PBMC – peripheral blood mononuclear 
cells.  
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Bm12.Kd.IE hearts were then transplanted into RAG2KO recipients, with the expectation that 
in the absence of innate immune recognition, and without adaptive immunity, long term graft 
survival should be observed. All grafts continued to beat beyond day 100, and histological 
examination revealed no evidence of vascular or parenchymal injury (Figure 3.16a). In keeping 
with the results for B cell transfer, analysis of recipient peripheral blood 7 days following 
transplant into wild-type and RAG2KO recipients, revealed a circulating population of 
passenger donor CD4 T cells in RAG2KO but not in wild-type recipients (Figure 3.16b). These 
results further support the absence of innate immune reactivity to bm12.Kd.IE allografts. 
 
 
Figure 3.16 Bm12.Kd.IE cardiac allografts do not develop evidence of rejection in RAG2KO recipients 
(a) Representative photomicrograph of paraffin sections of syngeneic donor cardiac allografts stained 
with elastin van Gieson. No evidence of allograft vasculopathy at 100 days following transplantation was 
observed - magnification indicated on panel. (b) Representative flow cytometry plots of CD4 T cells in 
recipient peripheral blood 7 days following transplantation of bm12.Kd.IE cardiac allografts into a 
wildtype (left) or RAG2KO (right) recipient (n=3). A population of donor CD4 T cells (as evidenced by H-
2K
d
 expression) is only identified in RAG2KO recipients. 
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3.3.5 Donor CD4 T cells augment alloimmune responses 
 
Work previously published from our laboratory has identified donor bm12 CD4 T cells to have 
a central role in driving the observed autoantibody responses in C57BL/6 recipients by 
providing direct-pathway GvH help to recipient B cells. Upon depletion of donor CD4 T cells, 
autoantibody responses do not develop and grafts survive long term with no evidence of 
myocardial or vascular injury274. I was interested to evaluate the role of donor CD4 T cells in 
this model, aware that unlike bm12 CD4 T cells which survive long-term, bm12.Kd.IE CD4 T 
cells are cleared by the recipient adaptive autoimmune response within the first week 
following transplantation (Figure 3.16b). Nevertheless, long-lived autoantibody responses 
develop in this model and the presumption was that this is similarly driven by donor CD4 T 
cells. 
 
3.3.5.1 The role of donor CD4 T cells in the bm12.Kd.IE to C57BL/6 model 
 
Donor CD4 T cells were depleted by administration of a depleting anti-CD4 antibody (YTS 
191.1; European Collection of Animal Cell Cultures, UK). Two 0.5mg i.p. doses administered to 
donors, 5 and 1 day prior to transplant, resulted in a significant depletion of circulating, splenic 
and cardiac parenchymal CD4 T cells (Figure 3.17). 
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Figure 3.17 Effective depletion of donor CD4 T cells is achieved with depleting anti-CD4 antibody 
Depleting anti-CD4 antibody (YTS 191.1) was administered i.p. to recipient mice (0.5mg day -5 and -1 
prior to transplantation). Effective depletion was confirmed with flow cytometry (all plots gated on live 
lymphocytes). (a) No circulating CD4 T cells are present 6 days following administration. On the day of 
transplantation effective donor depletion of CD4 T cells was observed in both splenic tissue (b) and in 
cardiac homogenates (c) as compared to an untreated, wildtype donor.   
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Donor CD4 T cell depletion had a significant impact on the adaptive responses against 
bm12.Kd.IE cardiac allografts and rejection kinetics. Long-term graft survival was seen with all 
hearts beating strongly at 100 days (n=8). As was anticipated, from our knowledge of the bm12 
to C57BL/6 model, no autoantibody developed in recipients of CD4 T cell deplete donors 
(Figure 3.18a).  
Perhaps more surprisingly was the impact on the alloimmune response. A significant reduction 
in the anti-H-2Kd and anti-I-E alloantibody responses was observed following donor CD4 T cell 
depletion (Figure 3.18b,c). Furthermore, depletion of donor CD4 T cells resulted in reduced 
CD8 alloimmunity as quantified on IFNγ CD8 ELISPOT, and reduced indirect CD4 T cell 
responses, examined by evaluating the proliferation of TCR75 CD4 T cells transferred four 
weeks following transplantation to indicate ongoing immunogenic presentation of H-2Kd 
allopeptide (Figure 3.18d-f). In keeping with this reduction in the autoimmune and alloimmune 
response, there was a significant reduction in donor myocardial and vascular injury (Figure 
3.18g). In support of this role of donor CD4 T cells augmenting the alloimmune responses, 
reconstituting recipients of CD4 deplete donors with donor CD4 T cells on the day of 
transplantation restored alloimmune effector responses and consequent chronic rejection 
(Figure 3.18). These results suggest that donor CD4 T cells, in addition to driving the 
autoantibody responses observed, also have a role in enhancing the adaptive alloimmune 
responses. 
 
 
Figure 3.18 Donor CD4 T cell depletion significantly attenuates auto- and alloimmune responses 
Following transplantation of CD4 deplete bm12.Kd.IE donor cardiac allografts into C57BL/6 recipients a 
significant reduction in auto and alloimmune responses is observed. Autoantibody levels were 
significantly reduced on weekly serum collections [(a), HEp-2 indirect immunofluorescence]. 
Additionally, significant reductions are seen in anti H-2K
d
 [(b), ELISA] and anti-I-E [(c), flow cytometric 
analysis of binding to I-E expressing BMDCs] alloantibody on weekly serum collection. (d) Indirect CD4 T 
cell alloresponses were assayed by adoptive transfer of 4-6x10
6
 CFSE labelled TCR75 CD4 T cells 
(recognising H-2K
d
 allopeptide indirectly) on the day of transplantation and extent of proliferation 
quantified 5 days later by flow cytometry using FlowJo software for analysis (n=3). (e) Cytotoxic CD8 T 
cell alloimmunity was assayed with an IFNγ CD8 ELISPOT 7 days following transplantation. (f) Percentage 
of follicles with germinal centre activity were quantified by immunofluorescence staining (B220 and GL-
7) of cryostat sections of recipient spleen at 50 days following transplantation. (g) Allograft vasculopathy 
was quantified by calculating luminal stenosis on elastin van Gieson stained paraffin sections. Adoptive 
transfer of 5x10
6
 donor (bm12.Kd.IE) enriched CD4 T cells (MACS sorted using anti-CD4 microbeads) on 
the day of transplantation restored humoral responses and allograft vasculopathy (a,b,f,g). P values 
using two-way ANOVA (a-c) and Mann Whitney test (d-g). n=5 unless otherwise stated.  
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3.3.5.2 Memory donor CD4 T cells 
 
In the setting of specific pathogen free mice negligible immunological memory exists. 
However, in clinical transplantation donors will possess a wide repertoire of memory 
lymphocytes. Since memory lymphocytes respond more vigorously and have reduced co-
stimulatory requirements, the possibility that memory donor CD4 T cells would augment the 
alloimmune response to a greater extent than naïve CD4 T cells was next explored. 
Donor bm12.Kd.IE mice were transplanted with tail skin from C57BL/6 (future recipient strain) 
mice. Six weeks later, hearts were procured and transplanted into naïve C57BL/6 recipients 
(Figure 3.19a). Analysis of splenocytes of the donor mice at the time of transplantation 
demonstrated an increase in proportion of CD4 T cells with a CD44+ CD62L- memory phenotype 
(Figure 3.19b). 
  
 
Figure 3.19 Priming of donors to generate recipient strain donor CD4 T cell memory 
(a) Donor bm12.Kd.IE mice were transplanted with C57BL/6 tail skin 6 weeks prior to their use as cardiac 
donors for transplantation into C57BL/6 recipients. (b) At 6 weeks following skin transplantation there 
was an increase in the proportion of antigen experienced CD44
+
 CD62L
-
 CD4 T cells reflecting this 
antigenic challenge  
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In recipients of primed donor cardiac allografts there was a notable acceleration in rejection 
kinetics, with all hearts rejected by 60 days with a median survival of just 30 days (n=4) (Figure 
3.20a). The autoantibody levels quantified in these recipients were significantly augmented in 
keeping with a primed GvH interaction between donor CD4 T cells and recipient B cells. There 
was also augmentation of anti-H-2Kd alloantibody, and a corresponding increase in germinal 
centre activity. The degree of AV though was similar to that observed with un-primed donors 
and this may reflect augmented cytotoxic CD8 alloimmunity contributing to the accelerated 
rejection observed – since the allografts are rejected within this time (Figure 3.20b-e). 
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Figure 3.20 Primed donors drive augmented alloimmune responses and accelerate allograft rejection 
Bm12.Kd.IE donor hearts, primed with a recipient strain 6 weeks prior, were transplanted into C57BL/6 
recipients (n=5). (a) Allograft survival was significantly poorer for primed donor allografts, as assessed by 
thrice weekly abdominal palpation. There were augmented humoral responses with significantly greater 
anti-H-2K
d
 alloantibody [(b), ELISA] and autoantibody [(c), HEp-2 indirect immunofluorescence] levels 
detected in weekly serum samples. A greater proportion of splenic follicles demonstrated germinal 
centre activity (d) as assessed by immunofluorescence staining of cryostat sections with B220 and GL-7. 
Allograft vasculopathy, as assessed on elastin van Gieson stained paraffin sections, was not significantly 
different (e). P values using Log Rank (Mantel Cox) test (a), two-way ANOVA (b,c) and Mann Whitney 
test (d,e). 
 
104 
 
3.3.5.3 Donor CD4 T cells become activated, but their survival in recipients is short-lived 
 
Unlike in the bm12 to C57BL/6 model, bm12.Kd.IE donor haematopoietic cells are rapidly 
cleared by recipient alloimmune effector responses as confirmed by identifying no donor CD4 
T cells in recipients at seven days following transplantation (Figure 3.16). This excludes the 
possibility that donor CD4 T cells are surviving long-term and mediating direct effects against 
the graft, or providing long-term help to recipient effector alloimmune responses. Rather, it 
suggests that donor CD4 T cells act to enhance the alloimmune response early and that this 
enhancement persists long-term despite rapid clearance of the initiating cells.  
To confirm that donor CD4 T cells do become activated and undergo proliferation in recipients, 
CFSE labelled donor bm12.Kd.IE CD4 T cells were adoptively transferred into recipients on the 
day of transplantation. As above, by seven days following transfer, these were not identifiable 
as they had presumably been cleared. However, at three days following transfer, there was 
significant CFSE dilution in a subset of the transferred cells, presumably the alloreactive 
component of the polyclonal donor CD4 T cell population. This confirms that a proportion of 
donor CD4 T cells become activated and divide vigorously early after transplantation (Figure 
3.21). 
 
Figure 3.21 Alloreactive donor CD4 T cells undergo significant proliferation following transplantation 
5x10
6
 enriched bm12.Kd.IE CD4 T cells (MACS separated with anti-CD4 microbeads) were CFSE labelled 
and adoptively transferred into C57BL/6 recipients of CD4 T cell deplete bm12.Kd.IE cardiac allografts on 
the day of transplantation.  Three days later, mice were sacrificed and splenocytes analysed by flow 
cytometry. Donor CD4 T cells were identified by gating on CD4 T cells that stained positive for H-2K
d
. 
Vigorous proliferation of the alloreactive subset of donor CD4 T cells is observed with significant CFSE 
dilution. 
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3.3.6 Recipient T and B cells are essential mediators of the accelerated rejection 
triggered by early graft-versus-host recognition 
 
Since donor CD4 T cells are short-lived, but their impact long-lasting, it appears likely that the 
augmented alloimmune responses and accelerated rejection observed is dependent upon 
alloreactive recipient T and B cell populations. To explore this, bm12.Kd.IE cardiac allografts 
were transplanted into T or B cell deplete recipients and the alloimmune responses examined. 
3.3.6.1 Recipient CD4 T cells are essential for allograft rejection 
 
To examine the role of recipient T cells, bm12.Kd.IE hearts were transplanted into TCRKO 
recipients: C57BL/6 with targeted disruptions of the TCR β and δ genes (Tcrbd-/-)256. These mice 
possess a normal B cell repertoire, but are deficient in CD4 and CD8 T cells. 
Work from our laboratory using these mice as recipients of bm12 cardiac allografts has 
revealed that strong autoantibody responses develop, driven by donor CD4 T cells. Despite 
high levels of autoantibody, no GCs develop suggesting the antibody to be of extra-follicular 
origin. Furthermore, analysis of donor cardiac allografts reveals the absence of AV suggesting 
that extra-follicular autoantibody responses are unable to drive the development and 
progression of AV (Saeed Quereshi, manuscript in preparation).   
Bm12.Kd.IE hearts were transplanted into TCRKO recipients to investigate the role of recipient 
CD4 T cells in the alloimmune response. Similar to previous results with bm12 donor hearts, 
high levels of autoantibody were detected, driven by GvH recognition of recipient B cells by 
donor CD4 T cells. There was only a weak early anti-H-2Kd alloantibody response observed. 
Despite the high levels of autoantibody, no GCs were detected, and as with bm12 donors, no 
C4d deposition nor AV or myocardial injury were evident (Figure 3.22). These data suggest that 
recipient T cells are essential for allograft rejection and whilst donor CD4 T cells play a critical 
role in augmenting the alloresponses, they are insufficient alone to drive allograft injury. 
Recipient CD4 T cells appear essential to drive the sophisticated GC responses resulting in 
development of class-switched, high affinity long-lived antibody responses, responsible for 
driving the predominantly humoral chronic rejection in this model. They may also provide help 
for CD8 cytotoxic alloresponses although these appear restricted to the first week following 
transplantation in this model. The CD4 T cells themselves may, of course, additionally 
contribute directly to allograft damage.  
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Figure 3.22 Absence of recipient CD4 T cells prevents development of damaging humoral alloimmunity 
Bm12.Kd.IE cardiac allografts were transplanted into T cell deficient Tcrbd
-/-
 recipients and alloimmunity 
evaluated over 50 days (n=4). Equivalent autoantibody responses were observed (a), despite absence of 
recipient CD4 T cells (HEp-2 indirect immunofluorescence) and a weak short-lived anti-H-2K
d
 
alloantibody response was seen (b). Despite high levels of autoantibody, unlike in wildtype recipients, 
no C4d deposition was observed on immunohistochemical staining of cryostat sections of day 50 donor 
cardiac allografts (c), and no germinal centre response was present (immunofluorescence staining with 
B220 and GL-7 on cryostat sections of day 50 recipient spleen) (d). Furthermore, no allograft injury was 
observed with minimal allograft vasculopathy observed on elastin van Gieson stained paraffin sections 
of day 50 donor hearts. P values using two-way ANOVA (a,b) and Mann Whitney test (d,e).  
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3.3.6.2 Absence of recipient B cells 
 
To further examine the dominant role humoral immunity appears to play in this model, 
recipients were depleted of B cells using a depleting murine anti-CD20 antibody (clone 18B12 
Biogen Idec, MA, US). A single 250 μg i.p. dose of this monoclonal antibody results in effective 
depletion of circulating and splenic B cells for greater than 14 days (Figure 3.23).  
 
Figure 3.23 Effective B cell depletion is achieved with murine anti-CD20 antibody administration 
(a) Representative flow cytometry plots of peripheral blood obtained prior to (left) and 7 days following 
(right) i.p. administration of 250μg murine anti-CD20 antibody (Biogen Idec) (n=3). Effective depletion of 
B cells is achieved as soon as 3 days following injection and reconstitution begins after 14 days (b). 
 
Recipients were treated 7 days prior to transplant, the day of transplant and every 14 days 
thereafter. As to be expected, there was a significant reduction in anti-Kd alloantibody and 
autoantibody. There was a corresponding reduction in the degree of vasculopathy present in 
intra-myocardial vessels when examined day 50 post-transplant (Figure 3.24a,b).  
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Figure 3.24 Humoral alloimmunity is significantly attenuated following recipient B cell depletion 
(a) Following recipient B cell depletion a significant reduction in anti H-2K
d
 alloantibody (ELISA, left) and 
anti-nuclear autoantibody (HEp-2 indirect immunofluorescence, right) at 50 days following 
transplantation of bm12.Kd.IE cardiac allografts into C57BL/6 recipients is observed (n=4). Histological 
examination of haematoxylin and eosin (i,ii) and elastin van Gieson (iii) stained sections of donor cardiac 
allografts 50 days following transplantation reveal minimal vasculopathy (b), but significant lymphocytic 
infiltrate (c). (d) CD8 IFNγ ELISPOT whilst negative in wildtype recipients 12 days following 
transplantation, is strongly positive in B cell deplete recipients at this time-point (n=4). P values using 
Mann Whitney test.  
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Interestingly though, the donor myocardium was not preserved. There was a significant 
lymphocytic infiltrate and more extensive myocyte damage and drop-out and replacement 
fibrosis than seen in untreated recipients (Figure 3.24c). This suggests that disrupting humoral 
immunity reveals a vigorous cell-mediated alloimmune response not observed in the presence 
of B cells. In keeping with this histological appearance, significantly increased CD8 alloreactivity 
was detected on ELISPOT at day 12 following transplantation when compared to B cell replete 
recipients, where no CD8 alloreactivity was seen at this time point (Figure 3.24d). This could 
simply reflect extended survival of donor haematopoietic cells, such as DCs, in the absence of 
adaptive humoral alloimmunity that could prime CD8 T cells by the direct-pathway. 
3.3.7 Donor CD4 T cells require recipient B cells for augmentation of CD4 indirect 
responses 
 
In the bm12 to C57BL/6 model, the GvH interaction between donor CD4 T cell and recipient B 
cells is central to the development of autoantibody and allograft injury. However, recipient 
CD4 T cells are clearly required for the ongoing provision of help, and my experiments suggest 
the recipient CD4 T cells provide help for driving GC development and CD8 T cell alloimmunity. 
Depletion of recipient B cells in this model results in abrogation of auto- and alloimmune 
humoral responses. However, what is less clear is if recipient B cells are required for the 
augmentation of other arms of the adaptive immune response, driven by the recipient CD4 T 
cells. It is possible, for example, that donor CD4 T cells could interact with other professional 
APCs priming them for enhanced antigen presentation and activation of indirect-pathway CD4 
T cells. 
To examine this, indirect-pathway CD4 T cell proliferation was examined in recipients four 
weeks following transplantation, by quantifying CFSE labelled TCR75 CD4 T cell proliferation. 
Proliferation was significantly reduced in B cell deplete recipients and notably this was reduced 
to a similar extent as was observed in recipients of CD4 deplete donors suggesting that the 
additional proliferation caused by the donor CD4 T cell fraction is mediated via host B cells. 
Furthermore, transplanting CD4 deplete donors into B cell deplete recipients resulted in no 
reduction of indirect-pathway CD4 T cell proliferation.  
Transfer of CFSE labelled donor bm12.Kd.IE CD4 T cells into B cell deplete recipients, as in 
Figure 3.21, revealed an equivalent degree of proliferation of the alloreactive component, 
suggesting that the role of recipient B cells is not simply as a source of recipient MHC class II 
for GvH activation of the donor CD4 T cells, since they appear to achieve similar activation 
110 
 
even in the absence of recipient B cells – but the interaction with non-B cell APCs is insufficient 
to drive augmented alloresponses (Figure 3.25).  
 
 
Figure 3.25 B cell depletion prevents donor CD4 T cell augmentation of recipient CD4 T cell activity 
(a) Wildtype or donor CD4 T cell deplete Bm12.Kd.IE cardiac allografts were transplanted into wildtype 
or B cell deplete recipients (250μg i.p.murine anti-CD20 antibody day -7) (n=4). Recipient indirect-
pathway CD4 T cell responses were examined by transfer of 5x10
6
 CFSE labelled TCR75 splenocytes 4 
weeks following transplantation. Proliferation was quantified by flow cytometry after 6 days. Whereas 
donor CD4 T cell depletion significantly reduced proliferation in wildtype recipients, this was not 
observed in B cell deplete recipients, where proliferation was reduced even in the presence of donor 
CD4 T cells. (b) 5x10
6
 enriched bm12.Kd.IE CD4 T cells (MACS separated with anti-CD4 microbeads) were 
CFSE labelled and adoptively transferred into wildtype or B cell deplete C57BL/6 recipients of CD4 T cell 
deplete bm12.Kd.IE cardiac allografts on the day of transplantation (n=4).  Three days later, mice were 
sacrificed and splenocytes analysed by flow cytometry. Donor CD4 T cells were identified by gating on 
CD4 T cells that stained positive for H-2K
d
. Vigorous proliferation of the alloreactive subset of donor CD4 
T cells is observed and a similar degree of proliferation was observed regardless of whether recipient B 
cells were present. P values using Mann Whitney test. 
 
Together, these results position the interaction between donor CD4 T cells and recipient B cells 
central to the augmentation of recipient CD4 T cell responses that are in turn responsible for 
augmentation of adaptive humoral and cellular immune responses that effect allograft  
rejection. 
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3.3.8 No evidence of systemic autoimmunity / graft-versus-host disease 
 
It is notable that despite significant levels of autoantibody and the significant contribution GvH 
recognition of recipient by donor CD4 T cells makes, the recipient mice show no overt signs of 
systemic autoimmunity or GvH disease. To further confirm this, recipient heart, kidneys and 
liver were analysed histologically. Analysis of these slides was performed by a consultant 
histopathologist (Dr Sue Davies, Addenbrookes Hospital, Cambridge, UK). No evidence of 
parenchymal injury nor evidence of GVHD were found in any of these tissues, suggesting the 
donor cardiac allograft is the sole target of the autoantibody response. 
 
 
Figure 3.26 No evidence of systemic graft versus host disease is apparent in recipients 
Representative photomicrographs of skin (a), kidney (b), liver (c) and native heart (d) retrieved from 
C57BL/6 recipients of bm12.Kd.IE cardiac allografts 100 days after transplantation and either 
haematoxylin and eosin staining (a-c) or elastin van Gieson's staining (d) of paraffin sections assessed for 
presence of inflammation. All tissues sampled were unremarkable and free from inflammation. 
Magnification detailed in panels.   
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3.3.9 Wider relevance of these findings to clinical transplantation 
 
The wider relevance of these observations to clinical transplantation is not immediately clear, 
because in this murine model the minimally mismatched nature of I-Abm12 to I-Ab is unusual. 
Nevertheless, there is increasing appreciation of the role of autoimmunity in 
transplantation291-293, and donor CD4 T chimerism has been described, and implicated in GvH 
disease309, and rarer clinical scenarios, such as passenger lymphocyte syndrome310-312. 
In the current model, whilst it is observed that donor cells evade innate immune surveillance, 
they are eventually cleared by recipient adaptive alloimmune responses. It is therefore likely 
that with more mismatched models, NK cells would recognise donor cells as non-self due to 
the absence of self MHC class I expression. Thus, in the bm12.Kd.IE to C57BL/6 model, lack of 
NK cell allorecognition may permit donor CD4 T cell survival long enough for them to interact 
with recipient B cells in a GvH manner and thus trigger augmented alloimmunity. One would 
therefore expect that this effect would not be observed in more mismatched models.   
To test this hypothesis, a fully mismatched BALB/c to C57BL/6 strain combination was studied. 
As demonstrated in Section 3.3.4, BALB/c cells are rapidly cleared by RAG2KO recipients due to 
innate immune recognition and clearance. However, if NK cells are depleted from RAG2KO 
recipients, with anti NK 1.1 monoclonal antibody (clone PK136) prior to cell transfer, long term 
survival of BALB/c CD4 T cells was observed, highlighting the importance of NK cell 
allorecognition (Figure 3.27a). 
In keeping with their rapid clearance by NK cells, no autoantibody was observed following 
adoptive transfer of BALB/c CD4 T cells into C57BL/6 recipients (Figure 3.27). However, when 
BALB/c CD4 T cells were transferred into C57BL/6 recipients that had been treated to deplete 
NK cells, strong autoantibody levels were observed suggesting that donor CD4 T cell GvH 
recognition of recipient B cells driving autoantibody is not simply a peculiarity of the bm12 to 
C57BL/6 model (Figure 3.27b). Rather, these results suggest that the GvH response will be 
relevant in any MHC class II mismatched donor-recipient combination in which NK cell 
allorecognition does not occur, and donor CD4 T cells survive for long enough to make cognate 
interaction with intact allogeneic MHC class II on recipient B cells. 
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Figure 3.27 NK allorecognition limits donor CD4 T cell GvH activity and development of autoantibody 
(a) 5x106 enriched BALB/c CD4 T cells (MACS separated with anti-CD4 microbeads) were adoptively 
transferred i.v. into untreated or NK cell deplete RAG2KO recipients (administration of anti-NK1.1 
antibody, clone PK136, 0.5mg i.p. day -2, 0 and +2). Flow cytometric analysis of peripheral blood at two 
weeks revealed survival of CD4 T cells only in NK deplete recipients. (b) Similarly, whilst i.v. 
administration of BALB/c CD4 T cells into wildtype C57BL/6 recipients resulted in minimal autoantibody 
development, a strong autoimmune response was observed when cells were transferred into NK 
deplete C57BL/6 recipients (HEp-2 indirect immunofluorescence). 
 
3.3.9.1 Augmentation of alloimmunity occurs in the absence of NK cell allorecognition 
 
The observation that autoantibody is detected after BALB/c CD4 T cell transfer into NK deplete 
C57BL/6 recipients suggests that donor CD4 T cell GvH interaction with recipient B cells is 
normally prevented in MHC-mismatched transplant models by host NK cell alloreactivity. The 
possibility that, in the absence of NK cell alloreactivity, augmentation of recipient alloimmune 
effector responses would occur with any donor-recipient mismatch was next evaluated. 
BALB/c cardiac allografts are acutely rejected within 7-10 days following transplantation and I 
thought it likely was too rapid to be potentially influenced by NK cell depletion. Therefore, the 
model was manipulated to become a model of chronic alloantibody-mediated rejection.  
Here, BALB/c cardiac allografts were transplanted into C57BL/6 T cell deplete TCRKO recipients 
which were reconstituted at transplantation with TCR75 CD4 T cells (H-2Kd antigen-specific 
indirect-pathway CD4 T cells), but at limiting numbers (103 per mouse), such that rejection 
occurs slowly and is mediated by anti-H-2kd germinal centre alloantibody responses, with help 
provided by differentiation of the transferred TCR75 T cells to follicular helper T cells (Figure 
3.28a; model developed and characterised by M Chhabra, manuscript in preparation). 
Such transplants were performed into untreated and NK deplete TCRKO recipients. In NK 
deplete recipients, as anticipated from the previous finding, development of autoantibody was 
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observed. Furthermore, the anti-H-2Kd alloantibody response was significantly augmented. 
Perhaps most striking though was the impact on allograft rejection. Whilst a median survival 
time of >50 days is achieved in untreated TCRKO recipients, depletion of NK cells resulted in 
acute rejection of the allografts, with all rejected in under 9 days. To confirm that this was due 
to donor CD4 T cell GvH interactions, a further group of NK deplete recipients received CD4 
deplete BALB/c cardiac allografts. When compared to NK cell-depleted recipients of 
unmodified BALB/c heart allografts, recipients of CD4 T cell-depleted BALB/c heart allografts 
developed auto- and alloantibody responses that were comparable to those observed in NK 
cell-replete recipients of unmodified heart grafts (Figure 3.28). Kinetics of graft rejection were 
similarly delayed (Figure 3.28). 
These results suggest that through preventing donor CD4 T cell GvH interactions in the 
recipient, NK cell allorecognition and clearance of passenger donor leukocytes may 
paradoxically prolong the survival of allografts. This clearly may have implications for donor 
and recipient combinations in which NK cell allorecognition does not occur. 
 
Putting together the previous observations with the bm12 to C57BL/6 model and the current 
findings, a model for how donor CD4 T cells may influence the alloimmune effector responses 
is presented in Figure 3.29. 
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Figure 3.28 Host NK cell alloreactivity is critical for preventing passenger donor lymphocytes from 
augmenting host adaptive alloimmunity 
(a) A model of chronic alloantibody-mediated vasculopathy was developed in which 10
3
 TCR75 CD4 T 
cells are transferred into T cell deplete TCRKO mice at transplant with a BALB/c cardiac allograft. Some 
recipients were treated to deplete NK cells (administration of anti-NK1.1 antibody, clone PK136, 0.5mg 
i.p. day -2, 0 and alternate days thereafter) and some donors were depleted of CD4 T cells prior to 
transplantation (administration of anti-CD4 antibody, clone YTS, 1mg day -5 and -1). Weekly serum 
samples were obtained and autoantibody [(b), HEp-2 indirect immunofluorescence] and anti-H-2K
d
 
alloantibody [(c), ELISA] was quantified. Autoantibody and a significant augmentation in the alloantibody 
response was observed following recipient NK cell depletion. A corresponding acceleration in allograft 
rejection was observed in NK cell deplete recipients (d). Depletion of donor CD4 T cells abrogated the 
augmented antibody responses and significantly delayed rejection. All groups n=5. P values using two-
way ANOVA (b,c) and log-rank analysis (d). 
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Figure 3.29 Proposed model for augmentation of host adaptive alloimmunity by passenger lymphocytes. 
NK cell allorecognition normally results in rapid destruction of passenger donor lymphocytes within solid organ allografts (1). If NK cell allorecognition is avoided, ‘direct-pathway’ 
graft-versus-host recognition by donor CD4 T cells can activate all recipient B cells (2), but class-switched antibody secretion is dependent upon simultaneous ligation of their B cell 
receptor with target antigen (3). Activated B cells drive enhanced activation of host CD4 T cells with indirect-pathway allospecificity (4), which provide reciprocal help for development 
of germinal centre alloantibody responses (5), presumably reflecting unique T follicular helper cell function of host CD4 T cells in providing cognate, allopeptide-specific help (5). This 
results in long-term augmentation of humoral alloimmunity (6), with more rapid progression of allograft vasculopathy and early allograft failure (7). Enhanced activation of indirect-
pathway CD4 T cells may also contribute to allograft rejection through the provision of help for generating heightened host CD8 T cell cytotoxic alloresponses (8).  
117 
 
3.4 Discussion 
 
Although the presence of passenger donor lymphocytes in the circulation of recipients of solid 
organ transplants was first demonstrated over two decades ago, the extent to which they 
impact on recipient alloimmunity has remained unclear308, 313. The realisation that significant 
populations of memory T lymphocytes are resident within non-lymphoid organs and tissues, 
including all solid organs transplanted in humans, has made understanding their role more 
pertinent304-306, 314. In human clinical transplantation, donor CD4 T cells have already been 
implicated in development of invariably fatal GVHD309 and passenger leukocyte syndrome311, 312 
In this chapter the bm12.Kd.IE to C57BL/6 model of heterotopic cardiac transplantation has 
been fully examined as a model of chronic rejection. The presence of mismatched MHC class I 
H-2Kd and MHC class II I-E and I-Abm12 lead to chronic rejection characterised by development 
of GC antinuclear autoantibody, anti-H-2Kd and anti-I-E alloantibody responses and short-lived 
CD8 cytotoxicity which resulted in the development of AV. Further characterisation revealed a 
significant role for passenger donor CD4 T cells in augmenting all arms of the alloimmune 
response through a GvH interaction with recipient B cells, with markedly reduced humoral and 
cellular alloresponses and AV evident in recipients of CD4 depleted donors. The presence of 
memory CD4 T cells augmented the alloimmune response, and significantly accelerated 
rejection kinetics. Examination of the role of donor CD4 T cells revealed that the alloreactive 
fraction of the polyclonal donor CD4 T cell population undergo several rounds of proliferation 
within the first few days of transplantation, but also that these cells are cleared within 7 days. 
Donor CD4 T cells therefore augment long-lived adaptive alloresponses within this early post-
transplant period, but are themselves cleared by the adaptive responses they augment, with a 
requirement for recipient T and B cells to drive the ongoing alloresponse. Bm12.Kd.IE donor 
cells evade innate immune recognition, and this was found to be critical for the passenger 
donor CD4 GvH interaction with recipient B cells. Depletion of recipient NK cells was found to 
reveal this role for passenger donor CD4 T cells in the BALB/c to C57BL/6 model, highlighting a 
novel role for NK cells in suppressing alloimmunity in NK cell receptor mismatched 
donor/recipient pairs. 
This work extends previous observations from the laboratory that attributed a role for 
passenger donor CD4 T cells in the development of autoantibody in the bm12 to C57BL/6 
model274. The results highlight that the cognate GvH interaction between donor CD4 T cells 
and recipient B cells additionally drives augmented alloimmune responses. This unusual form 
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of global B cell help arises due to the peptide-degenerate nature of direct-pathway 
recognition48, 63. Thus, all recipient B cells receive equivalent help, irrespective of their 
specificity, and show upregulated MHC class II expression (Saeed Qureshi, unpublished data). 
Differentiation into an antibody secreting plasma cell is determined by the availability of target 
antigen, as described in the introduction. However, it is clear that this interaction does not 
replicate conventional CD4 T cell help as in the absence of recipient CD4 T cells the auto and 
alloantibody responses were not sustained, GCs did not develop and allograft rejection did not 
occur. 
Recipient CD4 T cells therefore play a critical role in directing the augmented alloimmune 
responses. It would be predicted that donor CD4 T cell GvH interaction will drive increased 
allopeptide presentation by allospecific B cells (as evidenced by upregulation of MHC class II), 
resulting in increased indirect-pathway activation of recipient CD4 T cells. This was evidenced 
by increased TCR75 proliferation in CD4 T cell replete donors. Indirect-pathway CD4 T cells are 
known to be required for development of alloantibody responses100, and it is conceivable that 
the activated CD4 T cells will provide reciprocal help to those B cells with which they have 
interact, thus explaining the central role for recipient CD4 T cells in the process315. An 
additional role likely played by recipient CD4 T cells, is as follicular helper T cells (Tfh), which 
are pivotal for the development of GC responses providing antigen-specific cognate help to B 
cells driving the GC reaction316. Work underway in our laboratory has begun to dissect out the 
respective roles of recipient and donor CD4 T cells in initiating these GC reactions. Utilising a 
series of models including incorporating signaling lymphocyte activation molecule-associated 
protein (SAP) knock-out mice (in which T cells are unable to initiate GC reactions)317, we have 
demonstrated that donor CD4 T cells are not required to drive the GC responses observed 
(Saeed Qureshi, manuscript in preparation). Why donor CD4 T cells are unable to adopt a Tfh 
role is unclear. However, there is some evidence suggesting that the affinity of peptide-MHC – 
TCR interaction influences CD4 T cell differentiation into a Tfh program and subsequent 
function318. Direct-pathway interactions are peptide degenerate and may therefore not be of 
high enough affinity to initiate Tfh differentiation. 
It was notable that in the absence of recipient T cells, although alloantibody and autoantibody 
responses developed, there was no evidence of AV. Other work in our laboratory has 
demonstrated that the development of AV correlates with the development of GC responses 
(Saeed Qureshi, manuscript in preparation). GCs are responsible for the development of long-
lived, high-affinity antibody responses316, and it is plausible that high affinity antibody is more 
able to initiate the effector pathways upon binding to donor endothelium responsible for the 
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development of AV27. Alternatively, GC responses are also required to drive epitope 
diversification and it may be that diversification of the allo and autoantibody repertoires is 
required to develop the pathological humoral response132, 319. In support, we have 
demonstrated that anti-vimentin autoantibody only develops when GC responses occur (Saeed 
Qureshi, manuscript in preparation), and anti-vimentin autoantibody has previously been 
associated with development of AV in human cardiac transplant recipients297. 
Recipient B cells are central to the augmented alloimmune responses observed, both 
enhancing indirect-pathway CD4 T cell alloresponses and as humoral effectors. As expected, 
depletion of recipient B cells resulted in significantly reduced development of AV. Interestingly 
though, histological evaluation of the allografts revealed significant lymphocytic infiltration 
and parenchymal injury, and CD8 cytotoxic alloresponses were augmented. There are several 
possible explanations for this observation. In addition to production of antibody, B cells have 
other essential roles in adaptive immunity. B cells have an important role as antigen 
presenting cells for initiating adaptive immunity as they are able to efficiently detect and 
internalise their target antigen320. It is recognised that through this cognate interaction with 
naïve CD4 T cells, B cells are able to influence and direct the nature of helper CD4 T cell 
differentiation favouring Th2 commitment315. In the absence of B cells, perhaps Th1 cell 
mediated responses are favoured. A similar observation was made in human kidney 
transplantation where depletion of recipient B cells with rituximab (anti-CD20 mAb) resulted in 
increased rates of acute cellular rejection resulting in early suspension of a clinical trial240. 
Alternatively, rituximab administration may also deplete regulatory B cells that may play an 
important regulatory role in the alloimmune response321. Another possibility is that in the 
absence of humoral alloimmunity, donor APCs are able to survive longer term, and perhaps 
this permits ongoing direct-pathway CD8 T cell activation accounting for the augmented CD8 
cytotoxicity observed. 
The most interesting observation in this chapter is that the development of autoantibody 
through the GvH interaction between donor CD4 T cells and recipient B cells is not simply a 
quirk of the minimal nature of the MHC class II mismatch between I-Abm12 and I-Ab antigens. 
Rather, autoantibody development and augmentation of adaptive alloimmunity is limited by 
NK cell allorecognition and rapid clearance of passenger donor leukocytes. This perhaps helps 
to explain the inconsistent autoantibody development observed in human transplant 
recipients291-293. The results in this chapter suggest a novel mechanism by which NK cells inhibit 
allograft rejection. As described in Chapter 1, the role of NK cells in alloimmunity remains to be 
completely understood. There is both evidence that NK cells promote allograft rejection, for 
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example through the killing of opsonised cells, and evidence supporting a role in allograft 
tolerance197. The results in this chapter support that NK cells play an important role in limiting 
destructive cellular and humoral alloimmunity, but through a novel mechanism – the rapid 
deletion of passenger donor CD4 T cells. The tolerogenic mechanisms employed by NK cells 
previously described include rapid deletion of passenger DCs, therefore reducing adaptive 
immune priming, and deletion of activated recipient CD4 T cells202, 205, 207. It could be argued 
that clearance of donor CD4 T cells is a more important tolerogenic role for NK cells 
considering the impact that they can have on adaptive alloimmunity. For example, irrespective 
of NK cell allorecognition, allogeneic DCs would be expected to be cleared promptly by 
adaptive immune allorecognition, limiting their effect. In this regard it is notable that the 
model used to demonstrate NK deletion of donor DCs to influence CD4 T cell alloimmunity 
utilised CD8-/- mice preventing their clearance by CD8 T cell cytotoxicity208. In contrast, 
adaptive immune clearance is too slow to prevent the donor CD4 T cell GvH mediated 
augmentation of adaptive alloimmunity and there is a critical window within the first few days 
after transplantation during which evasion of NK cell mediated killing is essential. 
These results are of interest when considering the recent focus of some research which aims 
to improve allograft outcomes by achieving mixed haematopoietic chimeric states in recipients 
to achieve donor-specific tolerance322. The persistence of donor lymphocytes in recipients 
would imply that augmentation of recipient alloimmunity is not occurring. This may be due to 
the impact of myeloablative therapy the recipient is often subjected to prior to attainment of 
mixed chimerism322. In support of this, a study in murine skin transplant recipients 
demonstrated that chimerism was associated with stronger alloimmunity and more rapid 
allograft rejection in immunologically mature recipients, but tolerance in immature 
recipients323. It is also interesting to note that autoantibody, using HEp-2 immunofluorescence, 
has been observed in human kidney and bone-marrow transplant recipients in which mixed 
haematopoietic chimerism was achieved by non-myeloablative conditioning, supporting that 
donor CD4 T cell GvH interaction with recipient B cells may be an important factor to consider 
in these approaches.  
The prediction from this work would be that those with an NK KIR match (as is reported to 
occur in approximately 50% of kidney transplant pairs198) may have inferior outcomes because 
the avoidance of immediate host NK cell detection would enable donor lymphocytes to 
potentiate host alloimmunity.  These findings may then, have important clinical relevance, 
which could be elucidated by undertaking a clinical study. HLA and NK KIR typing of donors and 
recipients could be performed, and clinical outcomes following transplantation compared 
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between patients who do and do not possess an NK KIR mismatch. A retrospective clinical 
study which has partially addressed this, observed that a KIR mismatch was in fact associated 
with poorer clinical outcomes following kidney transplantation198. However, this analysis was 
restricted to minimally mismatched donor/recipient pairs with the aim of investigating the role 
of NK allorecognition in isolation of adaptive alloimmunity. The findings in this chapter though, 
would predict KIR matching to compromise outcomes only when donor and recipient are 
additionally mismatched at MHC class II loci (for direct-pathway GvH interaction). 
Furthermore, understanding of NK cell receptors and what constitutes a ‘match’ remains 
incompletely understood324. 
A further intriguing consideration is mother to child living organ donation. Should a mother 
become sensitised during pregnancy, it is conceivable that they would possess tissue-resident 
memory CD4 T cells targeted against the mismatched HLA of their child. The results in this 
chapter would predict that if there was a KIR match between the mother and child, following 
transplantation passenger memory lymphocytes may impact deleteriously on clinical outcome. 
This is a hypothesis that could be tested by examining sensitisation status, KIR type and clinical 
outcomes of relevant living donor-recipient pairs. 
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4 CD4 Direct-pathway allorecognition 
is short-lived and limited by both 
innate and adaptive immunity 
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4.1 Introduction 
 
4.1.1 Direct CD4 allorecognition 
 
Direct-pathway allorecognition is unique to transplantation. Here, recipient CD4 T cells 
recognise intact allogeneic MHC class II on passenger donor APCs48. There is an unusually high 
precursor frequency for direct-pathway allorecognition and the strength of mixed lymphocyte 
reactions in vitro have led many to conclude that direct-pathway allorecognition is responsible 
for acute rejection49-51. However, the precise contribution that direct-pathway allorecognition 
makes to allograft rejection remains uncertain. In animal models where allorecognition is 
restricted to the indirect-pathway, acute rejection can still be observed120, 121. Furthermore, 
clearance of passenger donor APCs soon after transplantation by innate immunity is thought 
to limit direct-pathway allorecognition to the period immediately following transplantation48. 
The development of TCR transgenic technology has enabled the development of mouse strains 
that permit investigators to track individual T cells of known antigenic specificity, thus 
providing additional insight into the in vivo fate and function of individual antigen-reactive T 
cells. Two TCR transgenic strains have been developed to investigate direct-pathway 
allorecognition: 4C and ABM 
 
4.1.2 TCR transgenic models to study direct allorecognition – 4C and ABM 
 
The 4C TCR transgenic CD4 T cell is on a Rag-/- C57BL/6 background and recognises intact I-Ad, 
an MHC class II molecule expressed by BALB/c81. In vitro these CD4 T cells could be activated 
by BALB/c DCs, B cells, macrophages and activated endothelial cells. Following transplantation 
of BALB/c skin or cardiac allografts into Rag-/- recipients significant proliferation of adoptively 
transferred 4C cells was observed. Skin allografts rejected acutely, whilst cardiac allografts 
developed AV. Priming of the 4Cs prior to challenge with a cardiac allograft resulted in acute 
rejection, suggesting that direct-pathway CD4 T cells alone have the potential to mediate 
allograft injury and rejection81. 
The ABM TCR transgenic CD4 T cell is similarly on a Rag-/- C57BL/6 background and recognises 
intact I-Abm12, the MHC class II expressed by bm12 mice261. Early work with this model 
demonstrated that the presence of ABM CD4 T cells could accelerate rejection of bm12 skin325. 
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This was extended to demonstrate that bm12 cardiac allografts could be acutely rejected by 
Rag-/-.ABM recipients, but only if the recipients were primed with bm12 skin prior to the 
cardiac allograft. Surprisingly, without priming, cardiac allografts survived long-term and did 
not develop significant injury326. These results again supported the assertion that direct-
pathway CD4 T cells may have the potential to mediate allograft rejection in certain 
circumstances. 
The studies described above using TCR transgenic direct-pathway CD4 T cells have focused on 
examining their ability to reject allografts in isolation. However, this does not replicate the 
clinical setting where there will be interplay of multiple adaptive immune pathways. 
Furthermore, the work has focused on examining proliferation in the early period following 
transplantation and has not examined the duration of these responses. 
The relevance of this to clinical transplantation is seen when considering the use of cellular 
immunotherapies, for example Treg. Research is currently underway to examine the relative 
efficacy of different Treg products – including direct and indirect-pathway antigen specific 
Treg, such as the One study215. The current focus is administration to recipients of living donor 
organs where the product can be prepared for administration on the day of transplantation. 
Looking forward, it is likely that Treg therapy will be extended to cadaveric organ recipients, 
administered later following transplantation. Having an insight into the relative duration of 
direct and indirect-pathway allorecognition may guide rational development of antigen-
specific Treg therapies at these later times following transplantation.  
 
 
 
  
125 
 
4.2 Aims 
 
The purpose of the research described in this chapter is to extend the findings reported with 
direct-pathway TCR transgenic CD4 T cells and to examine direct-pathway allorecognition in 
wildtype recipients of cardiac allografts in which the adaptive immune response is not 
restricted to direct-pathway allorecognition. 
 
The aims are: 
 
1) To determine the duration of direct-pathway CD4 T cell alloresponses. 
 
2) To examine the factors responsible for limiting direct-pathway allorecognition.  
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4.3 Results 
 
4.3.1 Challenges encountered using ABM transgenic CD4 T cells 
 
Direct-pathway CD4 T cell allorecognition was suggested to be short-lived in section 3.3.1, 
using ABM TCR transgenic CD4 T cells in C57BL/6 recipients of bm12 cardiac allografts.  To 
further investigate direct-pathway allorecognition, proliferation of ABM CD4 T cells was 
evaluated in C57BL/6 recipients of bm12.Kd.IE cardiac allografts. It was notable that a much 
larger number of splenocytes were required for adoptive transfer experiments in order to 
detect a population 6 days later, as compared to the 3 other transgenic populations used 
(TCR75, TEa and Mar), raising question as to the survival of ABM CD4 T cells in C57BL/6 mice. 
To investigate this, ABM CD4 T cells were adoptively transferred into naïve C57BL/6 mice with 
a congenic marker (CD45.1) to permit more definitive identification of transferred cells. Only a 
small population were identified 6 days after transfer (Figure 4.1a). Of more concern, a 
proportion of the ABM cells had undergone division, suggesting an element of cross-reactivity 
with I-Ab, and this was in keeping with the greater than expected proliferation of ABM in naïve 
C57BL/6 detected in Figure 4.1b, approaching 15% in comparison with <2-3% for the other TCR 
transgenic CD4 T cells (Figure 3.4). Despite these limitations, the time period following 
transplantation during which adoptively transferred ABM CD4 T cells underwent proliferation 
was short-lived, with proliferation being back to baseline at week 5 following transplantation 
(Figure 4.1b). 
Proliferation of ABM CD4 T cells was also evaluated in RAG2KO recipients of bm12.Kd.IE 
hearts. Since bm12.Kd.IE cells are not cleared by the innate immune response (Section 3.3.4), 
it was anticipated that donor APCs would continue to drive direct-pathway allorecognition 
long term, limited by their natural senescence. The hypothesis therefore, was that direct-
pathway allorecognition would be longer-lived in these recipients. The experimental data 
supported the hypothesis; in the absence of adaptive immune clearance, significant 
proliferation was observed at the late time-point (Figure 4.1c). As above, some proliferation 
was seen upon transfer into the naïve control mouse, which was not observed for the other 
transgenic CD4 T cell clones, raising concern over continued use of ABM CD4 T cells in this 
work. 
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Figure 4.1 ABM proliferation is short-lived in wildtype but long-lived in RAG2KO recipients 
(a) 6-8x10
6
 CFSE labelled ABM splenocytes were adoptively transferred i.v. into naïve control (left 
panels) or bm12.Kd.IE cardiac allograft recipient congenically marked CD45.1 C57BL/6 mice on the day 
of transplantation (day 0, right panels). Six days following transfer, spleens were harvested and analysed 
by flow cytometry. ABM CD4 T cells were gated on the basis of CD45.2 and Vβ8 expression (upper 
panels) and presented as histograms against CFSE (lower panels) Proliferation was quantified by FlowJo 
software (percentage proliferation as inset of panels). Of concern, a significant degree of proliferation 
was observed in naïve recipients. (b) Proliferation of CFSE labelled ABM CD4 T cells transferred at week 
1 or week 5 was quantified as above, following bm12.Kd.IE cardiac transplantation into wildtype 
C57BL/6 (n=3). (c) A significant degree of proliferation (inset percentages) was observed when ABM 
splenocytes were adoptively transferred, as above, but into RAG2KO recipients following 
transplantation at both early (day 0) and late (day 28) time-points (n=3). In RAG2KO recipients ABM CD4 
T cells were identified by Vβ8 expression since RAG2KO lack T cells. P values using Mann Whitney test.  
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4.3.2 Using TCR75 transgenic CD4 T cells for investigating direct allorecognition 
 
In view of the difficulties encountered with the ABM CD4 T cells, an alternative model of 
direct-pathway allorecognition was developed using TCR75 transgenic CD4 T cells. These cells 
recognise a peptide from MHC class I H-2Kd presented in the context of class II I-Ab, and have 
been used to evaluate indirect-pathway allorecognition162. TCR75 CD4 T cells can be restricted 
to direct-pathway allorecognition if the donor expresses both the MHC class I H-2Kd and the 
class II I-Ab, and if neither are expressed by the graft recipient (Figure 4.2). This scenario could 
be achieved by grafting a heart from a B6.Kd or a C57BL/6 x BALB/c F1 (CB6F1) donor into a 
bm12 recipient. 
 
Figure 4.2 Using TCR75 CD4 T cells to examine direct-pathway allorecognition 
(a) TCR75 CD4 T cells recognise I-A
b
 restricted H-2K
d
 allopeptide, and have been widely used to examine 
indirect-pathway CD4 T cell allorecognition in C57BL/6 recipients. (b) However, if a donor strain co-
expresses I-A
b
 and H-2K
d
 then donor APCs will present the TCR75 TCR epitope. Should the recipient 
strain lack I-A
b
 then the TCR75 can only become activated and induced to divide by recognition of intact 
donor class II and therefore represent direct-pathway allorecognition (albeit restricted to presentation 
of a single defined peptide, whereas direct-pathway recognition is usually considered peptide 
degenerate.) 
 
B6.Kd mice express the additional MHC class I H-2Kd as a transgene. Cardiac allografts are 
rejected chronically in C57BL/6 recipients153, with development of anti-H-2Kd alloantibody100. It 
would be anticipated that rejection kinetics will be similar if B6.Kd cardiac allografts are 
transplanted into bm12 recipients, identical to C57BL/6 other than the mutated class II I-Abm12, 
and therefore suitable for studying late direct-pathway allorecognition with TCR75 CD4 T cells. 
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Although I-Abm12 differs from I-Ab by only 3 amino acids, TCR75 CD4 T cells do not proliferate in 
response to H-2Kd allopeptide presented by I-Abm12 100. To evaluate the ability of TCR75 to 
recognise antigen by the direct-pathway, B6.Kd cardiac allografts were transplanted into bm12 
recipients, and TCR75 splenocytes adoptively transferred either on day 0 or day 28. As 
anticipated, proliferation was observed early confirming the strategy to employ TCR75 for 
examining direct-pathway allorecognition to be feasible. Proliferation was notably weaker than 
when TCR75 are utilised to examine the indirect-pathway (Section 3.3.1), likely reflecting lower 
antigen availability since the epitope will only be presented by passenger donor APCs.   
Furthermore, no proliferation was detected at the late point following transplantation in 
keeping with the earlier results. Consistent with the prevailing view that direct-pathway CD4 T 
cell allorecognition reflects recognition of intact donor MHC class II on professional APCs, 
subjecting B6.Kd donors to lethal irradiation prior to transplantation (to ablate the 
haematopoietic compartment) resulted in abrogation of direct recognition (Figure 3.3). 
As with bm12.Kd.IE donors, B6.Kd donor cells are sufficiently similar to ‘self’ to preclude innate 
immune recognition and clearance of donor cells125. Whilst it is commonly held that direct-
pathway allorecognition, although strong, is short-lived due to rapid clearance of donor DCs by 
recipient innate immunity – in particular NK cells76, the absence of a late direct-pathway 
response observed with ABM CD4 T cells with bm12.Kd.IE donors and with TCR75 CD4 T cells 
here indicate that adaptive immunity may play a role in clearing donor cells, limiting the 
duration of direct-pathway allorecognition. 
 
Figure 4.3 The direct-pathway is short lived and can be limited by adaptive immune responses 
B6.Kd cardiac allografts were transplanted into bm12 recipients and 4-6x10
6
 CFSE labelled TCR75 
splenocytes adoptively transferred i.v. at week 1 or 5 (n=4). TCR75 proliferation was quantified by flow 
cytometry 6 days later. Some donors were subjected to lethal irradiation with 13 Gray as a split dose 
and transplanted after 7 days. P values using Mann Whitney test.  
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4.3.3 Evaluating the role of innate immunity in limiting direct-pathway 
allorecognition 
 
4.3.3.1 Validating a model of TCR75 direct -pathway allorecognition in which there is NK 
mediated recognition 
 
To evaluate the role of NK cells in limiting direct-pathway allorecognition an alternative model 
was sought in which a greater mismatch results in NK mediated immune recognition of donor 
cells. CB6F1 animals (the F1 offspring of a cross between BALB/c and C57BL/6 mice) express 
both I-Ab and H-2Kd and if transplanted into bm12 recipients would be predicted to drive 
TCR75 direct-pathway allorecognition in similar fashion to that described in the previous 
section. The CB6F1 donor is a haplotype mismatch, with both shared and mismatched MHC 
molecules with the bm12 recipient. It was first important to confirm that NK recognition and 
killing of CB6F1 cells by donor mice occurs. This was achieved by adoptive transfer of purified 
CB6F1 CD4 T cells i.v. into H-2b RAG2KO recipients (lacking adaptive immunity) and Rag2IL2rg 
(RAG2KO mice with an additional IL-2 common γ chain knock-out, which renders the animals 
additionally deplete of NK cells)258. These experiments confirmed that CB6F1 CD4 T cells are 
subject to NK cell mediated clearance. Whilst CD4 T cells did not survive in RAG2KO recipients, 
survival was equivalent to syngeneic cells in Rag2IL2rg mice (Figure 4.4).  
Having confirmed that CB6F1 cells are subject to NK mediated clearance, the ability of TCR75 
CD4 T cells to recognise their epitope by the direct-pathway in this model was next evaluated. 
Adoptive transfer of CFSE labelled TCR75 splenocytes into bm12 recipients of CB6F1 cardiac 
allografts on the day of transplantation revealed that direct-pathway allorecognition does 
occur, although TCR75 proliferation was weaker than in the above B6.Kd to bm12 model, 
possibly due to the reduced proportion of direct ‘alloantigen’ present on donor cells as a 
consequence of the cells expressing a greater number of different class I and II molecules. 
TCR75 proliferation was restricted to the first week following transplantation reaffirming the 
observation that direct-pathway allorecognition is short-lived (Figure 4.4). 
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Figure 4.4 Evaluating direct-pathway allorecognition in the CB6F1 to bm12 model 
(a) CB6F1 donor cardiac allografts were transplanted into bm12 recipients, representing a haplotype 
mismatch, but with some common MHC class I molecules. 5x10
6
 enriched CB6F1 or syngeneic C57BL/6 
CD4 T cells (MACS separated with anti-CD4 microbeads) were adoptively transferred i.v. into RAG2KO 
[(b) lacking adaptive immunity]  or RagIL2rg [(c) additionally lacking NK cells] recipients (n=3). Weekly 
blood samples were processed by flow cytometry to quantify the surviving CD4 T cell population. CB6F1 
cardiac allografts were then transplanted into bm12 recipients and 4-6x10
6
 CFSE labelled TCR75 
splenocytes were adoptively transferred on the day of transplant. Spleens were harvested 6 days later 
TCR75 proliferation was observed on flow cytometry confirming TCR75 direct-pathway allorecognition 
occurs (d). Subsequently this was repeated with transfer of TCR75 at week 1, 2 and 3 (n=5) and extent of 
proliferation quantified with FlowJo software. P values using Mann Whitney test. 
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4.3.3.2 The role of donor APCs in priming direct allorecognition 
 
The observation in bm12 recipients of B6.Kd donor cardiac allografts, that direct-pathway 
allorecognition is abrogated by donor irradiation (Figure 4.3) alludes to direct-pathway 
allorecognition being principally dependent upon donor APCs as has been previously 
suggested76. To further investigate that donor APCs are the predominant donor cell type 
presenting MHC class II for recipient direct-pathway allorecognition, transplants were 
performed with donors that had been treated to deplete APC populations. For these 
experiments, CB6F1 mice expressing the diphtheria toxin receptor (DTR) gene under the CD11c 
promoter (CB6F1.DTR) were utilised, allowing for donor DC depletion with administration of 
Diphtheria toxin (DTx), in addition to depletion of other leukocyte subsets with depleting 
antibody administration257, 327, 328. It should be noted that although widely used, the CD11c.DTR 
model is not without significant limitations. It has been reported that expression of the 
transgene is ‘promiscuous’ and administration of DTX results in depletion of cells other than 
DCs – including some macrophage subtypes, CD8 T cells and even some GC B cells329-331. 
Therefore caution must be exercised in concluding that all differences observed following DTX 
administration are attributed to the absence of DCs. Furthermore, not all DC subsets express 
CD11c. 
First, the passenger leukocyte populations carried with donor cardiac allografts were examined 
to estimate the number of cells transferred. Donor hearts were harvested as if for use in 
transplantation and homogenates were analysed by flow cytometry. The most prevalent 
leukocytes were B cells which were present in 1000 fold greater number than CD4 T cells, 
CD11c+ (predominantly DCs), or CD11b+ (predominantly macrophages) cells (Figure 4.5). One 
technical difference between murine heterotopic cardiac transplantation and clinical 
transplantation is that donor organs used in the clinic are thoroughly flushed with organ 
preservation fluid following procurement. This is not typically performed in murine 
experimental models. To confirm that the identified leukocyte populations did not simply 
reflect blood remaining within the coronary vasculature, donor hearts were flushed 
immediately after procurement with 0.9% saline introduced retrogradely through the 
ascending aorta, and homogenates then similarly analysed by flow cytometry. Only a modest 
reduction in cell numbers was observed in the flushed hearts, suggesting that retained donor 
leukocytes in the coronary circulation are not artificially exaggerating the passenger leukocyte 
load administered to recipients (Figure 4.5). 
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Figure 4.5 Passenger leukocyte populations in cardiac allografts 
Donor CB6F1 cardiac allografts were procured as for transplantation. In half of the cases (n=3), 1ml of 
0.9% saline was flushed retrograde through the ascending aorta. Hearts were homogenised and 
incubated with a collagenase digestion mix. The samples were then analysed by flow cytometry using 
Trucount
TM
 tubes (BD Bioscience), staining for live CD4, CD19, CD11b and CD11c, and the number of 
cells quantified.  
 
CB6F1.DTR donors were either lethally irradiated 7 days prior to transplantation, or treated to 
deplete DCs (DTx administration 10ng/g daily from 7 days prior to transplantation) and/or B 
cells (depleting murine anti-CD20 antibody 250μg 7 days prior to transplantation), prior to 
transplantation into bm12 recipients. It was hypothesised that direct-pathway responses 
would be reduced or abrogated with these treatments due to clearance of the donor APC 
populations, as the major source of donor MHC class II. 
Analysis of peripheral blood by flow cytometry on the day of transplantation confirmed 
haematopoietic depletion following irradiation, and depletion of DCs and B cells following 
administration of diphtheria toxin or anti CD20 antibody (Figure 4.6). An attempt to deplete 
macrophages was also made utilising liposomal clodronate as has been described in the 
literature266-268. Despite following the manufacturer’s instructions and several attempts, a 
significant population of F4/80+ CD11b+ cells remained in both the circulation and spleen of 
treated animals and it was decided not to pursue this further (Figure 4.6). 
  
134 
 
 
 
135 
 
Figure 4.6 Donor antigen presenting cell depletion 
(a) Untreated, or antigen presenting cell (APC) subset depleted donor CB6F1.DTR cardiac allografts were 
transplanted into bm12 recipients. 4-6X10
6
 CFSE labelled TCR75 splenocytes were adoptively transferred 
and proliferation quantified after 6 days by flow cytometry. Representative flow cytometry data from 
splenocytes of treated and untreated donors on the day of transplantation (n=4): (b) following 
administration of 10ng/g diphtheria toxin i.p. daily for 7 days prior to transplantation there is a 
significant reduction in CD11c DCs as seen on dot plot, and overlay histogram data; (c) following lethal 
irradiation (13 Gray split dose) 7 days prior to transplantation there is a substantial paucity of leukocytes 
present and a significant reduction in CD4 T cells, CD8 T cells, B cells and CD11c DCs; (d) following 
administration of 1mg liposomal clodronate i.p. 7 and 2 days prior to transplantation an insignificant 
reduction in macrophage population (double gated on F4/80 and CD11b) was observed despite several 
attempts.  
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Lethal Irradiation of donors resulted in complete abrogation of direct-pathway TCR75 
proliferation, suggesting haematopoietic cells to be the major source of intact MHC class II 
antigen for direct-pathway allorecognition. This result was extended by demonstrating that 
depletion of both B cells and DCs resulted in a significant reduction of direct allorecognition, 
with depletion of both populations simultaneously appearing to achieve the greatest 
reduction. That this did not fall to the level achieved with irradiation likely reflects the 
incomplete nature of clearance of cells with diphtheria toxin and anti-CD20, and contribution 
from additional professional APCs for example, CD11c negative macrophages. Whilst it is 
widely held that donor DCs are the major driver of direct-pathway allorecognition, these 
results suggest that B cells, in addition to DCs, are important sources of alloantigen for CD4 T 
cell direct-pathway allorecognition. 
 
 
Figure 4.7 Donor APC depletion significantly attenuates direct-pathway allorecognition 
Untreated, lethally irradiated (13 Gray split dose) or APC subset depleted (DC with administration of DTx 
and B cells by administration of depleting murine anti-CD20 antibody) donor CB6F1.DTR cardiac 
allografts were transplanted into bm12 recipients. 4-6X10
6
 CFSE labelled TCR75 splenocytes were 
adoptively transferred and proliferation quantified after 6 days by flow cytometry. P values in 
comparison to proliferation observed with untreated donors, using Mann Whitney test. All groups n=4.  
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4.3.4 The role of NK cells in limiting direct-pathway allorecognition 
 
Having demonstrated that NK cells recognise CB6F1 cells as foreign and clear them rapidly 
(Figure 4.4b,c), the role of NK cells in limiting the duration of direct-pathway allorecognition 
was next examined. NK cells can be depleted by i.p. administration of anti-NK 1.1 antibody 
(clone PK136) with 0.5mg administered days -2, 0 and +2 following transplantation (Figure 
4.8a). To further investigate the role of NK cells in deleting passenger donor leukocytes, CD4 T 
cells were administered to RAG2KO mice that were, or not, treated with anti-NK 1.1 antibody 
(Figure 4.8b). CB6F1 CD4 T cells survived and expanded significantly in the NK depleted 
RAG2KO mice; the mice, moreover, demonstrated signs consistent with severe GVHD. This is 
therefore consistent with the findings in NK depleted RagIL2rg mice (Figure 4.8c) and verifies 
anti-NK 1.1 antibody to be efficacious. 
Having demonstrated the ability of NK cells to clear donor cells, and anti-NK 1.1 antibody to be 
effective at prolonging their survival, bm12 recipients of CB6F1 hearts were NK depleted and 
TCR75 cells adoptively transferred at various points following transplantation.  
When TCR75 cells were transferred on the day of transplant there was a small, and not 
statistically significant, increase in TCR75 proliferation in the NK depleted recipients. NK 
depletion was unable to prolong direct-pathway allorecognition, as no proliferation was 
observed when TCR75 cells were transferred on day 3, as was observed in the untreated 
recipients (Figure 4.8c). Although it is widely held that innate immune responses are 
predominantly responsible for limiting direct-pathway allorecognition, these results suggest 
that adaptive immune responses rapidly ensue and also contribute to donor APC clearance. 
Thus, in keeping with the results presented for the B6.Kd to bm12 model, even in the absence 
of innate immune recognition of donor cells, direct-pathway allorecognition was restricted to 
the immediate period following transplantation. 
To confirm a role for adaptive immunity in limiting direct-pathway allorecognition, T cell 
deplete recipients were used – bm12.TCRKO (bm12 mice were crossed with Tcrbd-/- mice and 
backcrossed to bm12). When transferred into bm12.TCRKO recipients of CB6F1 cardiac 
allografts, TCR75 cells underwent a significantly greater degree of proliferation than in 
wildtype recipients, suggesting a role for adaptive immune responses in clearing donor APCs. 
When NK cells were depleted from bm12.TCRKO recipients, to ablate both adaptive and innate 
immune responses, a substantially increased proliferation of TCR75 cells was observed and the 
response was prolonged, persisting into the second week, highlighting that both arms of the 
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immune response play a role in limiting the longevity of direct-pathway allorecognition (Figure 
4.8c). 
 
 
Figure 4.8 Adaptive immune responses in addition to NK killing limit direct-pathway allorecognition 
(a) Anti-NK 1.1 antibody (clone PK136, 0.5mg i.p.) was administered to wildtype C57BL/6 recipients 
(n=3).  Analysis of splenocytes by flow cytometry after 3 days revealed a substantial reduction in NK cell 
number compared with untreated mice. (b) 5x10
6
 CB6F1 CD4 T cells (MACS separated using anti-CD4 
microbeads) were adoptively transferred i.v. into RAG2KO recipients that were untreated, or treated 
with anti-NK 1.1 antibody (0.5mg i.p. day -2, 0, 2 in relation to injection). Flow cytometry performed 
after 7 days revealed a substantial CD4 T cell population in NK depleted recipients. (c) CB6F1 cardiac 
allografts were transplanted into bm12 or bm12.TCRKO (T cell deplete) recipients that had, or not, been 
treated with anti-NK 1.1 to deplete NK cells (0.5mg days -2, 0 and +2). All groups n=4. 4-6X10
6
 CFSE 
labelled TCR75 splenocytes were adoptively transferred on the day of transplantation (week 1) or after 7 
days (week 2) and proliferation quantified 6 days later by flow cytometry. Whilst absence of NK cells or T 
cells resulted in modest increases in proliferation, absence of both resulted in significant enhancement 
and prolongation of proliferation. P values using Mann Whitney test.  
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4.4 Discussion 
 
Traditionally, direct-pathway presentation of alloantigen by donor-derived DCs has been a 
primary focus of transplant immunology and has been regarded as the driving mechanism 
underlying T cell-mediated allograft rejection. However, in this chapter, adoptive transfer of 
ABM and TCR75 TCR transgenic CD4 T cells has enabled confirmation that direct-pathway 
alloresponses are very short-lived, limited by the rapid clearance of donor professional APCs. 
These results suggest that there is no parenchymal source of MHC class II sufficient to drive 
direct-pathway CD4 T cell activation, at least beyond the first week following transplantation. 
The results have also demonstrated that there is a role for both innate and adaptive immunity 
in clearance of donor APCs. Only in the absence of both arms of the immune response were 
direct-pathway responses significantly augmented and prolonged in duration. These results 
suggest that despite the high precursor frequency and strong mixed lymphocyte reactions 
observed in vitro50, the direct-pathway may only have a limited role in the alloimmune 
response. 
This position is in agreement with the results of Brennan et al. who similarly examined direct-
pathway allorecognition in the context of other adaptive immune responses142. They 
simultaneously transferred direct-pathway and indirect-pathway specific CD4, and direct-
pathway specific CD8 TCR transgenic T cells following cardiac transplantation. There was 
significantly greater proliferation of indirect-pathway than direct-pathway CD4 T cells, 
suggesting that there is preferential priming of indirect-pathway alloresponses. Examination of 
endogenous responses with ELISPOT verified these findings and excluded that intrinsic 
differences between the TCR transgenic cells were responsible for the findings. The authors 
also compared the ability of direct and indirect-pathway CD4 T cells to reject healed skin 
grafts, 100 days following transplantation. Only indirect-pathway CD4 T cells were able to 
mediate rejection of the skin at this late time-point.  However, if the direct-pathway CD4 T 
cells were primed, rejection of the skin was observed. This is consistent with results in this 
chapter, where direct-pathway CD4 T cell priming only occurs early. Brennan et al. have 
extended this by confirming that the lack of priming late following transplantation has 
implications for their ability to mediate allograft injury. They conclude by questioning the role 
of direct-pathway allorecognition in allograft rejection, suggesting that their findings reconcile 
previous observations that elimination of direct-pathway responses does not significantly alter 
experimental allograft rejection kinetics.  
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The absence of late priming of direct-pathway CD4 T cells is due to rapid clearance of 
passenger donor APCs, since irradiation of donors prior to transplantation abrogated direct-
pathway priming. Whilst murine endothelial cells have been demonstrated to express MHC 
class II early following transplantation – both in the literature86 and Chapter 5, and activated 
endothelial cells have been demonstrated to prime direct-pathway CD4 T cells in vitro326, this is 
clearly insufficient to prime direct-pathway CD4 T cells beyond the first week following 
transplantation in vivo. Even if expression persists beyond this time, lack of appropriate co-
stimulation may prevent productive cognate interactions from taking place82. 
Early reports highlighted the important role of NK cells in clearing donor APCs suggesting this 
occurs over the first days to weeks following transplantation207, 332. NK cells are thought to 
mediate this clearance through recognising ‘missing-self’ (absence of self MHC class I)179, 180. 
This was more definitively examined using two-photon microscopic studies, where live 
clearance of allogeneic DCs by NK cells was visualised76, 333. This process was much more rapid 
than initially appreciated – with ~80% of DCs cleared by just 12 hours following transfer or skin 
transplantation76. T cell priming by DCs occurs in three successive stages in a process that takes 
in excess of 24 hours: initial transient serial encounters during the activation phase, a second 
phase of stable contacts culminating in cytokine production, and a third phase of high motility 
with transient interactions and rapid proliferation334.  In keeping with this, rapid NK cell 
clearance of allogeneic DCs has been confirmed to limit the ability of allogeneic DCs to 
efficiently stimulate cognate CD4 T cells335.  
This is in keeping with the observation in this chapter that proliferation of TCR75 CD4 T cells (in 
bm12 recipients of CB6F1 cardiac allografts) was only observed when transferred on the day of 
transplantation – transfer just 2 days later was too late to yield TCR75 proliferation.  
In this chapter it is clearly demonstrated that adaptive immune responses also play a role in 
clearing donor APCs. In this regard it is interesting to note another study examining the role of 
NK cells in priming alloreactive CD4 T cell responses. Coudert et al. demonstrated that 
depleting NK cells from recipients, although resulting in enhanced early direct-pathway CD4 T 
cell priming, did not impact upon allograft rejection336. Although it was not examined, it is 
conceivable that this may reflect that although augmented initially, direct-pathway priming 
remained short-lived due to adaptive immune clearance of passenger donor APCs, thus 
limiting the duration of direct-pathway allorecognition which therefore failed to impact upon 
allograft rejection kinetics. 
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One argument in favour of direct-pathway CD4 T cells having an important role in the 
alloimmune response is the observation that direct-pathway CD8 T cells are one of the 
principal mediators of allograft injury and rejection337. CD8 T cell activation is thought to 
require formation of a three-cell cluster with a ‘licensed’ APC and a CD4 T cell92, 93. The APC 
must present antigen to both the CD4 and CD8 T cell in order to elicit CD4 T cell help. 
Therefore, activation of direct-pathway CD8 T cells requires an interaction with a donor APC, 
and requires direct-pathway CD4 T cells to licence the donor APC. Indeed, murine studies have 
confirmed that restricting CD4 T cell help to the direct-pathway generates strong cytotoxic CD8 
T cell alloresponses that effect rapid allograft rejection87. However, it is clearly not that simple, 
since direct-pathway CD8 T cell cytotoxicity has been demonstrated in the absence of direct-
pathway CD4 T cells, suggesting that indirect-pathway CD4 T cells can also provide the 
necessary help96. This has prompted the proposal that direct-pathway cytotoxic CD8 T cell 
alloimmunity may be initiated by the ‘semi-direct’ pathway, whereby intact donor MHC class I 
alloantigen is recognised after its acquisition onto the surface of recipient DCs. This 
phenomenon provides a possible mechanism by which the same recipient APC as re-presents 
intact MHC class I alloantigen could simultaneously present processed allopeptide for 
recognition by indirect-pathway CD4 T cells47. Thus, the semi-direct-pathway may enable 
disconnect between direct-pathway CD4 and CD8 T cells, explaining why direct-pathway CD8 
cytotoxicity appears an important long-lived effector arm of alloimmunity, whilst direct-
pathway CD4 T cell activity appears restricted to the period immediately following 
transplantation. 
It is notable that human endothelial cells are thought to constitutively express MHC class II, 
and so caution must be exercised in extrapolation of these findings to human clinical 
transplantation338. However, two clinical studies have attempted to examine direct-pathway 
allorecognition in long-term recipients of solid organ transplants. Baker et al. have studied 
kidney transplant recipients77, 148. They performed in vitro assays to examine direct and 
indirect-pathway CD4 T cell responsiveness. Significant widespread donor-specific direct-
pathway hypo-responsiveness was observed both in recipients with stable renal function and 
those with evidence of chronic allograft nephropathy. In contrast, high frequencies of CD4 T 
cells were identified responding to the indirect-pathway, with significantly higher 
responsiveness in those with evidence of chronic allograft nephropathy implicating indirect-
pathway responses in chronic rejection. Similarly, Hornick et al. studied cardiac transplant 
recipients78, 339. They too demonstrated direct-pathway donor-specific hypo-responsiveness 
and concluded that direct-pathway allorecognition appears unlikely to be responsible for the 
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progression of chronic rejection, implicating indirect-pathway allorecognition as the 
predominant immunological driving force. 
Therefore, despite potential differences in donor MHC class II expression, the findings in this 
chapter mirror observations in human clinical transplantation, and put into question the role 
of direct-pathway CD4 T cells in the on-going alloimmune response following transplantation. 
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5 Duration of indirect-pathway 
alloresponses vary 
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5.1 Introduction 
 
5.1.1 Indirect-pathway allorecognition and allograft rejection 
 
The indirect-pathway of allorecognition is now recognised to be central to allograft rejection48. 
This stems from early experimental data supporting a role for indirect-pathway allorecognition 
– such as rejection of leukocyte depleted donors70, 71, and rejection of MHC class II knock-out 
donors120, 121, both of which precluded direct-pathway CD4 T cell allorecognition. 
Whether indirect-pathway CD4 T-cells can themselves directly mediate rejection of 
vascularised allografts is controversial, because although one paper has described 
independent effector function340, there is no cellular target within the allograft to which 
indirect-pathway CD4 T-cells that have developed cytolytic potential could bind. In theory, 
replacement of graft endothelium by ingress from recipient progenitor cells could result in 
expression of a self-restricted allopeptide target for indirect-pathway CD4 T-cell 
allorecognition, but the limited extent to which this occurs is likely to limit its relevance341. 
Damage may alternatively occur through a delayed-type hypersensitivity response from 
interaction of indirect-pathway CD4 T-cells with recipient APCs within the parenchyma of the 
graft342 but again, it is not clear whether this is sufficient to cause allograft rejection.  
Indirect-pathway CD4 T-cells are more likely to influence rejection by providing help for 
generating CD8 T-cell and humoral alloimmunity. As described in Chapter 1, the provision of 
help to CD8 T cell for responses against conventional protein antigen involves CD4 T cell 
recognition of MHC class II restricted target antigen, presented by the same APC as presents 
MHC class I restricted antigen to the CD8 T cell343-345. One would therefore expect indirect-
pathway CD4 T cells to readily provide help for indirect-pathway CD8 T cells responses against 
self MHC class-I restricted allopeptide presented by host APCs. Nevertheless, as discussed 
above, it is unclear whether indirect-pathway CD8 T cell responses can mediate allograft injury, 
due to absence of expression of target epitope on the allograft. Instead, indirect-pathway CD4 
T cells have been demonstrated to be able to provide help to direct-pathway CD8 T cells, which 
are capable of directly interacting with the allograft96. Evidence is accumulating that the ‘semi-
direct’-pathway may reconcile these observations48. In contrast, indirect-pathway CD4 T cells 
appear pivotal for the development of humoral alloimmunity. Murine models incorporating 
either MHC class II deficient recipients or mice harbouring monoclonal populations of 
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alloreactive CD4 T-cells have now demonstrated conclusively that alloreactive B-cells can only 
receive help from indirect-pathway CD4 T-cells 100, 346.  
The contribution of antibody to allograft rejection was, for many decades, thought negligible. 
Previous work from our laboratory examining allograft rejection in an MHC class I-mismatched 
rat cardiac allograft model was amongst the first to suggest otherwise135, 347-349, because acute 
rejection was found to be dependent upon CD4, but not CD8, T-cells, and could be restored in 
T-cell-deficient ‘nude’ rats by passive transfer of immune serum. Subsequently, the 
introduction of staining for complement split products350, has led to a re-evaluation of the 
contribution of alloantibody to clinical transplantation351; acute antibody-mediated rejection is 
now a well-recognised cause of early kidney graft loss352, and may be encountered more 
frequently as HLA antibody incompatible kidney transplants are more widely performed using 
induction strategies that incorporate B-cell depletion240, 353-355. Furthermore, increasing 
numbers of human clinical studies have correlated the presence of donor-specific alloantibody 
development with failure of kidney356-359 and cardiac allografts360-362. Thus probably by far the 
most important role for indirect-pathway CD4 T-cells in acute graft rejection is as helpers for 
promoting humoral alloimmunity. 
 
5.1.2 Duration of allorecognition pathways 
 
Although the two main allorecognition pathways were first recognised over three decades ago, 
their respective contribution to allograft rejection remains unclear. Because donor DCs are 
thought to be eliminated early after transplantation, only indirect-pathway responses are 
thought to occur at late time points after transplantation and it is frequently stated that the 
direct-pathway is responsible for acute rejection, and the indirect for chronic rejection. 
Evidence to support this statement is, however, limited to a small number of clinical studies 
showing that in patients suffering from chronic rejection, self-restricted allopeptide responses 
are augmented whereas direct-pathway T-cell responses are unchanged 363-366. 
Much effort is currently being expended on developing cellular immunotherapies for the clinic 
in transplantation, such as Treg therapy. It is likely that possessing a greater understanding of 
allorecognition may facilitate the development of these cellular therapies, such as in decisions 
surrounding the optimal Treg product administered. For example, if it becomes clear that 
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direct-pathway alloreactivity is restricted to early following transplantation, then this would 
impact on Treg product development for administration late after transplantation. 
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5.2 Aims 
 
The purpose of the research described in this chapter is to examine the indirect-pathway of 
allorecognition using the bm12.Kd.IE to C57BL/6 model of chronic rejection, exploring the 
preliminary finding that duration of indirect allorecognition is variable dependent upon target 
alloantigen. 
 
The aims are: 
 
1. Examine the duration of indirect-pathway alloresponses against different groups of 
alloantigen 
 
2. Examine the factors responsible for limiting the duration of indirect-pathway 
alloresponses 
 
3. Examine the significance of indirect-pathway duration for the development of late 
humoral alloresponses  
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5.3 Results 
 
5.3.1 Duration of indirect allorecognition is variable 
 
Earlier results using individual models demonstrated that indirect-pathway allorecognition of 
donor MHC I, MHC II and minor H-Y antigen have variable duration (Section 3.3.1). The 
bm12.Kd.IE model was used to examine these three responses simultaneously. Since the donor 
class II I-Abm12 is very similar to I-Ab of the recipient, it was first necessary to confirm that the 
transgenic CD4 T cells (I-Ab restricted) did not recognise their target allopeptide presented by I-
Abm12. If this were the case, donor APCs could present antigen and induce division by the 
direct-pathway. Male BALB/c hearts (possessing both class I H2-Kd and class II I-Ed) were 
grafted into female bm12 recipients and TCR75, TEa and Mar splenocytes adoptively 
transferred on the day of transplant. No proliferation was observed confirming allorecognition 
by these transgenic cells is restricted to I-Ab (Figure 5.1). 
 
Figure 5.1 I-A
b
 restricted TCR transgenic CD4 T cells do not recognise antigen presented by I-A
bm12
 
Male BALB/c cardiac allografts were transplanted into female bm12 recipients (n=2). 4-6x10
6
 CFSE 
labelled TCR75, TEa and Mar splenocytes were adoptively transferred and proliferation examined after 6 
days by flow cytometry. No proliferation was observed, confirming the transgenic CD4 T cells are unable 
to recognise their allopeptide presented by the I-A
bm12
 MHC class II molecule. 
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To control for differences between the individual models presented previously (Section 3.3.1), 
the three indirect-pathway TCR transgenic CD4 T cell populations were transferred 
simultaneously. Mar and TEa cells are identified using antibodies against their specific Vα and 
Vβ subunits, whilst TCR75 cells express a congenic marker: CD90.1/Thy 1.1 (Table 2.1). 
Notably, TEa and Mar possess an identical Vβ subunit (Vβ6) so it was important to confirm the 
ability to distinguish between the two populations on flow cytometry. This was achieved using 
an antibody directed against the Vα2 subunit of the TEa TCR (Figure 5.2). It is noteworthy that 
double gating on Vα and Vβ subunits substantially reduced the number of non-transgenic, 
endogenous CD4 T cells present within the gate, resulting in cleaner proliferation histograms, 
similar to that achieved with TCR75 (Figure 5.1 left panel). This approach was adopted for TEa 
detection throughout the remainder of this thesis. 
 
 
Figure 5.2 Ability to distinguish TEa and Mar TCR transgenic cells, despite shared Vβ subunit 
A Bm12.Kd.IE cardiac allograft was transplanted into a C57BL/6 recipient and 4-6x10
6
 CFSE labelled TEa 
and Mar splenocytes adoptively transferred on the day of transplantation. After 6 days the spleen was 
harvested and processed by flow cytometry. Despite sharing Vβ6 subunit, TEa and Mar CD4 T cells could 
be distinguished by double staining TEa with Vα2. 
 
Examination of early (Week 1) and late (Week 5) proliferation following transplantation 
confirmed the previous findings. At the early time point robust indirect-pathway responses 
were detected against donor MHC class I, MHC class II and minor H-Y alloantigen. At the late 
time point the responses against MHC class I and minor H-Y antigen were preserved, albeit the 
anti-H-Y response was attenuated. In contrast, an indirect-pathway response against MHC 
class II was undetectable (Figure 5.3).  
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Figure 5.3 Duration of indirect-pathway allorecognition is variable depending on the alloantigen 
Representative flow cytometry plots (a) and bar chart summarising proliferation (b) following adoptive 
transfer of 4-6x10
6
 CFSE labelled TCR75, TEa and Mar splenocytes i.v. into C57BL/6 recipients of 
bm12.Kd.IE cardiac allografts, 0 (Week 1) or 28 days (Week 5) following transplantation or naïve 
C57BL/6 control mice (all groups n=5). Animals were sacrificed 6 days later and splenocytes analysed by 
flow cytometry. Proliferation of transgenic CD4 T cells quantified using FlowJo software (Tree Star, 
Oregon). P values using Mann Whitney test. 
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5.3.2 Indirect-pathway responses against MHC Class II are limited by antigen 
availability 
 
Examining MHC II indirect-pathway allorecognition more closely revealed that even at week 2 
following transplant no proliferation of TEa CD4 T cells was identified, suggesting the response 
decays within the first week following transplantation (Figure 5.4). It was hypothesised that 
the short-lived nature of MHC class II indirect-pathway allorecognition reflects rapid clearance 
of donor MHC class II expressing cells following transplantation. 
 
Figure 5.4 MHC class II indirect allorecognition is restricted to the first week following transplantation 
Bm12.Kd.IE cardiac allografts were transplanted into C57BL/6 recipients and 4-6x10
6
 CFSE labelled TEa 
splenocytes adoptively transferred i.v. at week 1, 2 and 5 (n=5). Six days following transfer recipient 
splenocytes were analysed by flow cytometry. Proliferation of transgenic CD4 T cells was quantified 
using FlowJo software (Tree Star, Oregon). P values using Mann Whitney test. Proliferation was only 
observed when transferred at week 1 suggesting MHC class II indirect allorecognition to be short-lived 
 
5.3.2.1 Primed transgenic TEa cells do not proliferate late after transplantation 
 
In experiments thus far only naïve transgenic CD4 T cells have been transferred. There is the 
possibility that beyond the first week following transplantation a source of donor class II 
persists and initiated indirect-pathway alloresponses are on-going. However, in the absence of 
adequate co-stimulation, naïve TEa CD4 T cells are insufficiently activated to undergo division. 
To examine this, antigen experienced, memory, TEa CD4 T cells were generated.  
Bm12.Kd.IE skin transplants were performed on to RAG2KO recipients. TEa splenocytes (1x107) 
were adoptively transferred the day following transplantation. Six weeks following skin 
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transplantation, CD4 T cells were stained by flow cytometry for surface expression of CD44 and 
CD62L (Figure 5.5a). Antigen experienced, memory, CD4 T cells are reported to up-regulate 
CD44 and down-regulate CD62L expression81. In keeping with this, when naïve TEa CD4 T cells 
are induced to undergo proliferation in transplant recipients, an up-regulation of CD44 and 
down-regulation of CD62L is observed (Figure 5.5b). 
However, CD4 T cells isolated from the skin-grafted RAG2KO recipients did not exhibit a 
memory phenotype and instead, appeared phenotypically similar to naïve TEa CD4 T cells 
(Figure 5.5c). Given the report that optimal CD4 T cell memory generation requires B cells367, 
the experiment was repeated using T cell deplete TCRKO recipients, which retain a functional B 
cell compartment256. Six weeks following skin transplantation, isolated CD4 T cells were found 
to have up-regulated CD44 and down-regulated CD62L, supporting a requirement for B cells in 
the development of CD4 T cell memory (Figure 5.5c). In support of their memory phenotype, 
these cells proliferated more vigorously upon transfer into C57BL/6 recipients of bm12.Kd.IE 
hearts when transferred on the day of transplantation (Figure 5.5d). However, when 
transferred four weeks following transplantation, no proliferation was detected (Figure 5.5e). 
These results suggest that beyond the first week following transplantation there is an absence 
of target processed I-E allopeptide epitope, rather than expression in a non-stimulatory 
fashion. However, it must be noted that constitutive human endothelial MHC class II 
expression may limit extrapolation of these findings to clinical transplantation. 
 
Figure 5.5 Antigen experienced TEa CD4 T cells do not proliferate late following transplantation 
To overcome the limitation of transferring naïve TEa CD4 T cells late after transplantation, antigen 
experienced, memory, TEa were generated. Bm12.Kd.IE tail skin was transplanted onto RAG2KO or 
TCRKO recipients and 1x10
7
 TEa splenocytes adoptively transferred i.v. on the day of transplantation (a). 
Antigen experienced CD4 T cells upregulate CD44 and downregulate CD62L
81
. This is demonstrated by 
staining TEa splenocytes for flow cytometry analysis 6 days following adoptive transfer into C57BL/6 
recipients of bm12.Kd.IE cardiac allografts on the day of transplantation, as described above. The parent 
population is CD44
low
 CD62L
hi
, and with proliferation, daughter population expression of CD44 increases 
and CD62L falls (b). Six weeks after skin transplantation, recipient RAG2KO and TCRKO spleens were 
processed by flow cytometry (c). An antigen experienced, memory, population of CD4 T cells was 
observed in TCRKO but not RAG2KO recipients. To confirm a memory phenotype 4-6x10
6
 antigen 
experienced TEa CD4 T cells (MACS separated with anti-CD4 microbeads) from TCRKO skin transplant 
recipients were CFSE labelled and adoptively transferred into C57BL/6 recipients of bm12.Kd.IE cardiac 
allografts on the day of transplantation (n=3). Augmented proliferation was observed when compared 
to naïve TEa on flow cytometry 6 days later (d). When similarly purified and CFSE labelled CD4 T cells 
(from both RAG2KO and TCRKO skin transplant recipients) were adoptively transferred into C57BL/6 
recipients of bm12.Kd.IE cardiac allografts 4 weeks following transplantation, no proliferation was 
observed (representative flow cytometry histogram plots from n=4). P values using Mann Whitney test. 
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5.3.2.2 Y-Ae antibody supports no ongoing MHC class II allopeptide presentation 
 
The Y-Ae antibody is a clonotypic monoclonal antibody specific for donor derived I-E α-chain 
peptide 52-68, presented in the context of recipient MHC II I-Ab (Figure 5.6a)368. This epitope is 
identical to the specificity of the TEa TCR. The Y-Ae antibody permits examination of indirect-
pathway donor MHC II antigen presentation in this model.  
The BALB/c x C57BL/6 F1 (CB6F1) strain provides a positive control for Y-Ae staining, since 
there is co-expression of MHC II I-E and I-Ab on all class II expressing cells. A naïve C57BL/6 and 
a C57BL/6 recipient of a bm12.Kd cardiac allograft (identical to bm12.Kd.IE, but lacking the 
MHC II I-E) were used as negative controls, to exclude that Y-Ae is cross-reactive with any non-
IE donor antigen. A degree of increased staining was observed with CD11b+ macrophages in 
the transplanted negative control, perhaps reflecting the previously reported degree of cross-
reactivity of the Y-Ae antibody368.  
Recipients of bm12.Kd.IE cardiac allografts revealed strongly positive Y-Ae staining of CD11c+ 
dendritic cells and CD11b+ macrophages at 4 days following transplantation, confirming 
antigen presentation to be occurring at this early time (Figure 5.6b,c). However, two weeks 
following transplantation, the majority of APCs stained negative for Y-Ae, further supporting 
that there is only limited, if any, MHC class II allopeptide presentation occurring, 
commensurate with the lack of TEa proliferation observed at this time.  
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Figure 5.6 Y-Ae clonotypic antibody permits assessment of allopeptide presentation 
(a) The epitope of the Y-Ae antibody is created by presentation of MHC class II I-E allopeptide presented 
by MHC class II I-A
b
, which in the bm12.Kd.IE to C57BL/6 model represents indirect-pathway 
presentation of donor mismatched MHC class II. (b) Splenocytes from naïve C57BL/6 (BL/6) and CB6F1, 
and from C57BL/6 recipients of bm12.Kd and bm12.Kd.IE cardiac allografts, in the first week following 
transplantation, were processed by flow cytometry and staining with Y-Ae of leukocyte subsets 
presented as histogram overlays (representative of n=3). (c) Left panel displays an overlay of CD11c 
positive leukocyte Y-Ae staining from naïve C57BL/6 (negative control), CB6F1 (positive control) and 
experimental C57BL/6 recipients of bm12.Kd.IE cardiac allografts 4 days following transplantation, 
demonstrating positive staining of the experimental group. Right panel additionally overlays C57BL/6 
recipients of bm12.Kd.IE cardiac allografts 2 weeks following transplantation demonstrating a marked 
reduction in Y-Ae staining by this time.  
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5.3.2.3 Donor APCs are the major source of MHC II alloantigen 
 
MHC class II is predominantly expressed by professional APCs (DC’s, macrophages and B cells), 
although endothelial expression has also been described86, 369. To examine the hypothesis that 
donor APCs are the major source of antigen for indirect-pathway priming, donors were 
depleted of professional APCs and the resultant proliferation of transgenic CD4 T cells 
quantified – in a similar manner to the previous chapter for direct-pathway allorecognition.  
To study the role of APCs, donor mice were either subjected to lethal irradiation to deplete 
their haematopoietic compartment, or were treated to deplete APC populations. CD11c+ DCs 
were depleted by administering diphtheria toxin to mice expressing the diphtheria toxin 
receptor under the CD11c promoter, and B cells by administering depleting murine anti-CD20 
antibody. An attempt was made to deplete macrophages using liposomal clodrinate, but this 
did not prove successful and was not pursued (Section 4.3.3.2). 
These experiments required development of a bm12.Kd.IE-CD11c.DTR donor strain in which 
CD11c+ DCs would be susceptible to diphtheria toxin and could be depleted (Figure 5.7).  
 
Figure 5.7 Developing bm12.Kd.IE.DTR strain 
(1) First, ABOIE were crossed with B6.DTR. (2) The F1 offspring expressing the DTR gene were 
backcrossed with ABOIE, selecting for offspring expressing: DTR gene and the MHC class II I-E but not I-
A
b 
(by flow cytometry of peripheral blood – left panel confirming I-E expression, right panel showing 
absence of I-A
b
). (3) These ‘ABOIE.DTR’ mice were then crossed with bm12.Kd to generate 
bm12.Kd.IE.DTR donors. Expression of the DTR gene was confirmed by PCR (performed by S Rehakova). 
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In this series of experiments, both TCR75 and TEa CD4 T cells were transferred in order to 
compare the impact of donor treatment on the donor MHC class I and II indirect-pathway 
responses. Lethally irradiating donors abrogated TEa proliferation whilst TCR75 proliferation 
was unchanged. This suggests that passenger donor professional APCs are the major source of 
MHC class II, but not class I, for indirect-pathway presentation. This finding was confirmed by 
depletion of donor APC subsets. DC or B cell depletion reduced TEa proliferation, although DC 
depletion had a greater impact. Depleting both DCs and B cells resulted in a similar degree of 
proliferation as was observed with lethal irradiation. In contrast, depletion of donor APCs had 
a negligible impact upon TCR75 proliferation (Figure 5.8a,b). 
Commensurate with absent TEa proliferation, depletion of donor DCs and B cells prevented 
binding of the clonotypic Y-Ae antibody to recipient DCs confirming absence of I-E allopeptide 
presentation in the recipients (Figure 5.8c). 
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Figure 5.8 Depletion of donor APCs significantly abrogates MHC class II indirect allorecognition 
(a) Bm12.Kd.IE.DTR cardiac allografts were transplanted into C57BL/6 mice following either lethal 
irradiation (13 Gray split dose) or treatment to deplete donor APC subsets (administration of 10ng/g 
diphtheria toxin daily for 7 days prior to transplantation to deplete DCs and/or administration of 250μg 
murine anti-CD20 antibody to deplete B cells). 4-6x10
6
 CFSE labelled TCR75 and TEa splenocytes were 
adoptively transferred i.v. on the day of transplantation and recipient spleens were harvested after 6 
days for analysis of transgenic CD4 T cell proliferation by flow cytometry. All groups n=4 (b) TCR75 and 
TEa proliferation quantified by FlowJo, revealing that donor APC depletion and irradiation significantly 
attenuate TEa proliferation, but TCR75 proliferation is unchanged. (c) Further confirmation that donor 
APCs are the major source of MHC class II allopeptide is provided by Y-Ae staining of recipient CD11c 
DCs. Following transplantation with DC and B cell deplete donors, no Y-Ae staining is detected in the first 
week, unlike with untreated donors (green line). P values using Mann Whitney test.  
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5.3.2.4 Innate immunity is not responsible for limiting class II indirect allorecognition 
 
Having confirmed passenger donor APCs to be the major source of donor MHC class II for 
indirect-pathway allorecognition, further experiments were designed to clarify what limits 
their survival. It is widely held that donor APCs are rapidly cleared by recipient innate immune 
responses and that this accounts for the short lived nature of the direct-pathway76. To examine 
the roles of the innate and adaptive responses in limiting the MHC II indirect-pathway 
response in this model, RAG2KO mice lacking adaptive immunity were utilised370. 
Cell transfer experiments described previously (Section 3.3.4) demonstrated that bm12.Kd.IE 
donor cells survive long-term, equivalent to syngeneic cells, in RAG2KO recipients, identifying 
that innate immunity is not responsible for donor APC clearance in this model. From this, it 
was hypothesised that class II indirect allorecognition may be long-lived in RAG2KO recipients.  
Bm12.Kd.IE hearts were therefore transplanted into RAG2KO recipients and TEa proliferation 
quantified at early and late time-points. Unlike in C57BL/6 recipients, class II indirect-pathway 
allorecognition occurred at the late time-point (Figure 5.9a). The degree of proliferation 
observed at the late time point though was attenuated, and likely reflects natural senescence 
of donor DCs, since they have an expected half-life of at most a few weeks depending on 
subtype371, 372. In contrast, B cells appear to establish a long-term splenic population in these 
RAG2KO mice, and may be the major source of class II at this late time point (Figure 3.15). In 
keeping with TEa proliferation at the late time-point in RAG2KO recipients, Y-Ae staining was 
demonstrated on recipient DCs confirming donor MHC II antigen processing and presentation 
to be occurring at this time (Figure 5.9b). 
To extend these findings an attempt was made to abrogate late MHC II indirect allorecognition 
in RAG2KO recipients by depleting donor B cells or DCs late after transplantation. Bm12.Kd.IE-
CD11c.DTR mice were used as donors, permitting sensitivity of donor DCs to diphtheria toxin; 
B cells were depleted using murine anti-CD20 antibody. No significant impact on late TEa 
proliferation was observed following this treatment (Figure 5.9c). Although surprising, in the 
case of DC depletion this may reflect incomplete depletion264, or that donor DCs have senesced 
by this point. Alternatively, it may reflect the difficulty in completely depleting donor B cells 
once they have established as the dominant splenic population373. 
Together, these results highlight a critical role for the adaptive immune response in limiting 
the survival of donor APCs, and therefore MHC class II indirect-pathway allorecognition. 
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Figure 5.9 Indirect-pathway recognition of donor MHC class II is long-lived in RAG2KO recipients 
(a) Bm12.Kd.IE cardiac allografts were transplanted into RAG2KO recipients (lacking adaptive immunity) 
and 4-6x10
6
 CFSE labelled TEa splenocytes were adoptively transferred i.v. on the day of transplantation 
(week 1) or week 5. Six days following transfer recipient spleens were harvested and processed by flow 
cytometry to quantify TEa proliferation. Left panel shows representative CFSE histograms and right 
panel comparing week 1 and week 5 proliferation (n=5 in each group) where it is notable that 
proliferation occurs at the late time-point, although it is significantly attenuated. (b) In contrast to 
wildtype recipients, where no Y-Ae staining of recipient DCs is observed beyond the first week following 
transplantation, positive staining was observed in RAG2KO recipients 5 weeks following transplantation 
(black line). (c) In an attempt to demonstrate longevity of passenger APCs in RAG2KO recipients as the 
reason for longevity of MHC class II allorecognition in this model, donor APCs were depleted in 
recipients 4 weeks following transplantation, prior to CFSE labelled TEa splenocytes transfer at week 5. 
Bm12.Kd.IE.DTR donors were utilised and donor DCs depleted by administration of 10ng/g diphtheria 
toxin daily for 7 days prior to TEa transfer and alternate days thereafter. B cells were depleted by 
administration of 250μg murine anti-CD20 7 days prior to TEa transfer. (RAG2KO mice do not possess B 
cells, therefore targeting only passenger donor B cells). Recipient spleens were analysed as above by 
flow cytometry to quantify TEa proliferation (all groups n=4). P values using Mann Whitney test. 
161 
 
5.3.2.5 Late class II indirect allorecognition can be reconstituted with antigen transfer 
 
To further confirm that lack of ongoing late MHC class II indirect-pathway allorecognition is a 
consequence of early antigen clearance, the possibility of reconstituting the response was next 
considered. Using an established protocol, bone marrow-derived DCs (BMDC’s) were cultured 
from donor bm12.Kd.IE bone marrow as a source of donor MHC class II antigen271, 272. 
Following an eight day period of culture, BMDCs were harvested and expression of the MHC 
class II I-E was confirmed by flow cytometry. These cells also expressed the activation and co-
stimulatory markers CD80, CD86 and CD40 (Figure 5.10a,b). The ability of donor BMDCs to act 
as a source of MHC class II that could be processed and presented by the indirect-pathway was 
confirmed by adoptive transfer into naïve C57BL/6 mice, where TEa proliferation was 
observed, in a dose-dependent manner (Figure 5.10c). The BMDCs demonstrated no Y-Ae 
reactivity themselves confirming that any TEa proliferation is a consequence of allopeptide 
processing and presentation by recipient APCs (Figure 5.10d). 
If BMDCs were adoptively transferred 28 days prior to injection of TEa splenocytes into a 
RAG2KO animal, no proliferation was observed suggesting that in vitro cultured BMDCs do not 
demonstrate long term survival in vivo, likely due to natural senescence. 
 
 
 
Figure 5.10 Bm12.Kd.IE bone marrow derived DCs (BMDCs) can act as a source of MHC class II for 
indirect-pathway processing and presentation 
Bm12.Kd.IE bone marrow was cultured in vitro under conditions encouraging DC differentiation (IL-4 
and GM-CSF)
271, 272
. (a) Upon harvest on day 8, BMDC phenotype was confirmed on flow cytometry with 
the majority of cells expressing CD11b and CD11c surface markers (left panel). Furthermore, strong 
expression of MHC class II I-E was observed (right panel, blue line; grey shaded histogram represents 
isotype control). (b) The BMDCs also demonstrated surface expression of co-stimulatory molecules: 
CD80, CD86 and CD40. (c) Increasing numbers of BMDCs were adoptively transferred i.v. into naïve 
C57BL/6 mice, with 4-6x10
6
 CFSE labelled TEa transferred i.v. the following day and proliferation 
quantified 6 days later. TEa proliferation was observed (left panel) in a dose dependent manner (right 
panel) following BMDC transfer confirming BMDCs can act as a source of antigen for recipient 
processing and presentation by the indirect-pathway (Proliferation was not observed in control animals 
not transferred BMDCs). All groups n=2. (d) BMDCs themselves did not bind the clonotypic Y-Ae 
antibody confirming they themselves do not possess the epitope for TEa recognition by the direct-
pathway.   
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Having confirmed that BMDCs are sufficient to drive an indirect-pathway class II alloresponse, 
next they were adoptively transferred into animals that had previously been transplanted to 
assess the possibility of reconstituting the late class II indirect-pathway response, thus 
supporting that the absence of a late class II alloresponse reflects a lack of donor antigen.  
Donor BMDCs were adoptively transferred into RAG2KO and C57BL/6 recipients of bm12.Kd.IE 
cardiac allografts 28 days following transplantation (Figure 5.11a). In RAG2KO recipients, 
proliferation of TEa CD4 T cells was restored to a level similar to that observed at the early 
time point, confirming that the late MHC class II indirect-pathway response had been 
reconstituted. Proliferation was greater in the grafted animals than the naïve positive controls 
receiving an identical number of cells, presumably due to the fact that the transferred BMDCs 
were supplementary to the natural donor APCs surviving in the RAG2KO animal, responsible 
for the indirect-pathway allorecognition usually observed at this late time point.  
Although late TEa proliferation was observed in C57BL/6 recipients following BMDC transfer, it 
was significantly attenuated compared with the extent of proliferation observed in non-
transplanted, naïve mice receiving the same number of BMDCs (Figure 5.11b,c). The difference 
in proliferation observed in naïve C57BL/6 and RAG2KO recipients reflects the lower number of 
BMDCs transferred in the RAG2KO experiment due to BMDC culture yield. When an identical 
number of BMDCs were transferred to naïve C57BL/6 and RAG2KO mice, similar proliferation 
was observed (Figure 5.11d). 
Why there was reduced proliferation in a transplanted, as compared to naïve, C57BL/6 mouse 
receiving the same number of BMDCs was not clear (Figure 5.11b). One possibility is that there 
was competition from endogenous, antigen experienced CD4 T cells which were primed to 
respond more vigorously and thus out-competed the naïve transferred TEa cells. To investigate 
this, the experiment was repeated but 7 days prior to BMDC transfer, recipient CD4 T cells 
were depleted by administration of a depleting anti-CD4 antibody. There was no significant 
increase in TEa proliferation observed despite removing the potential competition, suggesting 
this not to be the reason (Figure 5.11e). Perhaps, then, this previously encountered donor 
antigen is rapidly cleared in a quiescent manner not resulting in activation of naïve CD4 T cells 
by sensitised CD8 T cells or circulating alloantibody. In this regard, it is recognised that in the 
absence of inflammatory stimuli DCs can present antigen in a non-stimulatory manner374. 
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Figure 5.11 BMDC transfer into recipients following transplantation reconstituted MHC class II 
indirect-pathway allorecognition 
(a) Bm12.Kd.IE cardiac allografts were transplanted into wildtype or RAG2KO C57BL/6 recipients. 4-
6x10
6
 CFSE labelled TEa splenocytes were adoptively transferred i.v. 27 days later. The following day 
2x10
6
 BMDCs were transferred i.v. and TEa proliferation quantified 6 days later. (b) In naïve wildtype 
C57BL/6 mice, proliferation was again observed following BMDC transfer. Whilst minimal proliferation is 
seen at this late time point usually, transfer of BMDCs reconstituted TEa proliferation – although not to 
the same extent as observed in non-transplanted, naïve, C57BL/6 mice. (c) In naïve RAG2KO mice, BMDC 
transfer similarly resulted in TEa proliferation. In RAG2KO recipients a degree of proliferation is usually 
observed at the late time point due to donor cell survival. Transfer of BMDCs augmented the extent of 
proliferation observed in these recipients. (d) To compare the extent of proliferation driven by BMDCs in 
naïve wildtype and RAG2KO C57BL/6 mice, 2x10
6
 BMDCs were simultaneously transferred the day after 
CFSE labelled TEa. An equivalent degree of proliferation was observed. (e) To examine if endogenous 
CD4 T cell proliferation competes with TEa at the late time point following BMDC transfer (following the 
observation that less proliferation occurs in transplanted than naïve BMDC recipients), the experiment 
was repeated but this time, recipients were treated with 1mg depleting anti-CD4 7 and 5 days prior to 
TEa transfer. No substantial increase in TEa proliferation was observed. All groups n=4; p values using 
Mann Whitney test. 
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5.3.3 Persistent indirect-pathway CD4 T cell activation is driven by graft parenchymal 
alloantigen expression 
 
The data presented suggests that the short-lived nature of MHC class II indirect-pathway 
allorecognition is a consequence of alloantigen clearance. In contrast, donor APC clearance 
had little impact on allorecognition of H-2Kd allopeptide (Figure 5.8b). To confirm that late 
anti-MHC class I indirect-pathway responses are due to graft parenchymal expression of 
alloantigen (and not due to an intrinsic difference between TCR75 and TEa transgenic CD4 T 
cells such as affinity for epitope), the following series of experiments were performed. 
5.3.3.1 Ongoing proliferation is driven by recipient APC presentation of allopeptide 
 
Recipient B cells and DCs were depleted in order to confirm that late proliferation of TCR75 
CD4 T cells reflects ongoing antigen presentation by host professional APCs. For this 
experiment C57BL/6 x BL6.DTR chimeric mice were used as recipients to avoid the systemic 
complications of prolonged administration of DTX when administered to B6.DTR mice257. 
Recipients were treated with either depleting anti-CD20 mAb or diphtheria toxin from three 
weeks following transplantation, and week 5 proliferation of TCR75 assessed. Depletion of 
either cell type resulted in a significant abrogation of TCR75 proliferation, confirming the 
importance of recipient professional APCs to ongoing indirect-pathway alloresponses (Figure 
5.12). Administration of diphtheria toxin to a non-DTR gene expressing C57BL/6 had no impact 
on TCR75 proliferation, excluding the possibility that diphtheria toxin interferes with T cell 
proliferation directly (data not shown).  The inability to completely abrogate indirect-pathway 
presentation with both B cell and DC depletion likely reflect both the incomplete nature of 
depletion and the contribution of additional professional APCs not depleted, for example 
macrophages. 
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Figure 5.12 Ongoing professional APC presentation is required for late indirect-pathway alloresponses 
(a) Bm12.Kd.IE cardiac allografts were transplanted into C57BL/6.DTR bone marrow-chimeric mice. 
Twenty-one days following transplantation, recipient APCs were depleted: DCs by administration of 
10ng/g diphtheria toxin on alternate days and/or B cells by administration of 250μg depleting anti-CD20 
antibody, both i.p.. 4-6x10
6
 CFSE labelled TCR75 splenocytes were adoptively transferred on day 28 and 
proliferation quantified 6 days later. (b) Depletion of either APC subset resulted in attenuation of TCR75 
proliferation confirming a role in indirect-pathway presentation. All groups n=5. P values using Mann 
Whitney test. 
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5.3.3.2 Restricting H-2Kd alloantigen expression to haematopoietic lineage limits the 
longevity of class I indirect-pathway responses 
 
To confirm that ongoing indirect-pathway allorecognition of donor MHC class I reflects 
parenchymal expression, bone-marrow chimeric mice were developed in which H-2Kd 
expression was restricted to the haematopoietic lineage. The aim of this experiment was to 
provide the opportunity to use TCR75 transgenic CD4 T cells in a setting in which it would be 
predicted that proliferation would be short-lived from the findings with TEa CD4 T cells. This 
would then act as a control for any differences between the two transgenic CD4 T cells, and 
enable a direct comparison between indirect-pathway responses against MHC class I and MHC 
class II in this model using the same transgenic CD4 T cell population. 
Bm12.IE mice, identical to bm12.Kd.IE other than lacking the expression of the MHC class I H-
2Kd, were lethally irradiated and reconstituted with bm12.Kd.IE bone marrow. Chimerism was 
confirmed with expression of H-2Kd identified on lymphocytes 6 weeks following generation 
(Section 2.1.8). It was hypothesised that MHC class I indirect-pathway allopeptide 
presentation, and therefore TCR75 proliferation, would be restricted to the early phase 
following transplantation of these chimeric donors, because transferred haematopoietic cells 
will be rapidly cleared by the recipient. As expected, there was no TCR75 proliferation 
following transplantation of bm12.IE donors since they lack H-2Kd expression. Following 
transplantation of the chimeric mice, TCR75 CD4 T cells underwent robust proliferation at the 
early time-point, but did not proliferate when transferred late, unlike when transferred 
following transplantation of bm12.Kd.IE donors (Figure 5.13). This further confirms that 
ongoing indirect-pathway alloresponses are targeted against antigens expressed by graft 
parenchyma.  
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Figure 5.13 MHC class I indirect-pathway alloresponses are short-lived when antigen expression is 
restricted to haematopoietic lineages 
(a) Bm12.IE mice were lethally irradiated (13 Gray split dose) and adoptively transferred with 2x10
7
 
bm12.Kd.IE bone marrow cells. Reconstitution was confirmed by flow cytometry on peripheral bleeds 
prior to experimental usage. After six weeks, these chimeras were used as donors for cardiac 
transplantation into C57BL/6 recipients and 4-6x10
6
 CFSE labelled TCR75 splenocytes adoptively 
transferred on the day of transplantation (week 1) or after 28 days (week 5). (b) No proliferation was 
observed when bm12.IE mice were used as donors prior to bone-marrow chimerism. Robust TCR75 
proliferation was observed early following transplantation with chimeric donors, but this was short-
lived. All groups n=5. P values using Mann Whitney test. 
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5.3.3.3 Acute rejection of allografts restricts duration of indirect allorecognition 
 
The archetypal and most widely studied model of acute allograft rejection is the BALB/c to 
C57BL/6 model. Here, cardiac allografts are acutely rejected with a median survival time of 7-
10 days375 and presumably do not continue to shed alloantigen.  
Since BALB/c mice express the MHC class I H-2Kd (in addition to the MHC II I-E), following 
transplantation, unlike in the bm12.Kd.IE to C57BL/6 model, MHC class I alloantigen would not 
be continually shed in the recipient and it was hypothesised that this would restrict the 
duration of the H-2Kd-specific indirect-pathway response. To examine this, TEa and TCR75 CD4 
T cells were transferred at early and late time points following transplantation. As anticipated, 
whilst there was proliferation of both early, no proliferation was observed at the late time-
point, after the graft had been rejected (Figure 5.14).  
 
 
Figure 5.14 MHC class I and II indirect-pathway responses are short-lived in an acute-rejection model 
BALB/c cardiac allografts were transplanted into C57BL/6 recipients. 4-6x10
6
 CFSE labelled TCR75 and 
TEa splenocytes were adoptively transferred i.v. at either week 1 or week 5 (n=4). Both MHC class I (a) 
and MHC class II (b) indirect-pathway allorecognition were short-lived, with no late proliferation 
observed. P values using Mann Whitney test. 
 
 
These last two experiments suggest that ongoing indirect-pathway responses are driven by 
graft parenchymal antigen expression. They also strengthen the findings above in relation to 
class II indirect-pathway responses, excluding that differences in duration of TEa and TCR75 
proliferation are simply due to inherent differences between the transgenic cells, for example 
in affinity of the TCR for the respective allopeptide epitopes. 
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5.3.4 Endothelial MHC II expression 
 
There has been some debate in the literature regarding murine endothelial expression of MHC 
class II. Whilst it is accepted that human endothelial cells express MHC class II it is not 
generally thought to be expressed by resting murine endothelium338. However, activation-
induced up-regulation, as typically occurs within the endothelium of rejecting allografts, has 
been described in murine cardiac allografts86, 369, 376-378.  
An attempt was thus made to demonstrate the ability of donor murine endothelium to express 
MHC class II in the bm12.Kd.IE to C57BL/6 model. First, endothelial cells were cultured in vitro. 
Both bm12.Kd.IE and C57BL/6 strain endothelial cells were generated and expressed 
appropriate endothelial cell markers. MHC class II expression was evident, with bm12.Kd.IE 
expressing the class II: I-E but not I-Ab as expected (Figure 5.15a).  
Confirmation of in vivo MHC class II expression by endothelium was obtained by 
immunofluorescence staining of donor bm12.Kd.IE cardiac allografts explanted at one week 
following transplantation. Expression of donor MHC class II was evident on the endothelium at 
this early time-point (Figure 5.15b). By week 5 however, no such expression was identified, 
perhaps reflecting the reduced pro-inflammatory milieu. 
That clearance of haematopoietic cells from donor allografts abrogates class II indirect-
pathway responses is therefore potentially surprising since an endothelial source appears to 
exist, at least transiently; presumably endothelial I-E alloantigen is expressed at too low a level, 
and for too short a period, to drive a detectable indirect-pathway CD4 T cell response with TEa 
CD4 T cells. 
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Figure 5.15 Donor endothelial MHC class II expression 
(a) Bm12.Kd.IE (red) and C57BL/6 (blue) endothelial cells were cultured in vitro. Flow cytometric analysis 
of these cells revealed surface expression of endothelial cell markers: CD105 (top left panel) and 
isolectin B4 (top right panel) confirming them to be phenotypically endothelial cells. Surface expression 
of MHC class II was observed, compared to isotype control staining (grey). Bm12.Kd.IE endothelial cells 
expressed I-E and not I-A
b
 and the reciprocal was true of C57BL/6 endothelial cells (bottom panels). (b) 
Immunofluorescence staining (with CD31, I-E and I-A
b
) of cryostat sections of donor bm12.Kd.IE cardiac 
allografts harvested at week 1 and 5 following transplantation was performed. Endothelial expression of 
donor MHC class II was observed at week 1, but not at week 5. Representative photomicrographs at 40x 
magnification presented.  
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5.3.5 Development of late MHC class II humoral alloresponses 
 
Development of de novo donor specific MHC II class alloantibody has been detected in human 
transplant recipients379-381.  Because the late development of MHC class II alloantibody would 
not be expected in the absence of a simultaneous MHC class II allospecific indirect-pathway 
CD4 T cell response, these clinical findings question the relevance of the above findings in the 
murine model. 
However, recent work from our laboratory has introduced the concept of ‘unlinked-help’ in 
transplantation, whereby an antigen-specific B cell can receive help to produce alloantibody by 
a T cell of different allospecificity382. It was demonstrated that CD4 T cells specific for another 
alloantigen expressed by a graft could provide this unlinked-help.  
Upon ligation of its BCR, a B cell will internalise antigen320. Since alloantigen is membrane 
bound, it is proposed that an alloantigen specific B cell will internalise its antigen and 
membrane from target donor cells, which may contain additional cell surface donor antigens. 
These will also be processed and presented by the B cell which could therefore, potentially be 
able to receive help from an allospecific CD4 T cell specific for a different antigen, from the 
graft, to that recognised by the B cell itself382.  
To examine the possibility that this process could account for late MHC class II alloantibody 
responses in the bm12.Kd.IE to C57BL/6 model, bm12.Kd.IE hearts were transplanted into 
TCRKO mice, providing the ability to limit antigen specificity of CD4 T cell help by adoptive 
transfer of TCR transgenic CD4 T cells.  
Earlier experiments revealed that such transplants lead to the development of autoantibody 
and weak, short-lived, alloantibody responses in TCRKO recipients with no evidence of 
allograft rejection (Figure 3.22). Despite the short-lived nature of the alloantibody response, 
donor haematopoietic cells were cleared from recipients rapidly, and no TEa CD4 T cell 
proliferation was observed upon transfer four weeks after transplantation (Figure 5.16a,b). 
To examine the development of late alloantibody, TCR transgenic CD4 T cells were adoptively 
transferred 4 weeks following transplantation of bm12.Kd.IE cardiac allografts into C57BL/6 
recipients, and weekly serum samples collected. As predicted from their lack of proliferation, 
transfer of MHC class II specific indirect-pathway TEa CD4 T cells resulted in neither anti-IE nor 
anti-H-2Kd alloantibody (Figure 5.16c,d).  
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In contrast, transfer of MHC class I specific TCR75 CD4 T cells resulted in development of 
robust anti-H-2Kd and anti-IE alloantibody responses and the hearts were rapidly rejected 
(Figure 5.16c,d). This suggests, as previously described by our laboratory, that MHC class I 
specific CD4 T cells can provide help to MHC class II specific B cells and drive an anti-IE 
alloantibody response.  
To confirm that TEa CD4 T cells do possess the ability to drive alloantibody responses, TEa CD4 
T cells were transferred on the day of transplantation. In this experiment, TEa CD4 T cells 
drove a robust anti-IE alloantibody response. Furthermore, a short-lived low level anti-Kd 
alloantibody response was observed, confirming the reciprocal ability of these transgenic CD4 
T cells to provide help for B cells of a different allospecificity (Figure 5.16e,f). 
These findings potentially reconcile the observation that late class II alloantibody responses 
can develop de novo in human transplant recipients at a time when class II allospecific indirect-
pathway CD4 T cell responses appear not to remain active. 
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Figure 5.16 Linked presentation permits development of late MHC class II alloantibody responses 
(a) Peripheral bleeds of RAG2KO and TCRKO recipients of bm12.Kd.IE cardiac allografts 4 weeks 
following transplantation reveals that donor CD4 T cells do not survive long term in TCRKO recipients, 
unlike in RAG2KO recipients (absence of CD4
+
 H-2K
d+
 population). (b) In keeping with absence of donor 
haematopoietic cell survival in TCRKO recipients, no TEa proliferation was observed when 4-6x10
6
 
splenocytes were adoptively transferred i.v. 4 weeks following transplantation (n=2). In subsequent 
experiments 1x10
6
 purified TCR75 (red lines) or TEa (blue lines) CD4 T cells (MACS separated using anti-
CD4 microbeads) were adoptively transferred into recipients either 4 weeks following transplantation 
(c,d) or on the day of transplantation (e,f). All groups n=4. I-E alloantibody was quantified by flow 
cytometric labelling of I-E expressing BMDCs and H-2K
d
 alloantibody by ELISA, on weekly serum samples. 
When transferred late, TEa CD4 T cells did not drive alloantibody generation, whilst TCR75 CD4 T cell 
transfer resulted in both I-E and H-2K
d
 alloantibody production, suggesting that the TCR75 CD4 T cells 
provide unlinked-help to I-E specific B cells (c,d). TEa CD4 T cells are capable of driving alloantibody 
responses, because when transferred early a robust I-E alloantibody response was observed (f), and 
they also provided unlinked-help to H-2K
d
 specific B cells to drive a short lived H-2K
d
 alloantibody 
response (e). P values using two-way ANOVA. 
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5.4 Discussion 
 
In this chapter, the indirect-pathway of allorecognition has been explored. The use of the 
bm12.Kd.IE to C57BL/6 model allowed simultaneous comparison of TCR transgenic 
proliferation controlling for potential differences between individual models. Results have 
confirmed that the indirect-pathway, rather than being a single entity, is in fact a 
heterogeneous collection of responses against different donor alloantigens that can have 
different duration. Specifically, indirect-pathway responses against donor MHC class II are 
restricted to the immediate post-transplant period, with even memory responses not being 
primed at later time-points. Beyond the first week following transplantation there was no 
presentation of MHC class II allopeptide, confirmed with the Y-Ae clonotypic antibody. The 
short-lived nature of this response reflects the fact that donor professional APCs are the major 
source of MHC class II alloantigen. Although allograft endothelial cells can express MHC class II 
this was found to be short-lived, likely reflecting dampening of the inflammatory milieu with 
time following transplantation. Furthermore, the contribution of this antigen to MHC class II 
indirect-pathway responses is likely limited considering the abrogation of TEa proliferation 
when leukocyte depleted lethally irradiated donors were used. Use of chimeric mice with 
expression of MHC class I restricted to haematopoietic lineages supported that ongoing 
indirect-pathway alloresponses are targeted against alloantigens expressed by graft 
parenchymal cells, and it is plausible that these are the alloimmune pathways responsible for 
driving chronic rejection.  
One key concern in extrapolating these results to human transplantation surrounds 
endothelial expression of MHC class II. Whilst it is accepted that human endothelial cells can 
upregulate expression of MHC class II in the context of inflammatory stimulation with IFNγ383, 
murine endothelial expression has remained controversial338, 376. However, there are now 
several studies which report murine endothelial expression of MHC class II upon inflammatory 
stimulation – both in vitro and in rejecting allografts in vivo86, 376-378. These findings were 
replicated in this chapter, although expression appeared short-lived. Despite the fact that 
endothelial cells may be able to express MHC class II, if this is short-lived the relevance to the 
alloimmune response may be limited. Several studies have examined the ability of human 
donor endothelium to prime allogeneic CD4 T cells and the evidence suggests that they are 
unable to do so – even memory CD4 T cells with their reduced costimulatory requirements338, 
384-386. In these experiments, although direct-pathway recognition and activation specifically 
was being examined, the results led the authors to question the contribution endothelial MHC 
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class II expression can make to the alloimmune response. Similar findings have been observed 
in murine studies where endothelial cells were found unable to prime allogeneic CD4 T cells in 
vitro despite MHC class II expression being evident376. In this study the authors also developed 
chimeric mice in which MHC class II expression was restricted to haematopoietic lineages and 
observed no impact upon allograft rejection. Together, these observations question the 
importance of endothelial MHC class II expression to the alloimmune response in both humans 
and mice. However, endothelial MHC class II expression was found to be transient in this 
thesis, which differs from the constitutive expression observed in humans. Therefore, further 
studies to clarify the role of MHC class II in the human alloimmune response would be 
warranted prior to extrapolating these findings to clinical transplantation. 
Another important consideration when interpreting these results is epitope diversification387-
389. This is the process whereby the focus of the T cell response to an antigenic challenge may 
spread from the initial dominant determinant to other, initially cryptic, epitopes on either the 
same protein (intramolecular) or a different protein (intermolecular). Analysis of indirect -
pathway allorecognition in this chapter has been performed utilising monoclonal TCR 
transgenic CD4 T cell proliferation. There is the possibility that epitope diversification may 
occur within recipients resulting in reduced presentation of earlier dominant determinant 
epitopes with time. In support, a study examining indirect-pathway responses in human 
transplant recipients revealed evidence of epitope diversification, although this did not occur 
until relatively late (>6 months) following transplantation132. Interestingly, the identification of 
epitope diversification in these recipients correlated with poorer outcomes. It is unlikely that 
this could account for the absence of TEa proliferation just one week following transplantation 
since epitope diversification appears to be a manifestation of chronic immune responses. 
Furthermore, even in the human study described above, CD4 T cells reactive against the 
original dominant pathway remained prevalent despite diversification132. 
To date there have been only limited attempts to examine indirect-pathway responses in 
human transplant recipients, which may reflect the limited experimental techniques available 
for such a study. Examination of alloimmune pathway responses in human transplant 
recipients has tended to demonstrate that indirect-pathway CD4 T cell responses are long-
lived and remain active in recipients many years following transplantation77, 78, 148, 339. 
Furthermore, there is some correlation between these responses and development of allograft 
vasculopathy and chronic rejection. These studies have tended to examine the global indirect-
pathway response by pulsing stimulator APCs with donor cell homogenates, rather than 
considering indirect-pathway responses against individual alloantigens. One study though, 
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looked specifically at indirect-pathway responses against donor HLA-DR MHC class II molecules 
using synthetic peptides to prime stimulator APCs132. This study demonstrated recipient CD4 T 
cell reactivity against donor MHC class II late following transplantation. However, only a single 
snapshot was assessed rather than the evolution of these indirect-pathway CD4 T cells over 
time. Additionally it is important to consider that the use of in vitro limiting dilution analysis 
does not necessarily confirm that these CD4 T cells are activated and continue to proliferate in 
vivo and may represent the memory population of CD4 T cells that develop following an 
antigenic challenge. There are additional concerns regarding the techniques adopted in these 
studies390. When using cell fragments as a source of donor allopeptide it is, for example, 
possible that membrane containing intact MHC molecules could be trogocytosed and 
integrated within the APC membrane. This could potentially result in direct-pathway CD4 T 
cells, present at high precursor frequency, being erroneously measured as an indirect-pathway 
response. Similarly, there are significant concerns about studies using synthetic peptides as a 
source of donor allopeptide to prime APCs. For example, reactivity is often observed using 
synthetic peptides from self-MHC molecules. It is proposed this may relate to the creation of 
neo-epitopes – either due to the absence of post-translational modifications, or the creation of 
peptides that would not occur in vivo because of the absence of natural splicing sites in the full 
protein390.  
A recent publication has described the use of synthetic HLA monomers as a tool to monitor 
indirect allorecognition which the authors claim avoid the pitfalls described above391. The 
authors demonstrated that HLA monomers were able to detect indirect-pathway CD4 T cells 
with high sensitivity and specificity and may permit more reliable examination of indirect-
pathway CD4 T cell responses in human transplant recipients – although the current high cost 
may be prohibitive390. 
Another question that arises from the observations in this chapter relates to the development 
of de novo anti-MHC Class II antibody that is sometimes observed in human recipients late 
following transplantation379-381. One of the central tenets of immunology is the essential 
requirement for an antigen-specific B cell to present internalised, processed antigen in a self-
MHC restricted manner to permit a cognate interaction with antigen-specific CD4 T cells for 
effective delivery of help97. From this, it would be expected that in order to receive help, a 
donor MHC class II specific B cell would require an indirect-pathway, donor MHC class II 
specific CD4 T cell. However, the results in this chapter suggest that the MHC class II indirect-
pathway CD4 T cell response is quiescent late following transplantation, and raises the 
possibility that these results are not relevant to human transplantation. One possibility is that 
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the graft does continue to express MHC class II alloantigen but at very small levels that cannot 
be detected by the techniques employed in this work, but is nonetheless present in sufficient 
quantities to drive MHC class II alloantibody production. Against this, transfer of TEa CD4 T 
cells that would recognise this epitope do not drive an anti-MHC class II alloantibody response. 
An alternative explanation stems from work recently published from our laboratory which 
demonstrated that CD4 T cells specific for one alloantigen could provide help to B cells whose 
allospecificity is for a different alloantigen expressed by cells within the graft – a form of 
‘unlinked’ help382. In this work monoclonal Mar cells (recognising H-Y antigen dby by the 
indirect-pathway) were found capable of providing help for the development of anti-MHC class 
I alloantibody. This help required a cognate interaction between Mar CD4 T cells and MHC 
class I specific B cells, and required that both the dby antigen and the MHC class I were co-
expressed by the same donor cell – appearing to contravene the maxim of ‘linked recognition’. 
To examine this same phenomenon and offer a means of reconciling the observation in human 
transplantation regarding late development of anti-MHC class II alloantibody, an experiment 
was designed to examine the possibility of ‘unlinked-help’ in the bm12.Kd.IE to C57BL/6 
model. The results confirmed that monoclonal TCR75 CD4 T cells (recognising H-2Kd indirectly) 
could provide help at the late time-point for the development of anti-I-E alloantibody (and 
interestingly this could not be provided by TEa CD4 T cells which recognise I-E indirectly). 
These results demonstrated that ‘unlinked-help’ could provide a mechanism for development 
of de novo late MHC class II alloantibody. 
Although on the surface, these results appear similar to the published results described, there 
is an important difference, in that there is apparently no longer a source of donor MHC class II. 
In the study described above, both the dby and MHC class I were simultaneously expressed by 
donor cells, and such simultaneous expression of the target and helper alloantigen was 
essential. In considering these findings, it was postulated that BCR-mediated internalisation of 
antigen was central. It is recognised that B cells can internalise their target antigen in a BCR-
mediated fashion, permitting them to present antigen cognately to antigen-specific CD4 T cells 
in order to receive help320, 392. It is conceivable that upon internalisation of target antigen, B 
cells will simultaneously internalise surrounding fragments of donor cells permitting a means 
of capturing additional antigen. Against this, one study visualising B cell synapse formation 
real-time observed BCR mediated concentration of antigen in the synapse suggesting that non-
selective acquisition would be unlikely393. However, another study examining capture of 
cognate antigen from follicular dendritic cells (FDC), using a PE-HEL conjugate and anti-HEL 
transgenic B cells, identified that B cells also acquired FDC surface markers as they acquired 
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their target antigen, suggesting that acquisition of adjacent membrane proteins during B cell 
antigen uptake may be possible394.  
Whilst this mechanism appears to offer an explanation for the observations in the published 
work, with simultaneous expression of dby and MHC class I by the donor cells, the situation in 
this chapter is different since there is no longer a source of donor MHC class II. One possible 
explanation for this is that the MHC class II-specific B cell has internalised both I-E and 
neighbouring H-2Kd from donor cells around the time of transplantation and continues to 
present H-2Kd peptide long-term enabling the receipt of help when the TCR75 CD4 T cells are 
transferred – in effect the B cell is primed by engagement of target antigen, but antibody 
production is delayed until CD4 T cell help is provided. This raises several questions though. Is 
the alloantigen internalised and stored intact by I-E-specific B cells, or broken down but 
allopeptide presented long-term, or could another cell type act as the antigen store? Also, how 
long can a B cell retain in a dormant state having acquired antigen: for example, would anti-
MHC class II alloantibody still develop if the T helper cell population was adoptively transferred 
into the T cell deficient recipient several months after the transplant? 
Long term sequestration of antigen is not without precedent. FDCs for example, are known to 
act as ‘antigen libraries’ for B cell sampling, and long term antigen storage has been 
reported395, 396. It is possible then that I-E molecules are retained on the surface of FDCs which 
present intact alloantigen to B cells, but remains inaccessible to CD4 T cells. It is possible that I-
E specific B cells continue to acquire antigen from this source even late after transplantation. 
Alternatively, Bergtold et al have demonstrated that DCs possess two different antigen 
processing pathways for immune complexes397. Typically, immune complexes are internalised 
by activating Fc receptors and are targeted for lysosomal degradation398. However, they 
observed that immune complexes internalised by inhibitory receptor FcγRIIB were internalised 
into a recycling vesicular system and excluded from the degradative compartment399. This 
antigen could then be recycled intact to the DC cell surface for B cell priming some time after 
encounter and internalisation. This raises the possibility that DCs may act as a source of 
antigen, or perhaps even that B cells possess a similar antigen processing pathway permitting 
long-term storage of antigen, that is degraded and presented upon appropriate stimulation at 
a later time. Long-term storage of antigen could be explored by leukocyte subset depletion 
several weeks following transplantation and transfer of CD4 T cells following reconstitution. 
A related question though is: presumably I-E allopeptide would be presented as much as the H-
2Kd, so why are TEa CD4 T cells unable to provide sufficient help?  Perhaps this relates to 
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activation status. Late following transplantation, results in this chapter have demonstrated no 
TEa proliferation occurs, whilst TCR75 proliferate vigorously. B cell activation and production 
of alloantibody likely requires antigen experienced CD4 T cell help, potentially due to down-
regulation of B cell surface expression of costimulatory molecules preventing these B cells 
from being in a position to activate naïve CD4 T cells. This could be confirmed by transferring 
antigen experienced memory TEa which may be able to provide help to B cells without a 
requirement for costimulation. Alternatively this could be tested by transplanting bm12.IE x 
bm12.Kd.IE chimeric mice in which H-2Kd expression is restricted to haematopoietic lineages. It 
would be predicted that in this setting, late after transplantation, neither TEa nor TCR75 would 
be activated and able to provide help to I-E specific B cells.  
It is clear that there are many unanswered questions around this observation that will require 
further exploration. What though is the potential clinical significance? A situation could exist 
whereby a patient receives a transplant containing an alloantigen to which they have been 
previously sensitised through pregnancy, blood transfusion or previous transplant. Memory 
CD4 T cell responses against this alloantigen could drive augmented alloantibody responses 
against all other donor alloantigens. Alternatively, T cell recognition could be of non-transplant 
antigens for example against viruses such as CMV. Viral-specific memory CD4 T cells could, 
through ‘unlinked-help’, drive alloantibody responses whilst responding against CMV infection 
of the allograft. Interestingly, strong associations have been highlighted between CMV 
infection and graft failure400, with accelerated AV development observed possibly suggesting 
augmented humoral alloimmunity401. 
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6 Phenotypic examination of indirect-
pathway CD4 T cells 
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6.1 Introduction 
 
In the previous chapter, study of the indirect-pathway of allorecognition has been performed 
by adoptive transfer of exogenous monoclonal populations of TCR transgenic CD4 T cells. This 
approach has been used widely for study of non-transplant antigen277, but my approach differs 
in that the TCR-transgenic population was transferred at various time-points after the 
transplant. This raises the question how the division of the transferred T cell population relates 
to events occurring within the endogenous indirect-pathway CD4 T cell population.  I therefore 
sought to optimise an experimental approach that would enable identification and tracking of 
endogenous antigen-specific CD4 T cells. 
6.1.1 Detecting antigen-specific CD4 T cells 
 
Detecting antigen-specific CD4 T cells has traditionally been challenging. Due to the diversity of 
the T cell repertoire, the frequency of T cells specific for a single peptide-MHC ligand is very 
low within the naïve repertoire – estimated to be between 0.2-60 cells/106 naïve T cells402. The 
second challenge to their identification has been characterisation of the T cell epitope for a 
particular antigen since the TCR recognises only peptide fragments of protein antigens, unlike 
B cells which recognise conformational epitopes.  
As a result, efforts to identify antigen-specific T cells have involved challenging cells with 
antigen in vivo or ex vivo and examining for a response. Several strategies have been 
described402, 403: 
Examining proliferation – T cell proliferation in response to antigen can be detected by 
incorporation of radioactive (3H)-thymidine or bromodeoxyuridine (BrdU) into DNA. 
Alternatively proliferating T cells can be identified by isolating T cells that have undergone 
CFSE dilution. Limitations of this approach include the inability to exclude the contribution of 
bystander T cell proliferation and identification of only the proliferating antigen-specific T cells. 
Examining cytokine expression or secretion – Flow cytometric intracellular staining for cytokine 
expression and analysis of cytokine secretion from live cells are both techniques that have 
been adopted to examine T cell effector function in response to an antigenic challenge. Again 
the problem of bystander activation exists and it is difficult to quantify the antigen-specific 
population using this approach. 
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Examining activation markers – Detecting antigen-specific T cells on the basis of up-regulation 
of activation markers following antigen challenge. This permits identification of responding T 
cells regardless of their functional specialisation (and whether they proliferate or secrete 
cytokines). A number of activation markers have been used for this including CD69, CD25, 
CD71, CD137, CD154. However, bystander activation can be a problem as well as marker 
expression not being limited to activated T cells. 
All of these techniques have the advantage that the antigenic peptide epitope does not need 
to be characterised. However, the culture conditions required for many of these techniques 
themselves may influence T cell phenotype and function, precluding robust phenotypic 
assessment following identification of the responding antigen-specific T cells. Furthermore, it 
has been difficult to accurately quantify the antigen-specific population using these 
approaches402. 
 
6.1.2 Development and use of peptide-MHC tetramers 
 
To overcome the challenges detailed above, efforts turned to utilising TCR epitope, in a similar 
manner to the use of fluorochrome-conjugated protein antigen to detect antigen-specific B 
cells. Initially, peptide-MHC monomers were utilised but success was limited because of 
insufficient affinity for TCR to detect antigen-specific T cells404. However, in 1996 Altman et al. 
demonstrated that tetramerisation of biotinylated peptide-MHC monomers with avidin 
resulted in sufficient avidity to reliably detect antigen-specific T cell populations405. These 
tetramers are fluorochrome labelled permitting detection by flow cytometry. Much of the 
early work with MHC tetramers used MHC class I molecules to detect antigen-specific CD8 T 
cells. The development and success with MHC class II tetramers has lagged. It is thought that 
structural differences between MHC class I and II molecules and lower avidity of binding 
between the CD4 TCR and peptide-MHC complex are responsible for this402, 403. Over recent 
years there has been an expansion in MHC class II tetramer availability and they have been 
widely used to study antigen-specific CD4 T cell responses against bacterial and viral 
infection406, 407. There are limitations of this technique though. One challenge is the 
requirement to identify the immunodominant peptide for a particular protein antigen in order 
to load the MHC molecules. Analysing the TCR specificities of T cells responding to in vitro 
antigen challenge and using computer algorithm predictions, have both been employed to 
overcome this403. However, epitope spreading is known to occur during chronic immune 
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responses and restricting analysis to an initial immunodominant epitope may not therefore, be 
representative of the entire T cell response against protein antigen132. 
One further challenge has been the low precursor frequency of naïve T cells and the small 
proportion of responding T cells that are detected with tetramer. To overcome this, 
enrichment steps have been developed to allow for rapid processing of samples whilst 
increasing the sensitivity of antigen-specific T cell detection. Enrichment steps have involved 
magnetic separation of cell populations based upon tetramer binding (using anti-fluorochrome 
magnetic microbeads). The positive fraction additionally contains significant numbers of non-
target cells. Gating out non-T cells and dead cells, permits sensitive and specific identification 
of antigen-specific T cells408-411. 
Peptide-MHC tetramers have revolutionised the ability to detect and characterise endogenous 
antigen-specific T cell responses and are now increasingly used402, 407, 412. Not only can peptide-
MHC tetramers be used to identify and quantify antigen-specific T cells, they also permit the 
opportunity to examine their phenotype. To date, peptide-MHC tetramers have not been 
utilised to study alloimmune CD4 T cell responses against donor antigens in experimental 
transplantation. 
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6.2 Aims 
 
The purpose of the research described in this chapter is to extend the findings using TCR 
transgenic CD4 T cells reported earlier and utilise peptide-MHC class II tetramers to 
characterise the endogenous indirect-pathway CD4 T cell alloresponses in C57BL/6 recipients 
of bm12.Kd.IE cardiac allografts. 
 
The aims are: 
 
1) To examine the potential of utilising peptide-MHC class II tetramer to identify indirect-
pathway alloreactive CD4 T cells following challenge with an allograft. 
 
2) To quantify and compare kinetics and phenotype of the endogenous antigen-specific 
CD4 T cell response directed against short-lived and long-lived indirect-pathway 
alloresponses. 
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6.3 Results 
 
Data from the previous chapter suggest that in recipients of chronically rejecting cardiac 
allografts, ongoing indirect-pathway alloresponses are targeted against alloantigen expressed 
by the graft parenchyma. It is likely that these ongoing alloresponses are responsible for 
driving chronic rejection. 
Results thus far have relied upon transfer of exogenous monoclonal populations of transgenic 
CD4 T cells, which raises the potential for criticism that this may not be reflective of the 
endogenous alloimmune response. Examination of the endogenous T cell response would be 
very useful to verify the findings. There have been many approaches to identify endogenous 
antigen-specific CD4 T cells402, 403, 413, however the recent development of MHC class II tetramer 
technology has provided a novel approach that has been successfully used in models of 
infection407, 412.  
6.3.1 Identifying endogenous recipient alloreactive CD4 T cells with MHC class II 
tetramers 
 
Recipient type MHC class II (I-Ab) tetramers loaded with peptide derived from donor MHC class 
I (H-2Kd) and class II (I-E) were kindly gifted by the National Institute of Health Core Tetramer 
Facility, Emory, US (Figure 6.1). The tetramers are fluorescently labelled permitting 
identification of antigen-specific CD4 T cells using flow cytometry. 
 
Figure 6.1 MHC class II tetramers against donor MHC class I (H-2K
d
) and MHC class II (I-E) 
Recipient MHC class II (I-A
b
) tetramers loaded with donor MHC class I (H-2K
d
 - left) and class II (I-E - right) 
allopeptide were gifted by the NIH Core Tetramer Facility, permitting identification of endogenous CD4 T 
cells with indirect-pathway allospecificity.  
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6.3.1.1 Enrichment step enhances ability to detect tetramer bound CD4 T cell population 
 
Reading of the literature revealed that enrichment of tetramer bound cells has been 
successfully used to overcome the challenge of identifying the small antigen-specific CD4 T cell 
population407. This approach was adopted and tetramer binding to CD4 T cells was initially 
examined in C57BL/6 recipients two weeks following challenge with a bm12.Kd.IE cardiac 
allograft at which point it was anticipated an allospecific population would have developed.  
 
Tetramer binding to other cell subsets occurs requiring ‘dump-channels’ to accurately exclude 
non-CD4 T cells. The gating strategy is demonstrated in Figure 6.2. Enrichment very effectively 
permits identification of the antigen-specific CD4 T cells as can be seen from ‘before’ and 
‘after’ flow cytometry plots (Figure 6.3). Confirmation that binding is antigen-specific is 
achieved with negative-control tetramers, identical to the experimental tetramer, but loaded 
with peptide from the endogenous human CLIP protein.  
 
 
Figure 6.2 Gating strategy for identification of antigen-specific tetramer bound CD4 T cells 
Single cell suspensions of experimental spleens were obtained. They were incubated at 37
o
C for 2 hours 
with MHC class II tetramer at a 1/200 concentration. Subsequently enrichment was performed (see 
below) and surface marker staining was performed and cells analysed by flow cytometry. Tetramer 
bound CD4 T cells were identified as follows: lymphocytes were first gated (top left panel); dead cells 
and CD8 T cells were excluded (PerCP, top centre panel); CD11b
+
 macrophages and DCs were excluded 
(APC-Cy7, top right panel); CD19
+
 B cells were excluded (FITC, bottom left panel); CD4 T cells were 
positively gated from the remaining population (PE-Cy7, bottom centre panel); Tetramer bound CD4 T 
cells were then identified by plotting against PE (bottom right panel). 
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Figure 6.3 An enrichment protocol improves ability to detect tetramer bound CD4 T cells 
Staining was performed as described in Figure 6.2. For enrichment, following incubation with the 
tetramer cells were incubated with anti-PE microbeads (the tetramer bound flurochrome) and 
separated with MACS following the manufacturers instruction. The positive fraction, enriched for 
tetramer bound cells was then stained for surface markers and processed by flow cytometry. Here, both 
H-2K
d
 (a) and I-E (b) allopeptide tetramers were used to stain C57BL/6 recipient splenocytes 2 weeks 
following transplantation with a bm12.Kd.IE cardiac allograft. Very little, if any, tetramer bound CD4 T 
cells were detected with the I-E allopeptide tetramer, despite enrichment (a); but following enrichment 
a definite population of H-2K
d
 allopeptide tetramer bound CD4 T cells was identified  [(b), top left panel] 
– which was not identified without enrichment (bottom left panel). Antigen-specificity was confirmed by 
absence of binding to control tetramer loaded with human CLIP peptide (right panels). 
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Whilst a tetramer-bound CD4 T cell population was reproducibly identified with the H-2Kd 
peptide loaded tetramer, this was not the case for the I-E loaded tetramer. To further examine 
this difference, the two TCR transgenic strains: TCR75 and TEa, which possess TCRs recognising 
the exact epitope presented by the donor MHC class I and class II loaded I-Ab tetramers 
respectively, were employed as positive controls. Similar to the previous results, the H-2Kd 
loaded tetramer was effective at binding to TCR75 CD4 T cells, with all binding the tetramer. 
However, the I-E loaded tetramer did not appear to bind to TEa CD4 T cells (Figure 6.4).  
 
 
Figure 6.4 Using T cell receptor transgenic mice as positive controls for tetramer binding 
Staining and enrichment were performed as described in Figure 6.3. Naïve TCR75 and TEa splenocytes 
were employed as positive controls for tetramer binding since their TCR epitopes are formed by the H-
2K
d
 and I-E peptide loaded tetramers respectively. Whilst TCR75 CD4 T cells were all bound to tetramer 
(left panel), TEa CD4 T cells appeared not to bind to the I-E tetramer with similar binding to control 
tetramer observed (not shown). Representative flow cytometry plots from three independent 
experiments. 
 
 
Concerned that this lack of binding was a problem with the tetramer the NIH Core Tetramer 
Facility was contacted to seek advice. This tetramer has been previously used to detect 
antigen-specific CD4 T cells following immunisation with synthetic I-E peptide, rather than 
following challenge with intact, conformational I-E class II antigen. In an attempt to replicate 
this, 100μg synthetic I-E peptide in CFA was injected subcutaneously to drive an indirect-
pathway response against the MHC class II I-E. Staining with the tetramer was performed after 
seven days and revealed a population of antigen-specific CD4 T cells (Figure 6.5). 
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Figure 6.5 MHC class II - I-E allopeptide loaded tetramer binds CD4 T cells responding to synthetic I-E 
allopeptide immunisation 
C57BL/6 mice were immunised with 100μg synthetic I-E peptide in CFA s.c. and after 10 days spleens 
were harvested (n=2).  Staining and enrichment were performed as described in Figure 6.3. Recipient 
antigen-specific CD4 T cells binding to the I-E allopeptide loaded I-A
b
 tetramer were identified following 
this challenge (left panel) with negligible binding to the control tetramer (right panel).  
 
 
Why there should be a difference between synthetic I-E peptide immunisation and exposure to 
endogenous I-E antigen is not clear. Perhaps this relates to absence of post-translational 
modification; or differences in peptides such as different lengths of peptide bound in the 
groove, such that although the core motif is similar, flanking regions outside the groove alter 
the confirmation of the central motif. These possibilities are considered further in the 
discussion. As a result, subsequent experiments were performed with the H-2Kd peptide 
loaded tetramer only. 
It is recognised that CD4 T cells become resident in tissues, and populations are known to 
reside within organs such as the heart (Figure 3.17)306, 414. It was therefore interesting to 
consider if alloantigen-specific populations of T cells specifically traffic to donor allografts. 
Donor and native recipient hearts were harvested two weeks following transplantation and 
homogenates stained with tetramer as described. Whilst CD4 T cell populations were 
identified within both allograft and native hearts, a significant tetramer positive population 
was only found within the donor allograft, suggesting that CD4 T cells have a predilection to 
traffic to and become concentrated within donor tissues (Figure 6.6). Perhaps this is because 
they are retained by infiltrating recipient APCs presenting cognate antigen, and/or are 
exhibiting or driving adaptive effector function from within the allograft. 
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Figure 6.6 Antigen-specific CD4 T cells identified to reside within the donor allograft 
Bm12.Kd.IE cardiac allografts were transplanted into C57BL/6 recipients (n=2). Fourteen days following 
transplantation donor and native recipient hearts were harvested and homogenised to obtain a single 
cell suspension. Staining and enrichment were performed as described in Figure 6.3, using the H-2K
d
 
allopeptide loaded tetramer. Recipient antigen-specific CD4 T cells binding to the H-2K
d
 allopeptide 
loaded I-A
b
 tetramer were identified following this challenge within donor (left panel) but not native 
recipient (right panel) hearts. 
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6.3.2 Quantifying the endogenous indirect-pathway donor class I alloreactive CD4 T 
cell population 
 
In a similar manner to that described for CD4 T cell responses against conventional protein 
antigens, the endogenous donor H-2Kd specific indirect-pathway response to a bm12.Kd.IE 
cardiac allograft was next quantified and mapped over time407. Spleens from recipient mice 
were harvested at weekly intervals following transplantation and the number of antigen-
specific CD4 T cells estimated as described in Figure 6.7407, 412. 
 
 
Figure 6.7 Stages in quantification of tetramer bound cells within a recipient spleen 
A step-by-step description of how an estimate of the number of tetramer bound CD4 T cells in a 
recipient spleen was quantified. Adapted from the work of M Jenkins (University of Minnesota, US)
407, 412
 
 
This revealed that H-2Kd allopeptide-specific CD4 T cells undergo typical expansion, contraction 
and memory phases following transplantation with bm12.Kd.IE donor cardiac allografts (Figure 
6.8a).  In comparison, when recipient mice were challenged with an acutely rejecting BALB/c 
cardiac allograft the expansion phase was much less marked and furthermore, in the order of 
10,000 fold fewer cells persisted into the memory phase. This finding is despite similar levels of 
H-2Kd alloantigen being expressed on BALB/c and bm12.Kd.IE cardiac myocytes (Figure 6.8b,c).  
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Figure 6.8 Quantification of the donor MHC class I indirect-pathway CD4 T cell alloresponse 
(a) Bm12.Kd.IE, or acutely rejecting BALB/c, cardiac allografts were transplanted into C57BL/6 recipients. 
At weekly intervals following transplantation, recipient spleens were harvested. Staining and 
enrichment using the H-2K
d
 allopeptide loaded tetramer were performed as described in Figure 6.3, and 
number of tetramer bound cells quantified as described in Figure 6.7. Each time point n=3. Expression 
level of H-2K
d
 by naïve bm12.Kd.IE (blue lines) and BALB/c (red lines) cardiac myocytes was examined by 
homogenising hearts to obtain a single-cell suspension. (b) Flow cytometry histogram of BALB/c and 
bm12.Kd.IE H-2K
d
 expression with anti-H-2K
d
 antibody at 1/100 dilution. (c) Mean fluorescence intensity 
H-2K
d
 staining of cardiac myocytes with a series of antibody dilutions. 
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The increased number of H-2Kd-specific CD4 T cells following challenge with a bm12.Kd.IE 
cardiac allograft is presumably a consequence of ongoing allopeptide presentation. This 
hypothesis was tested using co-stimulation blockade therapy to abrogate acute rejection of 
BALB/c allografts375. Administration of anti-CD154 monoclonal antibody around the time of 
transplantation (which interferes with the CD40-CD40L co-stimulation pathway disrupting the 
activation of CD4 T cells) prolongs the survival of BALB/c allografts, which are rejected 
chronically (Figure 6.9a)375. There is also a marked reduction in the anti-H-2Kd alloantibody 
response in treated recipients (Figure 6.9b). In keeping with anti-CD154 treatment prolonging 
persistence of alloantigen, proliferation of the TCR transgenic TCR75 CD4 T cells was observed 
at the late time point following transplantation. This is in contrast to untreated recipients of 
BALB/c allografts where no such TCR75 proliferation is seen (Figure 6.9c). 
In keeping with these findings, a less profound contraction in the H-2Kd alloantigen-specific 
CD4 T cell population was observed in recipients of BALB/c cardiac allografts that received 
anti-CD154 antibody, with a significantly greater population of tetramer-bound CD4 T cells 
quantified six weeks following transplantation (Figure 6.10a).  
Persistence of alloantigen correlates with proliferation of adoptively transferred naïve indirect-
pathway CD4 T cells. Tetramer staining provides the opportunity to examine whether 
endogenous CD4 T cells are similarly undergoing proliferation at these late time-points. This 
was achieved by staining for Ki-67, an intracellular protein whose expression is strictly 
associated with cellular proliferation415, 416. Ki-67 staining of tetramer-bound CD4 T cells 
revealed that expansion of the late endogenous alloreactive T cell population in recipients of 
chronically rejecting allografts correlates with ongoing proliferation. The percentage of Ki-67 
positive, H-2Kd allopeptide-specific CD4 T cells was higher at 6 weeks in unmodified recipients 
of bm12.kd.IE or anti-CD154-treated recipients of BALB/c grafts than in C57BL/6 recipients of 
acutely-rejecting BALB/c heart allografts (Figure 6.10b,c). 
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Figure 6.9 Co-stimulation blockade delays allograft rejection and prolongs indirect allorecognition 
BALB/c cardiac allografts were transplanted into C57BL/6 recipients +/- administration of anti-CD154 co-
stimulation blockade (1mg i.p. days -2, 0, +2, +4 in relation to transplantation). (a) Abdominal palpation 
of heartbeat demonstrated that co-stimulation blockade abrogated acute allograft rejection (n=5). (b) 
Weekly serum was collected and anti-H-2K
d
 alloantibody quantified by ELISA. A substantial reduction in 
the level of alloantibody occurred following treatment with anti-CD154. (c) Following transplantation 4-
6x10
6
 CFSE labelled TCR75 splenocytes were adoptively transferred either on the day of transplant or 
four weeks later, and extent of proliferation quantified after 6 days. Proliferation was attenuated in 
CD154 treated recipients at week 1. However, the indirect-pathway response against donor MHC class I 
was prolonged in CD154 treated recipients, with robust proliferation observed at the late time point. P 
values using Mann Whitney test. 
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Figure 6.10 Persistent indirect-pathway responses are characterised by expanded populations of 
antigen-specific CD4 cells that continue to proliferate 
Bm12.Kd.IE, or acutely rejecting BALB/c cardiac allografts +/- anti-CD154 treatment (1mg i.p. days -2, 0, 
+2, +4 in relation to transplantation), were transplanted into C57BL/6 recipients. At 4 weeks following 
transplantation, recipient spleens were harvested. Staining and enrichment using the H-2K
d
 allopeptide 
loaded tetramer were performed as described in Figure 6.3, Each group n=3. (a) The number of tetramer 
bound cells was quantified as described in Figure 6.7. In keeping with prolongation of the indirect –
pathway alloresponse, a significantly greater number of tetramer bound cells was observed in recipients 
of BALB/c cardiac allografts following treatment with anti-CD154. Separately, following enrichment, cells 
were additionally stained for expression of intracellular protein Ki-67, a marker of recent proliferation 
and the proportion of tetramer bound cells expressing Ki-67 quantified. The expanded population of 
tetramer bound cells observed in recipients of bm12.Kd.IE and BALB/c with anti-CD154 treatment are 
actively undergoing proliferation, unlike the contracted population following BALB/c acute rejection (b). 
Representative flow cytometry plots demonstrating Ki-67 staining. P values using Mann Whitney test.  
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6.3.3 Phenotypic characterisation of endogenous H-2Kd specific indirect CD4 T cells 
 
In addition to quantifying the size of the endogenous CD4 T cell response to an alloantigen, 
tetramer staining provides the opportunity to examine additional details of the phenotype of 
endogenous antigen-specific CD4 T cells.  
6.3.3.1 Assessing memory status of antigen-experienced CD4 T cells 
 
Following population expansion a significant proportion of CD4 T cells undergo apoptosis 
during the contraction phase306, 417, 418. Some effector T cells though, develop into memory T 
cells that persist as heterogeneous populations in lymphoid and mucosal sites. Two subsets of 
memory CD4 T cells are commonly described: ‘effector memory’ Tem (CD44+ CD62Llo CCR7lo) 
and ‘central memory’ Tcm (CD44+ CD62L+ CCR7+)418-421.   
The memory status of antigen-specific tetramer bound CD4 T cells following a transplant 
challenge was next examined. Of interest was if there is any difference in the characteristics of 
antigen-specific CD4 T cell memory status following challenge with an acutely or a chronically 
rejecting allograft.  
BALB/c and bm12.Kd.IE cardiac allografts were transplanted into C57BL/6 recipients and 6 
weeks later the memory phenotype of tetramer bound cells was examined. The percentage of 
antigen-experienced CD44hi CD4 T cells was comparable after transplantation with BALB/c or 
bm12.Kd.IE cardiac allografts, but the antigen experienced CD4 T cells in recipients of a 
bm12.Kd.IE heart graft were predominantly CD44hiCCR7loCD62Llo effector memory, while those 
in BALB/c heart-grafted recipients were more skewed towards CD44hiCCR7hiCD62Lhi central 
memory (Figure 6.11). 
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Figure 6.11 Memory phenotype of tetramer bound CD4 T cells 
Bm12.Kd.IE, or acutely rejecting BALB/c cardiac allografts were transplanted into C57BL/6 recipients. At 
6 weeks following transplantation, recipient spleens were harvested. Staining and enrichment using the 
H-2K
d
 allopeptide loaded tetramer were performed as described in Figure 6.3, Each group n=4. a) 
Representative flow cytometry plots showing tetramer bound CD4 T cell population (left panel) and 
gating strategy for identifying CD44
+
 antigen experienced cells. b) Comparison of proportion of tetramer 
bound CD4 T cells that are CD44
+
 following transplantation with bm12.Kd.IE or BALB/c allografts. c) 
Representative flow cytometry plots of CD44
+
 CD4 T cells from a naïve C57BL/6 mouse (left 2 panels) 
and tetramer bound CD4 T cells from recipients of bm12.Kd.IE or BALB/c allografts (right 2 panels) with 
CD62L plotted against CCR7 (Far left panel is with isotype control antibodies). Proportion of CD44
+
 
tetramer bound CD4 T cells that were d) CD44
hi
CCR7
lo
CD62L
lo
 effector memory or e) 
CD44
hi
CCR7
hi
CD62L
hi
 central memory. P values using Mann Whitney test.  
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To assess the functional consequences of this difference in memory phenotype, T cell-deficient 
TCRKO (Tcrbd-/-) C57BL/6 mice were reconstituted with CD4 T cells purified from recipients of 
bm12.Kd.IE or BALB/c heart grafts 6 weeks following transplantation, and the reconstituted 
TCRKO mice then challenged with a C57BL/6 donor heart that expressed H-2Kd as a transgene 
(B6.Kd) while simultaneously receiving co-stimulation blockade treatment with anti-CD154 
mAb (Figure 6.12a). 
 
It was anticipated that only established H-2Kd-specific memory CD4 T cells would be able to 
provide co-stimulation-independent help for development of anti-H-2Kd alloantibody 
responses against the B6.Kd graft382. Whereas anti-H-2Kd alloantibody was not observed in 
TCRKO recipients reconstituted with CD4 T cells from bm12.Kd-IE grafted mice, weak, but 
consistent, anti-H-2Kd alloantibody responses developed in TCRKO recipients reconstituted 
with CD4 T cells from BALB/c grafted mice (Figure 6.12b), despite the vastly reduced number 
of H-2Kd allopeptide-specific CD4 T cells present in this latter group at late time points after 
transplantation (Figure 6.10a). Thus, chronic allopeptide presentation drives continual division 
of the responding alloreactive CD4 T cell population, with persistence of a greatly expanded 
population, but with functional evidence of altered memory development.   
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Figure 6.12 Assessing functional relevance of CD4 T cell memory cell phenotype differences 
a) BALB/c or bm12.Kd.IE cardiac allografts were transplanted into C57BL/6 recipients. After 6 weeks, 
recipient spleens were harvested and CD4 T cells purified using MACS separation (using anti-CD4 
MicroBeads). 5x10
6
 CD4 T cells from recipients of either bm12.Kd.IE or BALB/c allografts were adoptively 
transferred i.v. into T cell deficient TCRKO mice that were recipients of B6.Kd cardiac allografts (each 
group n=3). The TCRKO recipients were treated with anti-CD154 500μg i.p. on days -2, 0, +2, +4. b) 
Weekly serum samples were collected from TCRKO recipients and anti-H-2K
d
 alloantibody was 
quantified using ELISA. P value using two-way ANOVA 
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6.4 Discussion 
 
This chapter has examined the endogenous indirect-pathway alloresponses targeted against 
donor MHC class I H-2Kd in recipients following cardiac transplantation. The results have 
confirmed peptide-loaded MHC class II tetramer to be an effective tool to examine alloantigen-
specific CD4 T cells. To date, MHC class II tetramer use in human transplantation to study 
alloresponses has been limited, perhaps due to a lack of knowledge of the immunogenic 
peptides for all HLA molecules, and the requirement to generate different peptide loaded 
tetramers for each donor/recipient HLA combination. However, tetramers have been used 
more widely in studies of infection, where immunodominant peptides have been characterised 
for many organisms. One such study was performed in human transplant recipients, utilising 
MHC class I tetramers loaded with immunodominant peptide from CMV in order to examine 
CMV specific CD8 T cell responses422. Experimentally, MHC class I tetramers have also been 
recently reported as a tool to examine alloreactive recipient B cells423. 
In recipients of acutely rejecting BALB/c allografts, the alloantigen-specific CD4 T cell 
population undergoes typical expansion followed by contraction phases. By contrast, in 
recipients of chronically rejecting bm12.Kd.IE allografts the expansion phase was much more 
marked, and approximately 10,000 fold greater cells persisted into the memory phase, despite 
similar levels of H-2Kd alloantigen expression. In support that this reflects ongoing alloantigen 
availability, a less profound contraction was observed in recipients of BALB/c allografts treated 
with anti-CD154 co-stimulation blockade. Furthermore, ongoing alloantigen presence 
correlated with continued division of the H-2Kd alloantigen-specific CD4 T cell population. In 
addition to these differences in kinetics, there were also phenotypic differences between the 
acute and chronically rejecting models. The antigen experienced CD4 T cells in recipients of a 
bm12.Kd.IE heart graft were predominantly CD44hiCCR7loCD62Llo effector memory, while those 
in BALB/c heart-grafted recipients were more skewed towards CD44hiCCR7hiCD62Lhi central 
memory, with functional evidence of altered memory development. 
MHC class II tetramers have been successfully used to examine CD4 T cell responses following 
infection, with much of this work performed by the group of Marc Jenkins412. Adoption of the 
enrichment technique they describe permitted successful evaluation of alloreactive CD4 T cells 
in this work407. It was disappointing that the donor MHC class II peptide-loaded tetramer was 
unable to bind to I-E allopeptide-specific CD4 T cells responding to a cardiac allograft, as this 
would have provided interesting insight into the dynamics of the CD4 T cell alloresponses 
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against MHC class II alloantigen. It is interesting to consider why there should be differential 
recognition of CD4 T cells with this tetramer following challenge with identical synthetic 
peptide and endogenous protein. There are however two possible explanations for this 
observation. Otvos et al. have demonstrated using rabies virus peptides that post-translational 
side-chain modifications can affect the MHC binding ability and conformation of the T cell 
epitopes424. It may be that post-translational modification of the I-E molecule leads to 
processed allopeptide adopting a slightly different confirmation within the tetramer that does 
not correspond to the epitope presented on APCs. Alternatively, Viner et al. have observed, 
using natural protein and synthetic peptides of hen egg lysozyme, that the interaction of 
synthetic free peptides with MHC class II molecules can generate complexes that are 
antigenically dissimilar to those resulting from endosomal processing of intact antigen425. Thus, 
the I-E peptide may be able to adopt different confirmations within the I-Ab peptide binding 
groove and use of synthetic peptide to generate the tetramer create an epitope not 
recognised by the endogenous alloreactive CD4 T cells. 
To overcome the limitation of not using the I-E-peptide loaded tetramer, the indirect-pathway 
responses following short-lived and ongoing alloantigen exposure were examined using acute 
and chronic rejection models, using the H-2Kd-loaded tetramer in both cases.  Most notably, 
the expansion of the H-2Kd specific CD4 T cell population was much more modest in acute, 
than in chronic, rejection. This may simply reflect that the multiple allogeneic epitopes against 
which the CD4 T cell population is responding in the acute BALB/c to C57BL/6 model results in 
the response against each epitope being proportionally smaller. Alternatively, it has been 
reported that polyclonal CD4 T cell populations expand in proportion to the frequency of their 
naïve progenitors412. Thus, this difference could be also explained by the presence of a higher 
precursor frequency specific for a different epitope presented by BALB/c allografts that 
proliferate preferentially, or other factors that have been proposed to affect the magnitude of 
CD4 T cell responses such as antigen abundance, efficiency of antigen processing by APCs, 
MHC binding affinity and stability of the peptide-MHC complexes412. 
Comparison of antigen-specific CD4 T cell responses using MHC class II tetramers has also been 
made in acute vs chronic infection models. Acute infections include lymphocytic 
choriomeningitis virus and Listeria monocytogenes426, 427. Following exposure to these 
infections there is a substantial expansion of the antigen-specific CD4 T cells with the 
population peaking at one week. Subsequently ~90% of effector cells die leaving a memory 
population which continues to decline in number after the infection has been cleared since 
their death rate is greater than their low rate of homeostatic proliferation427, 428. In 
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comparison, chronic infection has been studied using Salmonella species406. Following 
infection, the typical expansion phase was observed; however, less than 80% of the population 
was cleared and the population stabilised at an augmented level and was maintained long-
term. Furthermore, the authors observed increased proliferation of these cells, thought to 
account for the maintenance of an augmented population. The authors were able to confirm 
that ongoing antigen presentation was responsible for population maintenance since 
treatment of the mice with antibiotics to clear the infection resulted in a significant reduction 
in antigen-specific CD4 T cells. A similar finding was also observed in work using TCR transgenic 
CD4 T cells – Obst et al. reported a significantly reduced proliferation rate (and therefore 
contraction of population size) following early withdrawal of antigen, reaffirming that antigen 
persistence is required throughout the maintenance phase to ensure a stable population 
size429. 
These results, in models of infection, are consistent with the results presented in this chapter. 
The use of a single tetramer in both the acute and chronic rejection models in this work help to 
control for any differences that there may be between infection models, such as in tetramer-
TCR affinity and precursor CD4 T cell frequency, and allows for a more robust comparison to be 
made. 
The differences in population kinetics observed between acute and chronic rejection models in 
the maintenance phases is of interest when considering the development of CD4 T cell 
memory. Much work has been performed examining CD8 T cell memory, and it is well 
established that persistent stimulation by their peptide-MHC class I epitope results in 
functional exhaustion430-432. For CD8 T cells it is observed that a single encounter with their 
epitope is sufficient to initiate a program to drive cells through multiple rounds of division as 
well as acquiring effector and memory functions, without requiring further antigenic 
stimulation – described as being on ‘autopilot’433-435. This appears not to be the case for CD4 T 
cells. The data described above, and findings in this chapter seem to suggest that there is not a 
similar programme initiated within CD4 T cells, but rather CD4 T cell population dynamics are 
intimately related to availability of antigen – not only for their expansion, but also for the 
manifestation of their effector functions429. It has been highlighted that this perhaps makes 
sense considering the central helper role of CD4 T cells within the adaptive immune response. 
Their requirement for antigen exists as an additional control checkpoint on their activity429. 
Despite this apparent requirement for on-going antigen persistence to maintain an antigen-
specific CD4 T cell population, there is also some evidence that a lengthened period of 
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antigenic stimulation during the primary response may be deleterious to memory generation, 
similar to that observed in CD8 T cells417, 436. However, in that study description of memory 
generation was simply based upon number of surviving adoptively transferred CD4 T cells and 
no phenotypic examination was performed to confirm memory status. Nevertheless, it is 
conceivable that ineffective memory generation occurs whilst antigen expression persists. In 
support of this possibility, in the chronic rejection model described in this chapter, a 
significantly higher proportion of the H-2Kd-specific CD4 T cells stained positive for Ki-67, 
indicating recent proliferation, than in the acute rejection model. A recent study, similarly 
using MHC class II tetramers to examine memory CD4 T cell responses in infection, suggested 
that antigen-specific CD4 T cells divide at a rate of <1% per day415. The higher proliferation rate 
observed here may indicate that memory CD4 T cell development is dysfunctional in the 
setting of ongoing antigen presentation.  
The use of peptide-MHC class II tetramer to identify endogenous alloantigen-specific CD4 T 
cells has the advantage over other techniques of identifying these cells, as it provides 
opportunity to examine their phenotype. There are two functionally distinct subsets of CD4 T 
cell memory: CD44hiCCR7loCD62Llo effector memory (Tem) described to reside in the blood, 
spleen and non-lymphoid tissues that will rapidly respond to antigen by producing effector 
molecules and CD44hiCCR7hiCD62Lhi central memory (Tcm) found in lymph nodes, spleen and 
blood (but not in non-lymphoid tissues) that are slower in making cytokines or becoming 
effector cells420, 437. Examination of the H-2Kd-specific CD4 T cells revealed a phenotypic 
difference in the acute and chronic models. In the acute model, there was a predominance of 
Tcm, whilst in the chronic model there was a predominance of Tem. There is some evidence 
that CD8 T cells appear to follow a linear differentiation pathway from naïve → effector → Tem 
→ Tcm, with progressive acquisition of memory characteristics437. There is some data 
suggesting that this may also be true for CD4 T cells. The predominance of a Tem population in 
the presence of ongoing antigen presentation may then reflect incomplete memory 
development in this setting.  
Other data though suggests that Tem and Tcm develop in parallel – with Tem developing from 
Th1, Th2 and Th17 effectors, whilst Tcm develop independently of Tem from alternative 
precursors, possibly Tfh cells427, that become quiescent following termination of GC 
reactions438. If this model proves to be correct, then the lack of Tcm in the chronic model 
observed in this chapter, could be accounted for by the on-going nature of the adaptive 
alloimmune responses (as described in Chapter 3), retaining Tfh within the GCs. 
206 
 
The functional relevance of phenotypic differences between memory CD4 T cells in the acute 
and chronic model was highlighted by adoptive transfer of CD4 T cells, from recipients at 6 
weeks following transplantation, into T cell deficient recipients of H-2Kd expressing cardiac 
allografts (Figure 6.12). In the presence of anti-CD154 co-stimulation blockade (which would 
be expected to prevent naïve but not memory CD4 T cell alloresponses382), anti-H-2Kd 
alloantibody was only observed following transfer of CD4 T cells from recipients of acutely 
rejected BALB/c donors. That is despite the significantly smaller proportion of H-2Kd-specific 
CD4 T cells remaining in these recipients. These results suggest that persistence of antigen, 
although supporting augmented antigen-specific CD4 T cell populations, may lead to the 
development of altered, perhaps dysfunctional, memory responses. 
Work in this chapter demonstrates the potential of utilising peptide-MHC class II tetramers in 
examining the alloimmune response following transplantation. The supply of tetramer limited 
further examination, but future work with this tetramer could include characterising other 
aspects of the H-2Kd-specific CD4 T cell alloresponse such as comparing the Th1/Th2/Th17 
phenotype between the acute and chronic models and characterising the Tfh population. 
Additionally, having defined the normal alloimmune response tetramers, could be used as 
tools to more precisely examine the impact of immunosuppressive therapies on the CD4 T cell 
alloresponse in these models.  
Furthermore, although not considered in this work thus far, donor MHC class I tetramers can 
be used to examine B cell alloresponses, since they form the conformational epitope423, 439-441. 
H-2Kd tetramer could be utilised to quantify and compare the population kinetics and 
phenotypic characteristics of alloreactive B cells corresponding to the CD4 T cell alloresponses 
characterised with the H-2Kd peptide-loaded I-Ab tetramer providing further insight into the 
anti-H-2Kd alloimmune response generated within these recipients. 
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7 Knowledge of allorecognition 
pathways can inform development 
of effective immune regulatory 
cellular therapies 
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7.1 Introduction 
 
Developing regulatory cellular immunotherapy has become one of the main goals of current 
transplant immunological research. At the forefront of this are regulatory T cells (Treg) as the 
most widely characterised and studied regulatory cell. Work in animal models has 
demonstrated the efficacy of Treg therapy at preventing allograft rejection and clinical 
translation has already begun209, 250. There is evidence that antigen-specific Treg may be more 
effective than polyclonal Treg at preventing allograft rejection165, 224. It seems likely that 
understanding of allorecognition pathways will be important to understanding how best to 
utilise these regulatory cells therapeutically. 
 
7.1.1 Alloantigen specific regulatory T cells 
 
A variety of techniques have been adopted to induce and expand polyclonal and alloantigen-
specific Treg in vitro (Table 7.1). These techniques have permitted examination and 
comparison of the efficacy of polyclonal and alloantigen-specific Treg in murine models of 
transplantation, including humanised models (where severely immunocompromised murine 
strains are irradiated and reconstituted with human bone marrow cells and are then 
transplanted with human tissues225, 442). 
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Paper Treg type Culture conditions Origin 
Chen 2003
443
 Polyclonal nTreg isolated (CD4
+
 CD25
+
) and cultured with plate-
bound anti-CD3, IL-2, soluble anti-CD28, TGF-β +/- IL-
10 
Murine 
Nadig 2010
444
 Polyclonal nTreg isolated (CD4
+
 CD25
+
 CD127
-
) and cultured with 
anti-CD3/anti-CD28 coated beads and IL-2 
Human 
Scotta 2013
445
 Polyclonal nTreg isolated (CD4
+
 CD25
+
) and cultured with anti-
CD3/anti-CD28 coated beads, IL-2 +/-rapamycin +/- 
ATRA 
Human 
Takasato 
2014
446
 
Polyclonal Naïve CD4 T cells isolated and cultured with anti-CD3, 
anti-CD28, IL-2, TGF-β and ATRA 
Murine  
Huang 2013
447
 TCR transgenic 
antigen specific 
CD4 T cells isolated and cultured with IL-2, plate-
bound anti-CD3 and TGF-β 
Murine 
Jiang 2006
448
 Indirect-pathway 
antigen specific 
nTreg isolated (CD4
+
 CD25
+
) and cultured with self 
DCs from peripheral blood, pulsed with allopeptide 
and IL-2 
Human 
Tsang 2008
449
 Indirect-pathway 
antigen specific 
nTreg isolated (CD4
+
 CD25
+
) were transduced with 
transgenic TCRα and β genes specific for a self-MHC 
restricted allopeptide 
Murine 
Veerapathran 
2011
450
 
Indirect-pathway 
antigen specific 
nTreg isolated (CD4
+
 CD25
+
 CD127
-
) and cultured with 
irradiated donor cell lysate loaded self DCs and IL-2, 
1L-15 and rapamycin 
Human 
Takasato 
2014
446
 
Indirect-pathway 
antigen specific 
Naïve CD4 T cells isolated and cultured with syngeneic 
BMDC pulsed with allopeptide, anti-IFNγ, anti-IL-4, IL-
2, TGF-β and ATRA 
Murine 
Tsang 2008
449
 Direct-pathway 
antigen specific 
nTreg isolated (CD4
+
 CD25
+
) and cultured with 
immature allogeneic DCs, IL-2 
Murine 
Nouze 2011
451
 
 
Direct-pathway 
antigen specific 
nTreg isolated (CD4
+
 CD25
+
) and cultured with 
irradiated allogeneic splenocytes and IL-2 
Murine 
Sagoo 2011
224
 Direct-pathway 
antigen specific 
nTreg isolated (CD4
+
 CD25
+
 CD127
-
) and cultured with 
irradiated mature CD1c
+
 DCs from peripheral blood or 
skin with IL-2 
Human 
Veerapathran 
2011
450
 
Direct-pathway 
antigen specific 
nTreg isolated (CD4
+
 CD25
+
 CD127
-
) and cultured with 
irradiated allogeneic DCs or CD4 depleted splenocytes 
and IL-2, 1L-15 and rapamycin 
Human 
Putnam 
2013
452
 
Direct-pathway 
antigen specific 
nTreg isolated (CD4
+
 CD25
+
 CD127
-
) and cultured with 
allogeneic CD40L stimulated B cells 
Human 
Landwehr-
Kenzel 2014
453
 
Direct-pathway 
antigen specific 
nTreg isolated (CD4
+
 CD25
+
) and cultured with 
allogeneic B cells, IL-2 and rapamycin 
Human 
Takasato 
2014
446
 
Direct-pathway 
antigen specific 
Naïve CD4 T cells isolated and cultured with 
allogeneic BMDC, anti-IFNγ, anti-IL-4, IL-2, TGF-β and 
ATRA 
Murine 
 
Table 7-1 In vitro culture conditions for generating regulatory CD4 T cells 
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7.1.2 Direct vs Indirect-pathway alloantigen specific regulatory T cells 
 
Both direct and indirect-pathway CD4 T cell alloresponses are thought likely to play a role in 
allograft rejection and it could be predicted that to achieve tolerance would require Treg of 
both direct and indirect allospecificity. However, results from Chapter 4 highlight that direct-
pathway alloresponses are short-lived and may only play a role early after transplantation, 
raising the possibility that indirect-pathway specific Treg may be most effective. Several 
studies have utilised direct and/or indirect-pathway Treg and compared their efficacy in 
transplant models. 
A study by Sanchez-Fueyo et al. in 2007 demonstrated that although Treg activation in vivo can 
occur through both direct and indirect-pathways, their immunoregulatory function was 
significantly pronounced when allorecognition was restricted to the indirect-pathway454. They 
found that directly presented alloantigens elicited a significantly weaker Treg 
immunoregulatory response. This finding was in keeping with other early reports suggesting 
that Treg induced immune regulation was mediated primarily against indirect alloresponses455, 
456. This finding has also been demonstrated in human clinical transplantation. It has been 
shown that depleting Treg in stable renal transplant recipients reveals significant indirect-
pathway alloresponses, highlighting the importance of Treg in suppressing indirect-pathway 
allorecognition457. In contrast, depleting Treg did not lead to enhanced direct alloresponses, 
suggesting that Treg are not responsible for the observed direct-pathway hypo-responsiveness 
in these stable human kidney transplant recipients458. One possible explanation for this is the 
observation that the naturally occurring Treg TCR repertoire appears to be heavily biased 
towards high affinity recognition of self-MHC peptide complexes – perhaps relating to their 
role in suppressing autoreactivity454. Indeed it is observed that a smaller frequency of Treg 
cross-react with allogeneic MHC molecules in vitro, compared to effector T cells50. 
Further understanding of the relative importance of direct and indirect-pathway Treg was 
provided by Joffre et al. who generated Treg specific for directly, and Treg specific for directly 
and indirectly presented alloantigen222. They demonstrated that direct-pathway Treg alone 
could abrogate acute rejection of skin and cardiac allografts, but could not prevent the 
development of the vascular changes of chronic rejection. This required administration of 
direct and indirect-pathway Treg – emphasising the role of indirect-pathway Treg in preventing 
the development of AV. This was also the finding of Tsang et al., who used Treg with direct 
allospecificity, and Treg with dual direct and indirect allospecificity (the indirect allospecificity 
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being conferred by TCR gene transfer)449. They demonstrated that Treg with both direct and 
indirect specificity showed superior protection compared with Treg with direct specificity in a 
semi-mismatched heart transplant model. In a fully mismatched strain combination, Treg with 
direct specificity were also able to induce indefinite survival in some animals. However, 
histological analysis of the heart grafts from mice treated with Treg that only had direct-
pathway anti-donor allospecificity revealed clear signs of rejection which was completely 
absent in those treated with dual Tregs. However, in neither of these studies was there 
comparison of direct and indirect-pathway Treg used alone. This was the focus of a recent 
publication by Takasato et al. who generated indirect-pathway Treg using allopeptide pulsed 
recipient DCs446. They observed that indirect-pathway induced Treg (iTreg) were significantly 
more effective then direct-pathway Treg at prolonging graft survival and suppressing AV and 
chronic rejection. The efficacy of indirect-pathway Treg alone to confer long term graft survival 
has also been demonstrated by Tsang et al.in a different study across a complete mismatch 
combined with short-term immunosuppression223.  
It is apparent considering these findings that indirect-pathway Treg are likely to be a key 
component of successful Treg cellular therapy. However, the results presented in Chapter 5 
report that the indirect-pathway is a heterogeneous collection of responses against all 
mismatched alloantigens and that the responses have variable longevity. It is conceivable that 
this may have implications for effectiveness of indirect-pathway Treg of different antigen 
specificities, and this will be examined in this chapter. 
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7.2 Aims 
 
The purpose of the research described in this chapter is to extend the findings from earlier 
chapters and investigate the relevance of the finding that indirect-pathway responses against 
MHC class I are long-lived and against MHC class II are short-lived, to the development of 
regulatory T cell therapy in the bm12.Kd.IE to C57BL/6 model of transplantation. 
The aims are: 
1. To develop an in vitro culture protocol for the generation of induced polyclonal and 
indirect-pathway antigen specific regulatory CD4 T cells. 
 
2. Examine the relative effectiveness of polyclonal and MHC class I and MHC class II 
alloantigen-specific indirect-pathway regulatory CD4 T cells in the abrogation of 
chronic rejection in the bm12.Kd.IE to C57BL/6 model of chronic allograft rejection. 
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7.3 Results 
 
7.3.1 In vitro induction of regulatory T cells 
 
Evidence from murine models is mounting that antigen specific Treg may be more effective at 
abrogating allograft rejection than polyclonal non antigen-specific Treg. In the bm12.Kd.IE to 
C57BL/6 model results previously presented revealed that the indirect-pathway response 
against donor MHC class I is long-lived and therefore likely responsible for the development of 
chronic rejection, whilst the response against donor MHC class II, and similarly the direct-
pathway, is short-lived. This raises the possibility that Treg specific for different donor antigens 
may be variably effective due to the duration of the response against the particular antigen of 
interest. This knowledge will be useful in guiding ongoing development of Treg 
immunotherapy. 
To investigate this, Treg were induced in vitro (iTreg) using the protocol of Huang et al.447, 
whereby CD4 T cells are cultured in the presence of plate-bound anti-CD3, the interleukin Il-2 
and the inhibitory cytokine TGF-β. This protocol proved to be very effective at inducing Treg 
from naïve CD4 T cells (C57BL/6) with the vast majority of live CD4 T cells exhibiting the CD25+ 
FOXP3+ phenotype (Figure 7.1a). Despite the relatively straight forward nature of the induction 
protocol the iTreg proved effective at inhibiting polyclonal CD4 T cell proliferation (induced 
with anti-CD3/anti-CD28 DynabeadsTM in vitro as further evidence of their regulatory 
phenotype (Section 2.6.6; Figure 7.1b). 
One outstanding question in the literature relates to the stability of in vitro iTreg phenotype 
upon transfer in vivo with the concern that they may revert to an effector phenotype and 
exacerbate the alloimmune response. To explore this, fluorescently labelled polyclonal 
C57BL/6 iTreg (expressing the CD45.1 congenic marker) were adoptively transferred into 
C57BL/6 recipients of bm12.Kd.IE cardiac allografts on the day of transplantation and 
examined after seven days for evidence of proliferation and loss of regulatory phenotype. The 
iTreg had undergone only a small degree of proliferation and reassuringly retained their CD25+ 
FOXP3+ phenotype (Figure 7.1c). 
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Figure 7.1 Regulatory CD4 T cells can be induced in vitro and exhibit inhibitory properties 
C57BL/6 CD4 T cells were purified (MACS separated with anti-CD4 microbeads) and subjected to a 5 day 
period of in vitro culture in the presence of plate-bound anti-CD3, IL-2 and TGF-β
447
. (a) Analysis by flow 
cytometry, before and after culture, confirmed effective conversion to a CD25
+
 FOXP3
+
 Treg phenotype. 
(b) To further confirm a regulatory phenotype Treg were used in a suppression assay, whereby they 
were co-cultured with CFSE labelled naïve C57BL/6 CD4 T cells at different ratios, in the presence of anti-
CD3/CD28 Dynabeads™ to drive naïve CD4 T cell proliferation
276
. The extent of proliferation was 
quantified and displayed graphically, confirming the ability of Treg to suppress CD4 T cell proliferation. 
(Assay performed on 3 independent occasions) (c) To evaluate the behaviour of the Treg in vivo, CFSE 
labelled congenically marked Treg (from CD45.1-C57BL/6 mice) were adoptively transferred into 
C57BL/6 recipients of a bm12.Kd.IE cardiac allograft on the day of transplant. Six days later, recipient 
spleens were analysed by flow cytometry. The transferred Treg were readily identifiable with anti-
CD45.1 (left panel). Reassuringly the Treg retained their CD25
+ 
FOXP3
+
 phenotype (centre panel) and 
had not undergone significant proliferation (right panel). 
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7.3.2 Generation of antigen-specific indirect-pathway regulatory T cells 
 
An attempt was next made to obtain indirect-pathway antigen-specific iTreg using the TCR 
transgenic strains: TCR75 (H-2Kd allopeptide specific) and TEa (I-E allopeptide specific). Within 
the CD4 T cell population wildtype mice possess a small population (2-5%) of natural Treg 
(nTreg). However, it is recognised that TCR transgenic mice lack populations of nTreg 459-462, 
raising the possibility that Treg induction would not be so straightforward since in some 
protocols iTreg generation may not represent true induction of undifferentiated CD4 T cells to 
a Treg phenotype, but rather selective expansion of the nTreg population. 
TCR75 and TEa CD4 T cells were therefore subjected to the same in vitro culture conditions as 
above. There was effective induction of a CD25+ FOXP3+ Treg phenotype resulting in 
monoclonal populations of antigen-specific indirect-pathway CD4 iTreg being generated 
(Figure 7.2a). It is apparent from the profiles however, that there is some variation in Treg 
conversion between the two transgenic cells – for example an apparently higher proportion of 
CD25+ FOXP3- cells with TCR75. Why this should be is not clear but perhaps reflects an intrinsic 
difference between these two transgenic CD4 T cells and could be explored further. 
When CFSE labelled TEa CD4 Treg were transferred in vivo into a C57BL/6 recipient of a 
bm12.Kd.IE cardiac allograft, as with polyclonal iTreg, there was minimal proliferation of the 
TEa CD4 T cells one week later and the transferred CD4 T cells retained the CD25+ FOXP3+ 
phenotype (Figure 7.2b).  
However, in the case of TCR75 iTreg there was a significant degree of proliferation observed, 
with associated loss of FOXP3 expression, following transfer into recipients of bm12.Kd.IE 
cardiac allografts. This suggests that at least a proportion of the population reverted to a non-
regulatory phenotype (or that a residual population of transferred non-iTreg – perhaps the 
CD25+ FOXP3- cells alluded to above - were undergoing significant expansion) (Figure 7.2c). 
Further analysis revealed that the greater the number of divisions, the lower the level of 
FOXP3 expression (Figure 7.2d). To exclude that this proliferation was spontaneous and non-
antigen specific, CFSE labelled TCR75 iTreg were similarly transferred to naïve C57BL/6 mice. In 
this setting no proliferation was observed and iTreg phenotype was retained, suggesting that 
the findings in the transplanted recipients represent antigen-specific proliferation, of at least a 
proportion, of the transferred population (Figure 7.2e). It was unclear why this difference 
between TCR75 and TEa iTreg was observed since both naive TCR transgenic populations are 
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found to undergo proliferation when transferred early following transplantation (Chapter 5).  
Perhaps this relates to the slightly different CD25/FOXP3 profiles observed following culture. 
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Figure 7.2 T cell receptor transgenic induced regulatory T cells 
(a) TEa and TCR75 CD4 T cells were purified (MACS separated with anti-CD4 microbeads) and subjected 
to a 5 day period of in vitro culture in the presence of plate-bound anti-CD3, IL-2 and TGF-β
447
. Analysis 
by flow cytometry, before and after culture, confirmed effective conversion to a CD25
+
 FOXP3
+
 Treg 
phenotype for both TEa (top panels) and TCR75 (bottom panels). To examine their behaviour in vivo, 
1x10
6
 CFSE labelled TEa (b) and TCR75 (c) iTreg were adoptively transferred into C57BL/6 recipients of a 
bm12.Kd.IE cardiac allograft on the day of transplant. Six days later, recipient spleens were analysed by 
flow cytometry. TEa iTreg (b) retained their CD25
+ 
FOXP3
+
 phenotype (left panel) and had not undergone 
significant proliferation (right panel). In contrast, TCR75 iTreg (c) had undergone significant proliferation 
(right panel) and loss of their CD25
+ 
FOXP3
+
 phenotype was suggested (left panel). (d) To examine the 
TCR75 iTreg following transfer to transplant recipients in more detail, the identified iTreg were divided 
into three populations based upon CFSE dilution (right panel). Presenting CD25
 
vs
 
FOXP3 for these gated 
populations revealed that the cells which had not undergone any proliferation (top left panel) retained 
their CD25
+ 
FOXP3
+
 phenotype, whilst those undergoing the most proliferation (bottom left panel) had 
completely lost their CD25
+ 
FOXP3
+
 phenotype, suggesting that with proliferation there was a loss of 
iTreg phenotype. (e) 1x10
6
 CFSE labelled TCR75 iTreg were adoptively transferred into naïve C57BL/6 
recipients and examined six days later by flow cytometry. In naïve recipients the TCR75 iTreg did not 
undergo proliferation (right panel) and retained their CD25
+ 
FOXP3
+
 phenotype. 
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7.3.3 In vivo effectiveness of iTreg at abrogating chronic rejection 
 
The effectiveness of iTreg at abrogating chronic rejection in the bm12.Kd.IE to C57BL/6 model 
was next evaluated. Initially 1x106 iTreg were adoptively transferred to recipients on the day of 
transplantation, a similar number as has been reported previously in murine studies446, 447. The 
impact of C57BL/6 polyclonal and TCR75 and TEa monoclonal iTreg on the alloimmune 
response was evaluated by quantifying anti-class I and class II alloantibody and autoantibody, 
examining for germinal centre (GC) activity, and quantifying the degree of allograft 
vasculopathy (AV) at 50 days following transplantation. 
Polyclonal and TEa iTreg had a similar impact on antibody responses. There was minimal 
impact on generation of MHC class I alloantibody although TEa iTreg appeared effective at 
reducing class II alloantibody. However, a significant reduction in autoantibody generation was 
observed with both iTreg (Figure 7.3a-c). Neither iTreg population significantly reduced day 50 
GC activity, although TEa iTreg treated mice typically possessed phenotypically smaller GCs 
(Figure 7.3d,e). Although TCR75 iTreg administration similarly abrogated autoantibody and had 
little impact on MHC class II alloantibody, it markedly augmented the early MHC class I 
alloantibody response; perhaps a consequence of proliferation of the TCR75 iTreg population 
following intravenous administration, as described above (Figure 7.3a-c). Despite this, there 
was a significant reduction in day 50 GC activity (Figure 7.3d,e).  
Examining the cardiac allografts revealed that in keeping with recent reports, alloantigen 
specific iTreg were more effective at reducing the development of AV, with a significant 
reduction observed only for TEa and TCR75 iTreg (Figure 7.3f). In addition to the reduced AV, 
the parenchyma was notably more preserved with only minimal evidence of cardiomyocyte 
drop-out and fibrous replacement. This suggests that although a proportion of TCR75 iTreg 
revert to an effector phenotype, enough retain their Treg phenotype to prevent the 
development of GC responses which are responsible for the development of high affinity, 
class-switched allo- and autoantibody that appear dominant in driving the development of AV 
in this model. The augmented anti-H-2Kd alloantibody may then reflect extrafollicular antibody 
production. Allograft survival was not considered in these experiments since rejection is 
chronic in this model and typically occurs beyond 50 days. 
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Figure 7.3 In vivo effectiveness of iTreg when transferred early following transplantation 
Polyclonal C57BL/6 (n=6) and TCR transgenic TEa (n=5) and TCR75 (n=5) CD4 T cells were purified (MACS 
separated with anti-CD4 microbeads) and subjected to a 5 day period of in vitro culture in the presence 
of plate-bound anti-CD3, IL-2 and TGF-β
447
. Analysis by flow cytometry prior to use confirmed effective 
conversion to a CD25
+
 FOXP3
+
 Treg phenotype. 1x10
6
 iTreg were transferred to C57BL/6 recipients of 
bm12.Kd.IE cardiac allografts on the day of transplantation. Weekly blood samples were taken and 
tissue samples were harvested at 50 days following transplantation. From weekly serum samples, anti-
H-2K
d
 alloantibody [(a), ELISA], anti-I-E alloantibody [(b), flow cytometric labelling of I-E expressing 
BMDCs] and antinuclear autoantibody [(c), HEp-2 indirect immunofluorescence] was quantified. (d) The 
proportion of splenic follicles demonstrating germinal centre (GC) activity was quantified on 
immunofluorescence stained cryostat sections of recipient spleen, 50 days following transplantation 
(B220 and GL-7). (e) Representative immunofluorescence images of splenic follicle (B220 stain, left 
panels) and GC B cells (GL-7 stain, right panels), demonstrating the smaller nature of GCs observed in 
TCR75 and TEa iTreg treated recipients (bottom panels) compared with untreated recipients (upper 
panels). (f) The extent of allograft vasculopathy (AV) was quantified on elastin van Gieson stained 
paraffin sections of donor heart allografts 50 days following transplantation. Representative images are 
presented highlighting the AV and fibrous change typical in untreated recipient allografts (left panel). In 
recipients treated with TEa (middle panel) and TCR75 (right panel) iTreg, negligible AV is observed in the 
majority of vessels and parenchyma is well preserved. P values using two-way ANOVA (a,b,c) and Mann 
Whitney test (d,f) * = p<0.01. 
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7.3.4 Effectiveness of antigen-specific regulatory T cells administered late after 
transplantation requires insight into duration of alloresponses 
 
One of the challenges facing adoption of cellular immunotherapies in transplantation is the 
ability to generate antigen-specific Treg for administration at the time of transplant where, 
other than in the case of living donor transplants, the donor is unknown until shortly prior to 
transplantation. An alternative option would be to administer Treg at some point after 
transplantation – perhaps even to treat episodes of rejection. However, identification that the 
longevity of direct and indirect-pathway alloresponses varies according to target alloantigen 
raises the possibility that antigen-specific Treg will not be equally effective when administered 
late after transplantation. 
Given that donor MHC class II indirect alloresponses are short-lived and MHC class I long-lived 
in this model, I hypothesised that TCR75 iTreg may be more effective at abrogating chronic 
rejection than TEa iTreg when administered beyond the first week following transplantation. 
Therefore, TCR75 or TEa iTreg were adoptively transferred 3 weeks following transplantation 
and responses examined. 
Late administration of either iTreg had no impact on MHC class I alloantibody (Figure 7.4a). 
There was no augmentation of the response following administration of TCR75 iTreg as was 
observed when they were administered early. TCR75 iTreg were more effective at attenuating 
autoantibody responses than TEa iTreg (Figure 7.4b). This was also the case when examining 
GC responses and AV, where TEa iTreg were inferior to TCR75 iTreg (Figure 7.4c). With late 
administration of TCR75 iTreg, the majority of parenchymal vessels displayed no evidence of 
AV and the parenchyma was markedly better preserved than seen with TEa iTreg (Figure 7.4d-
f). In both cases, as expected, early administration of iTreg proved more efficacious at 
attenuating AV progression than late administration. 
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Figure 7.4 Effectiveness of TCR75 and TEa iTreg administered three weeks following transplantation 
TCR transgenic TEa (n=5) and TCR75 (n=5) CD4 T cells were purified (MACS separated with anti-CD4 
microbeads) and subjected to a 5 day period of in vitro culture in the presence of plate-bound anti-CD3, 
IL-2 and TGF-β
447
. Analysis by flow cytometry prior to use confirmed effective conversion to a CD25
+
 
FOXP3
+
 Treg phenotype. 1x10
6
 iTreg were transferred to C57BL/6 recipients of bm12.Kd.IE cardiac 
allografts 3 weeks following transplantation. Weekly blood samples were taken and tissue samples were 
harvested at 50 days following transplantation. From weekly serum samples, anti-H-2K
d
 alloantibody 
[(a), ELISA] and antinuclear autoantibody [(b), HEp-2 indirect immunofluorescence] was quantified. (c) 
The proportion of splenic follicles demonstrating germinal centre (GC) activity was quantified on 
immunofluorescence stained cryostat sections of recipient spleen, 50 days following transplantation 
(B220 and GL-7). (d) The extent of allograft vasculopathy (AV) was quantified on elastin van Gieson 
stained paraffin sections of donor heart allografts 50 days following transplantation. Representative 
images are presented highlighting the preserved parenchyma and absence of AV typical in TCR75 iTreg 
treated recipients (e) and the presence of myocyte dropout and fibrous regeneration observed in TEa 
iTreg treated recipients (f). P values using two-way ANOVA (a,b) and Mann Whitney test (c,d) in 
comparison to ‘no-Treg’ group * = p<0.01. Data in absence of Treg and with TCR75 and TEa iTreg 
administered on the day of transplantation are included to permit comparison. 
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To extend these observations, and exclude any functional difference between TCR75 and TEa 
iTreg accounting for the differences observed, the bm12.IE x bm12.Kd.IE bone marrow 
chimeric mice were once again employed (Section 2.8.1.2). In these mice expression of MHC 
class I H-2Kd is restricted to the haematopoietic lineage. Previously it was observed that whilst 
TCR75 CD4 T cells proliferated in recipients early, they did not proliferate upon late transfer 
(Section 5.3.3.2). Thus, following the previous finding, it was hypothesised that TCR75 iTreg 
would only be effective at attenuating progression of chronic rejection when transferred early 
after transplantation of these chimeric donors. 
Bm12.IE x bm12.Kd.IE chimeric donor cardiac allografts were therefore transplanted into 
C57BL/6 recipients and TCR75 iTreg transferred on the day of transplantation or after three 
weeks. TCR75 iTreg were equally effective at abrogating autoantibody responses, GC activity 
and AV when transferred on the day of transplantation, as previously observed in recipients of 
wildtype donors. Again, an augmentation of the early H-2Kd alloantibody response was 
observed. However, when TCR75 iTreg were administered three weeks following 
transplantation allo- and autoantibody responses and GC activity were unaffected. In keeping 
with these observations, there was no amelioration of AV (Figure 7.5). 
Together, these results suggest that identifying the alloimmune pathways active in a transplant 
recipient is essential for the rational development of effective antigen-specific Treg therapy 
following transplantation. 
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Figure 7.5 Effectiveness of TCR75 iTreg in recipients of bone-marrow chimeric donor allografts 
TCR transgenic TCR75 CD4 T cells were purified (MACS separated with anti-CD4 microbeads) and 
subjected to a 5 day period of in vitro culture in the presence of plate-bound anti-CD3, IL-2 and TGF-β
447
. 
Analysis by flow cytometry prior to use confirmed effective conversion to a CD25
+
 FOXP3
+
 Treg 
phenotype. 1x10
6
 iTreg were transferred to C57BL/6 recipients of bm12.IE x bm12.Kd.IE bone-marrow 
chimeric cardiac allografts on the day of transplantation or 3 weeks later (n=4). Weekly blood samples 
were taken and tissue samples were harvested at 50 days following transplantation. From weekly serum 
samples, anti-H-2K
d
 alloantibody [(a), ELISA] and antinuclear autoantibody [(b), HEp-2 indirect 
immunofluorescence] was quantified. (c) The proportion of splenic follicles demonstrating germinal 
centre (GC) activity was quantified on immunofluorescence stained cryostat sections of recipient spleen, 
50 days following transplantation (B220 and GL-7). (d) The extent of allograft vasculopathy (AV) was 
quantified on elastin van Gieson stained paraffin sections of donor heart allografts 50 days following 
transplantation. P values using two-way ANOVA (a,b) and Mann Whitney test (c,d) in comparison to ‘no 
Treg’ group * = p<0.01. Data in absence of Treg and with TCR75 iTreg administered on the day of 
transplantation or 3 weeks later into recipients of bm12.Kd.IE allografts are included to permit 
comparison. 
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7.4 Discussion 
 
This chapter has examined the effectiveness of Treg in abrogating chronic rejection in C57BL/6 
recipients of bm12.Kd.IE cardiac allografts. Polyclonal Treg were least effective at abrogating 
chronic rejection as has previously been reported250. When administered on the day of 
transplantation, both MHC class I and MHC class II indirect-pathway allospecific Treg were 
effective at delaying the progression of chronic rejection, confirming that indirect-pathway 
specific Treg are able to ameliorate the development of chronic rejection alone, without 
direct-pathway Treg. However, when administered after 3 weeks following transplantation, 
only MHC class I antigen specific Treg were effective at abrogating chronic rejection. These 
results suggest that antigen-specific Treg therapy may only be effective when their allospecific 
responses are active in a recipient and perhaps explain the observation that in general, most 
studies have recognised indirect-pathway antigen-specific Treg to be more effective than 
direct-pathway antigen-specific Treg. 
Many of the protocols to obtain alloantigen specific Treg begin with obtaining enriched 
populations of nTreg (Table 7.1). There is some evidence to suggest that nTreg are more stable 
than iTreg which is the basis of this preference. In one study, Koenecke et al. demonstrated 
that whilst nTreg were effective at abrogating development of GVHD in their model, iTreg 
were not, and underwent significantly greater proliferation which was associated with loss of 
FOXP3 expression463. However, in another study in which nTreg and iTreg of the same 
specificity were generated, iTreg performed equivalently, if not slightly better than nTreg, and 
no concern over iTreg reversion was raised447. 
This is relevant because it is recognised that TCR transgenic strains on a RAGKO background 
typically lack nTreg459-462. There are several factors which are proposed to account for this. 
nTreg are generated in the thymus after high affinity interaction with peptide-MHC, of 
affinity/avidity on the brink of resulting in clonal deletion464. In the case of TCR transgenic 
strains, no ‘agonist’ epitope is available for the TCR in the thymus for such selection to take 
place465. The absence of endogenous TCR chain rearrangement on the RAGKO background 
therefore prevents potential nTreg clones from developing465.  
For this work it was therefore necessary to generate iTreg from the TCR75 and TEa strains 
rather than being able to isolate nTreg. This was achieved using the method of Huang et al. 
who similarly developed iTreg from TCR transgenic strains447. As with many protocols, this 
involves incubating CD4 T cells with inhibitory cytokine TGF-β which is thought to induce Treg 
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through the induction of FOXP3 and down-regulation of Smad7 signalling466. As alluded to 
above, stability of Treg in vivo is clearly an important issue that needs to be addressed prior to 
their usage in human clinical transplantation215, 467. As has been recognised previously, iTreg 
induced with TGF-β have the potential to lose FOXP3 expression and regulatory phenotype463, 
468, 469. In my work, TCR75 iTreg underwent significant proliferation when transferred to 
transplant recipients and this was associated with loss of FOXP3 expression. Furthermore, 
there was augmentation of the anti-H-2Kd alloantibody response acting as further evidence 
that some of these cells convert to an effector phenotype.  It should be stressed that this 
augmentation in alloantibody was not sustained and the kinetics of the alloantibody response 
are in keeping with an initially rapid burst of alloantibody production that is switched off 
almost immediately, with the decay phase simply reflecting the half-life of antibody. Certainly, 
subsequent GC activity was barely above naïve background, inferring that the escaped helper 
CD4 T cells are either incapable of full differentiation to follicular helper cells, or are prevented 
from doing so by the residual FOXP3-expressing Tregs. Hence the net effect was still profound 
inhibition of host alloimmunity and prolonged allograft survival. Nevertheless, this is clearly a 
concern when considering transferring antigen-specific Treg to a human transplant recipient 
due to the potential for accelerating rejection. 
It is worth considering that rather than an issue of stability, this reflects transfer of non-Treg 
(CD25+ FOXP3- cells). To avoid transfer of non-Treg following in vitro culture would require an 
ability to sort cells. Unfortunately, as an intracellular marker, FOXP3 expression cannot be used 
as a basis of sorting. Human Treg are sorted on the basis of CD25 and CD127 expression442 and 
similar reliable cell surface markers may be discovered for murine Treg making this possible in 
murine experimental work. 
One strategy that has reported to improve the stability of iTreg is addition of rapamycin and/or 
all-trans retinoic acid (ATRA) to the culture medium445. Rapamycin, an mTOR kinase inhibitor, 
is an immunosuppressive drug that inhibits effector T cell proliferation and activation and 
appears to selectively promote Treg expansion470. ATRA is a vitamin A metabolite that is 
thought to stabilise FOXP3 expression471. Treg induced in the presence of rapamycin and ATRA 
were found to be functionally stable in vivo even in the presence of a severe systemic 
inflammatory response suggesting that this approach should be considered in future 
development of iTreg445. 
More recently it has been recognised that the FOXP3 locus is subject to epigenetic control. 
Specifically, an element termed ‘Treg-specific demethylated region’ (TSDR) has been identified 
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in the 5’ untranslated region of the FOXP3 locus472. Demethylation of CpG motifs within the 
TSDR element is observed only in stable Treg populations. TGF-β-induced Treg have been 
reported to display only weakly demethylated CpG motifs and that this is not heritable, likely 
accounting for loss of FOXP3 expression upon proliferation466, 473. This is informative since 
determination of TSDR methylation status may prove to be an effective quality control check 
for iTreg prior to their clinical use. 
Despite the apparent conversion of a proportion of the TCR75 iTreg when administered early, 
in the context of the acute inflammatory milieu post-transplantation, they proved effective at 
abrogating the development of GC antibody responses and progression of chronic rejection. 
Indeed, the augmented anti-H-2Kd alloantibody was short-lived, suggesting that the early 
response was not sustained. This likely indicates that sufficient cells retain a regulatory 
phenotype to tip the balance towards regulation. Treg are believed to regulate by acting both 
in recipient secondary lymphoid tissue and directly in the allograft219. A study by Takasato et al 
investigated the impact of their indirect-pathway antigen-specific iTreg following 
transplantation446. They observed that presence of iTreg resulted in DCs exhibiting an 
immature phenotype, as demonstrated by down-regulated co-stimulation. They also 
demonstrated significantly greater numbers of recipient Treg within the cardiac allografts, 
suggestive of ‘infectious tolerance’. Furthermore, their transferred iTreg did not survive long-
term, suggesting that ongoing regulation was dependent upon the generation of recipient 
Tregs.  
The idea of ‘infectious tolerance’ was elegantly demonstrated in a study by Pasquet et al. who 
developed mice which express the diphtheria toxin receptor (DTR) gene under the FOXP3 
promoter474. This renders Treg susceptible to deletion by diphtheria toxin. In this study the 
authors were able to demonstrate that after 2 weeks following transfer, the iTreg were no 
longer required for maintenance of tolerance, and that their tolerogenic role had been 
transferred to recipient Treg. They postulated that this was due to the transferred iTreg 
inducing tolerogenic APCs that would subsequently favour conventional recipient T cell 
differentiation into Treg . 
This may therefore, explain why TCR75 iTreg were effective in regulating allograft survival, 
despite a significant proportion reverting to non-regulatory phenotypes. As long as sufficient 
iTreg are present to induce ‘infectious tolerance’, the recipient Treg will then ensure ongoing 
regulation, and not require long-term survival of the administered iTreg population. 
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One of the key observations from this chapter is that iTreg transfer could be effective at 
abrogating progression of allograft rejection, even when transferred late following 
transplantation. These are clearly preliminary studies, and effectiveness at the late time point 
was not uniform, however these experiments are at least proof of principal that iTreg therapy 
administration may be considered beyond the early phase following transplantation. Current 
efforts to develop Treg therapy are focusing on living-donor transplantation where the surgery 
is performed on an elective basis and the donor is known in advance of the transplant228. The 
majority of transplants though, are performed using cadaveric donors and the donor HLA type 
will be known only a few hours prior to transplantation providing insufficient time to prepare 
an antigen-specific cellular therapy. The results in this chapter demonstrate that cellular 
immunotherapy may be effective even when administered after transplantation. It could even 
be used as a treatment for episodes of acute rejection for example. 
The results also highlight that efficacy of Treg is dependent upon ongoing alloresponses 
against the antigen to which the Treg are directed. This suggests that TCR signalling is 
important for the function of these iTreg. This is in agreement with a recent publication by 
Levine et al. who developed a system in which they could induce ablation of the TCR475. They 
demonstrated that continuous engagement of the TCR on Treg is essential for driving the 
transcriptional programme that maintains the immunosuppressive function of Treg. This helps 
to explain why iTreg were effective at impacting upon allograft rejection only when their TCR 
epitope continued to be present, in this chapter. This likely also accounts for why indirect-
pathway Treg appear more efficacious than direct-pathway Treg at abrogating chronic 
rejection in transplant models. The short-lived nature of intact donor MHC class II likely limits 
the opportunity for TCR ligation to the period immediately following transplantation48. If they 
have been unable to induce effective infectious tolerance by the time the antigen is cleared, 
then the regulation may be less effective. In this regard it is also worth highlighting that 
previous success with monoclonal indirect-pathway iTreg have both been targeted against 
donor MHC class I allopeptide446, 448. Had the authors of these studies generated indirect-
pathway Treg directed against donor MHC class II allopeptide, the results may have been 
different. 
One of the notable impacts of Treg in this chapter was abrogation of GC responses. GCs are 
specialised microenvironments that form in B-cell follicles within secondary lymphoid organs 
upon immunisation with T-dependent antigens. The outputs of GCs are long-lived, high-affinity 
antibody secreting cells and memory B cells316. When Treg are transferred at the time of 
transplantation, it is likely that they act principally by inhibiting initiation of the GC response.  
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When Treg are transferred after transplantation, it is likely that the GC responses will have 
already developed316. However, the TCR75 iTreg were effective at limiting the GC responses 
even when transferred three weeks following transplantation, suggesting that regulation of 
GCs by Treg can occur after they have developed. 
FOXP3+ T cells were first identified within GCs a decade ago, and are now referred to as 
follicular regulatory T cells (Tfr), a subset of Treg476. To date Tfr’s are not well characterised, 
however they are thought to express the transcription factor bcl-6, and cell surface molecules 
ICOS and SAP which facilitate T-B cell interactions, adopting features similar to follicular helper 
T cells which are responsible for driving GC responses, enabling them to migrate into GCs and 
exert their regulatory effect477. There is evidence that Tfr’s are able to limit the size of GC 
responses and may control production of antigen-specific antibody, however the mechanism 
and targets of their suppression remain controversial477, 478. It could be postulated therefore, 
that a proportion of the iTreg generated in this chapter differentiate into a Tfr phenotype 
permitting them access to GCs and effectively limiting the response. It could alternatively be 
that Tfr are of recipient origin and develop through infectious tolerance. This could be 
examined by incorporating SAP knock-out mice317. SAP (signaling lymphocyte activation 
molecule-associated protein) expression on T cells is found to be essential for stable T-B cell 
interactions in GCs and thought to be important for Tfr differentiation. It would be anticipated 
that SAP deficient iTreg would be unable to differentiate into Tfr’s and the impact of this on GC 
responses and allograft rejection could be examined. This would provide evidence for a role 
for Tfr’s in transplantation tolerance that has not been examined to date. 
Clinical translation of Treg immunotherapy has already begun with some phase-1 trials 
demonstrating safety and some efficacy226-228, 479. Over the last few years several studies have 
been published describing use of human Treg therapy in humanised mouse models of human 
skin224, 225, islet442 and arterial444 transplantation. Although many hurdles to translation have 
been overcome through these studies, such as optimising culture conditions for expanding 
human Tregs, there are still several questions outstanding209, 215. Perhaps most pertinent is the 
concern about Treg stability described above. Another outstanding issue is the effect of 
immunosuppression on Tregs. Certainly initially, cellular immunotherapy will be administered 
with conventional immunosuppression whilst the efficacy of Treg therapy is evaluated. 
Calcineurin inhibitors such as tacrolimus are the mainstay of current immunosuppression but 
there is some evidence that they may adversely affect Treg suppressor activity480, 481, although 
there are some conflicting results482. Rapamycin on the other hand has been observed to have 
beneficial effects on Treg function, and is thought to be the least deleterious 
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immunosuppressive drug for Tregs483. Similarly, the exact Treg product that will be most 
effective has yet to be identified. The multicentre, international ONE study aims to test the 
safety of several regulatory cellular therapies including polyclonal Treg and alloantigen-driven 
Treg228. However, current efforts in developing alloantigen-specific Treg are focusing on direct-
pathway antigen specificity using allogenic B cells as target alloantigen452, 453. The results in this 
chapter have some significance for clinical translation of Treg immunotherapy and would 
suggest that more effective immune regulation may be achieved with indirect-pathway 
alloantigen-specific Treg and that direct-pathway alloantigen-specific Treg will be effective 
only if transferred immediately following transplantation. Certainly if Treg therapy is to be 
administered after the immediate post-operative period it seems likely that indirect-pathway 
Treg will be most effective and these results would suggest that efforts should also be focused 
on developing techniques to induce and expand human indirect-pathway antigen-specific Treg. 
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8 Final Discussion 
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Solid organ transplantation is now an established and effective treatment option for end-stage 
organ failure. Whilst early outcomes have improved significantly over recent decades, longer-
term outcomes have changed little. Despite advances in immunosuppression, most 
transplanted organs suffer an inevitable decline in function. The decline in function is likely 
multifactorial with ‘alloimmune’ chronic rejection at least partly responsible. The alloimmune 
response remains incompletely characterised. Crucially, despite its description several decades 
ago, the precise contributions that the direct (recognition of intact allogeneic MHC) and 
indirect (recognition of self-MHC restricted allopeptide) pathways make to allograft rejection 
remain incompletely understood48. In this thesis, murine models of heterotopic cardiac 
transplantation have been utilised to analyse these pathways. The key findings are discussed 
below: 
 
 
1) Direct-pathway CD4 T cell allorecognition is restricted to the immediate post 
transplantation period. Donor APCs are the major source of MHC class II for direct-
pathway priming and are cleared rapidly by both innate and adaptive responses of the 
recipient, effectively limiting the duration of direct-pathway allorecognition. 
 
Although it is commonly held that direct-pathway allorecognition is most important early 
following transplantation48, the duration of direct-pathway CD4 T cell allorecognition has not 
been definitively demonstrated. In Chapter 4 the results confirm that direct-pathway CD4 T 
cell allorecognition is indeed short-lived and limited by both innate and adaptive alloimmune-
mediated elimination of donor APCs. The use of TCR transgenic CD4 T cell transfer does not 
rule out the possibility that CD4 T cells activated early following transplantation go on to play 
an important role late after transplantation as memory cells. Against this, however, human 
clinical studies have reported general direct-pathway hypo-responsiveness in recipients late 
after transplantation77, 339. Moreover, the work with tetramer staining presented in Chapter 6 
suggests that, at least for indirect-pathway CD4 T cells, a rapid contraction of the antigen-
specific T cell population occurs following loss of target antigen. 
Whilst these findings question the exact role of recipient CD4 T cell direct-pathway responses 
in allograft rejection, due to its surprisingly short duration, findings from Chapter 3 have 
revealed a potentially more important, previously unrecognised, role for direct-pathway 
allorecognition in the alloresponse – but for donor CD4 T cells. 
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2) If able to evade NK cell killing, passenger donor CD4 T cells can make cognate, direct-
pathway, interactions with recipient B cells. This interaction results in augmentation of 
all arms of the alloimmune response and acceleration of allograft rejection. 
 
The role of passenger leukocytes in solid organ transplantation is unclear. Previous work from 
our laboratory revealed a role for donor CD4 T cells in driving the development of 
autoantibody in the limited-mismatch bm12 to C57BL/6 model through interaction via the 
direct-pathway with intact allogeneic MHC class II on recipient B cells274. Work in this thesis 
has extended this observation to reveal that passenger CD4 T cells can additionally, if able to 
survive long enough, significantly augment alloimmune responses, accelerating allograft 
rejection. It was identified that ability to evade NK cell killing was critical to their ability to 
mediate this augmentation, supporting a previously undescribed mechanism by which NK cells 
could play a role in dampening the alloimmune response following transplantation. The 
precise role played by NK cells in the alloimmune response remains incompletely 
understood197. Nonetheless, this work strongly suggest that they play an important immune 
regulatory function. 
Although the findings have been confirmed in two independent models there are potential 
criticisms of both. In the bm12.Kd.IE to C57BL/6 model, allografts are rejected very slowly 
without any immunosuppression which is very different to that observed in clinical 
transplantation. The BALB/c to TCRKO (reconstituted with TCR75 CD4 T cell) model is also 
unlike the clinical situation in that there is a monoclonal population of recipient CD4 T cells. As 
such, wider acceptance of this novel finding may be achieved with further work seeking to 
verify the role of passenger donor CD4 T cells in a model more aligned to the clinic.  
In clinical transplantation, recipients typically receive induction therapies at the time of 
transplantation with the intention of rendering them immunosuppressed. It is plausible that 
these treatments will also affect passenger donor CD4 T cells, especially since therapies, such 
as anti-thymocyte globulin, are T cell ablative. Anecdotally, a colleague who has been studying 
donor CD4 T cell chimerism in human cardiothoracic transplantation has observed frequent 
chimerism in lung transplant recipients, but none in cardiac transplant recipients (O. 
Gjorgjimajkoska, manuscript in preparation). Although this may relate to differences such as 
the presence of greater lymphoid tissue in lung allografts, it is notable that cardiac transplant 
recipients receive anti-thymocyte globulin as part of their induction immunosuppression at the 
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studied centre. Therefore, it would be important to examine the impact of donor CD4 T cells in 
the setting of immunosuppression.  One proposed experiment to investigate this is to 
administer anti-CD154 costimulation blockade to C57BL/6 recipients of BALB/c cardiac 
allografts, which is known to attenuate acute rejection in this model375. Were recipient NK 
depletion to result in accelerated rejection in this experiment, it would add weight to the 
clinical relevance of the findings in this thesis. 
As discussed in Chapter 3, the relevance of these findings to solid organ transplantation could 
also be verified by clinical studies. Specifically, inferior outcomes would be predicted in donor-
recipient pairs in which there are HLA mismatches, but NK cell receptors are matched such 
that donor cells evade NK cell killing. The immediate challenge with this approach, however, is 
the lack of a complete understanding of NK cell receptors179. Yet, if proven to be the case, this 
novel role for NK cells in the alloimmune response may have implications for matching of 
donors and recipients in clinical transplantation. 
Donor T cell direct-pathway interaction with recipient APCs is not restricted to solid organ 
transplantation. It is also of significant importance in bone-marrow transplantation where 
donor CD4 T cells are responsible for the development of graft-versus-host disease (GVHD). In 
a similar manner to that proposed in this thesis, in GVHD mature donor CD4 and CD8 T cells 
within the graft can be activated by recognising alloantigen on recipient APCs that have 
themselves been activated to upregulate antigen presentation by the bone-marrow transplant 
conditioning regimen. When interacting with mismatched MHC molecules, the recognition is 
by the direct-pathway, explaining the magnitude of the response observed. Following 
activation, a cascade of cellular mediators including CD8 T cells and NK cells, in combination 
with soluble inflammatory mediators results in inflammation and target tissue destruction484. 
The difference in bone-marrow transplantation is the absence of recipient lymphocytes and 
adaptive immunity to limit the longevity of donor T cell survival, resulting in the significant 
morbidity and mortality associated with GVHD in this setting309, 484.  
Results in this thesis (Chapter 3) highlight the important role for recipient NK cells in clearing 
donor CD4 T cells, limiting their impact on the alloimmune response following solid organ 
transplantation. In bone-marrow transplantation the situation is more complex since the NK 
cells will also be of donor origin since recipients are typically subject to a myeloablative 
conditioning regimen (total body irradiation with additional administration of a 
chemotherapeutic agent) which acts to both clear disease and suppress immune reactions to 
the transplant. Additionally, bone-marrow transplant recipients and donors are usually very 
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well matched since the severity and frequency of GVHD is directly related to the degree of HLA 
mismatch484, 485. Despite HLA matching, other factors contribute to the development of GVHD 
such as the presence of minor histocompatibility mismatches. Despite well matched donors 
and recipients, NK cells seem to have a similarly important impact on outcomes in bone-
marrow transplantation, perhaps due to the fact that donor NK cell recognition of recipient 
also depends on the presence of matched NK receptors, which can be independent of HLA 
matching189. There is evidence that donor NK cells have a role in limiting GVHD203. To achieve 
this, NK cells are thought to act both by lysing chronically activated self-T cells and by deleting 
residual recipient DCs that are thought to be central to driving GVHD486, 487. 
In order to prevent GVHD, strategies to deplete mature T cells from bone-marrow transplants 
have been utilised. Substantial reductions in GVHD have been observed with this approach, 
supporting the central role of donor CD4 T cells488-490. However, the benefit of reduced GVHD 
was offset by high rates of graft failure, infections and loss of ‘graft-versus-leukaemia’ effect 
with high rates of malignant disease relapse highlighting that donor CD4 T cells do not simply 
have deleterious effects and that their role in bone-marrow transplantation is much more 
complex484. Currently, pharmacological manipulation of CD4 T cells in the recipient with 
calcineurin inhibitors such as cyclosporine is the mainstay of GVHD prophylaxis, although 
newer therapies such as Treg immunotherapy are undergoing investigation and clinical 
assessment485. In one study, for example, expanded populations of nTreg were used to treat 
two patients who developed GVHD following bone-marrow transplantation, and clinical 
improvement was seen in both patients479. Together, these findings have revealed the role 
played by donor CD4 T cells following bone-marrow transplantation to be particularly complex, 
which is unlikely to be the case in solid organ transplantation in which although impaired, the 
recipient’s immune response remains intact. If the findings in this thesis relating to donor CD4 
T cell augmentation of alloimmunity prove to be clinically significant, then the greater 
understanding of GVHD in bone-marrow transplantation will be useful in guiding management 
of transplant recipients in whom it is predicted donor CD4 T cells may have a deleterious 
impact on outcome. 
 
3) The duration of indirect-pathway responses against different alloantigens is variable, 
limited by availability of donor antigen. Expression of donor MHC class II is restricted 
to APCs and possibly endothelium (where expression is transient) limiting the duration 
of indirect-pathway allorecognition against MHC class II alloantigen. In response to 
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continual presentation of target epitope, indirect-pathway CD4 T cell responses 
against parenchymal expressed alloantigen are long-lived, and can provide help for 
generating alloantibody against different MHC alloantigens. The continual division of 
these cells results in greatly increased numbers of alloantigen-specific CD4 T cells in 
the chronic phase of the response, but despite this, memory responses are impaired. 
 
The role of indirect-pathway allorecognition in allograft rejection has been increasingly 
appreciated48. Despite this, the intricacies of the pathway remain incompletely understood, 
and the heterogeneity in duration of responses against different alloantigens reported in this 
thesis – although perhaps intuitive – has not been previously demonstrated. The findings in 
Chapters 4-7 suggest that the driving force for development of progressive AV is continued 
presentation of immunogenic MHC class I allopeptide by the indirect-pathway, although this 
concept has not been addressed formally. By extension, this suggests that MHC class II 
indirect-pathway responses are stimulated early, provoke a memory response, but do not 
influence chronic rejection. There is indirect evidence supporting this: i) in the BALB/c to 
C57BL/6 acute rejection model the tetramer staining CD4 T cell population rapidly contracts 
following clearance of alloantigen and exhibit a quiescent memory phenotype; and ii) a lack of 
impact of MHC class II indirect-pathway Treg when administered late following 
transplantation. Nevertheless, it would be important to demonstrate this formally, for example 
by utilising tetramers to deplete MHC class I indirect-pathway CD4 T cells and observing the 
impact on progression of AV to confirm their dominant role in the pathophysiology of chronic 
rejection. As alluded to throughout, caution must be exercised when considering the 
extrapolation of these findings to human transplantation. There is an important difference in 
MHC class II expression between humans and mice which may lead to observations in this 
work not being relevant in human transplantation254. It is conceivable that constitutive MHC 
class II expression in humans will provide a source of MHC class II long-term and therefore 
indirect-pathway responses will continue. It would be interesting to examine this in human 
transplant recipients. To date studies examining alloresponses have looked at global ‘direct’ 
and ‘indirect’ alloreactivity, perhaps this could be refined to examine responses against 
individual alloantigens in order to compare findings in humans to those in this research. 
Perhaps the most unexpected finding of this work, described in Chapter 5, was that MHC class 
I specific indirect-pathway CD4 T cells can provide help for the generation of late MHC class II 
alloantibody, a time when MHC class II indirect-pathway specific CD4 T cells could not – 
apparently contravening the central tenet of ‘linked’ help97. This phenomenon of ‘un-linked’ 
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help is likely restricted to the unique circumstances of transplantation, since in a conventional 
antigenic challenge such as an infection, internalised adjacent membrane bound antigens of 
infected cells, including MHC molecules, will be of self-origin to which the host will be tolerant. 
Previous work from our laboratory describing the concept of ‘un-linked’ help in transplantation 
whereby a B cell acquires neighbouring membrane bound alloantigen whilst internalising its 
target epitope provides a possible explanation382. However, as discussed in Chapter 5 this 
would suggest that an MHC class II specific B cell will continue to present MHC class I long after 
expression of its target epitope by the allograft has ceased. This is an aspect that requires 
further work to elucidate the mechanisms involved. One approach being considered is the 
creation of mice that express green fluorescent protein (GFP) linked to MHC class I protein. 
Hence B cells that acquire MHC class I alloantigen could be identified on the basis of GFP 
expression. This strain could then be utilised to definitively confirm the ability of B cells to 
acquire accessory alloantigens and potentially to examine the sequestration and processing 
pathways utilised for the accessory alloantigens that may help explain the observations in this 
thesis. 
MHC class II tetramers have been invaluable to permitting comprehensive evaluation of the 
endogenous CD4 T cell indirect-pathway alloresponse and have provided a novel insight into 
the impact of chronic antigen exposure on memory development. The findings in this thesis 
reassuringly mirror observations following challenges with infection - the finding that antigen-
specific CD4 T cell memory declines following antigen clearance has also been seen in previous 
studies of chronic infection. A report from Marc Jenkins laboratory observed a profile of 
antigen-specific CD4 T cell population dynamics following acute (Listeria monocytogenes) and 
chronic (Salmonella species) infections concordant with those observed targeted against 
cleared and persisting alloantigen406. Together, these findings suggest that maintenance of 
memory CD4 T cells requires ongoing TCR stimulation – in stark contrast to the case identified 
in CD8 T cells where antigen persistence is associated with exhaustion430, 431. 
Future work with MHC class II tetramers aims to further explore the phenotype of indirect-
pathway CD4 T cells, examining T helper subset differentiation and specifically examining T 
follicular helper cell differentiation. Furthermore, as alluded to in Chapter 6, equally important 
findings are expected to be obtained utilising tetramers to examine B cell alloresponses, 
quantifying antigen specific B cell populations that develop following transplantation and how 
they relate to the indirect-pathway CD4 T cell responses providing their help. 
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4) Generating indirect-pathway regulatory T cells specific for parenchymal expressed 
alloantigen appears to be the most effective strategy to ameliorating chronic rejection. 
 
The clinical significance of understanding intricacies of the pathways of allorecognition is most 
apparent when considering the findings in Chapter 7. Regulatory cellular immunotherapies are 
being widely studied with clinical translation of Treg on the horizon, however there are many 
unanswered questions, such as which type of Treg product is most effective, how many Tregs 
to transfer and how often215. It is now appreciated that ‘antigen-specific’ Treg are more 
effective than polyclonal Treg, and that direct-pathway Treg generally perform inferiorly to 
indirect-pathway Treg48. Work in this thesis provides insight into why this may be and 
highlights that antigen specificity must relate to epitopes being presented in an immunogenic 
fashion at the time of Treg administration. Whilst this may have limited bearing on the 
specificities of Treg administered at the time of transplantation, it is of importance when Treg 
are administered later – as will likely be the case for cadaveric organ transplant recipients 
where donors are not known until only hours before the transplant providing insufficient time 
to generate a Treg product. The role regulatory cellular immunotherapies will have in 
transplantation is yet to be defined, but it is conceivable that they may be utilised as a rescue 
therapy to treat episodes of rejection. In this setting, results in Chapter 7 would suggest that 
the most effective Treg product may be generated by first establishing the specificity of the 
on-going alloimmune response in that recipient – something that may become easier with the 
recent development of HLA monomers as a technology to examine indirect-pathway CD4 T cell 
specificity in transplant recipients391. 
Regulatory T cell therapy is not only relevant to transplantation and there may be wider 
relevance of these findings. There is now a body of work examining the potential of Treg to 
treat autoimmune diseases, in which adaptive immune responses are directed against self-
antigens. It is worth highlighting that lack of functional FOXP3 expression results in severe 
autoimmune phenotypes (scurfy in mice and ‘immune dysregulation, polyendocrinopathy, 
eneteropathy X-linked’ in humans)216. In keeping with this, several reports have observed 
reduced numbers of Treg in patients with various autoimmune diseases and that the degree of 
deficit was associated with disease activity491. Furthermore, in a murine model of collagen-
induced arthritis deletion of Treg, with administration of a depleting anti-CD25 mAb, 
significantly augmented and accelerated the onset of disease492. In addition to a reduced 
frequency of Treg, it has also been reported that autoimmune disease can alter the functional 
activity of Tregs. Tregs isolated from active rheumatoid arthritis (RA) patient’s demonstrated 
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significantly impaired suppressive activity than disease-free controls493. It may similarly be the 
case that with ongoing inflammatory alloimmune responses, Treg in transplant recipients 
demonstrate impaired regulatory function.  
A result of these observations is a move to utilising Treg therapy against autoimmune disease. 
Work in this thesis, and the transplantation literature, has highlighted the greater efficacy of 
antigen-specific Treg. Similar findings have also been observed in autoimmunity. Whilst 
polyclonal Treg were able to prevent the onset of diabetes in NOD mice, they were unable to 
alter the progression of disease once established494-497. Similar findings have been observed in 
models of autoimmune gastritis498, collagen induced arthritis492, 499 and multiple sclerosis500. In 
these reports, TCR transgenic iTreg have been generated in vitro and demonstrated 
significantly greater efficacy than polyclonal nTreg501. 
In this thesis (Chapter 7) it has been observed that the most effective iTreg were those specific 
for targets of on-going alloimmune responses. Unlike in transplantation where the HLA 
mismatch is known, identification of the target antigens in autoimmunity is not so 
straightforward. In RA for example, the autoantigens remain incompletely characterised502. 
Although several putative autoantigens have been identified by examination of patient serum 
– such as collagen type II and human chondrocyte glycoprotein 39, there is little evidence 
implicating most of them in the disease pathogenesis503. Furthermore, a feature of chronic 
immune responses is epitope diversification – both inter and intra-molecular, potentially 
complicating identification further since the dominant determinant driving the autoimmune 
response may change over the course of the disease132, 319, 504. One proposal to aid the 
generation of antigen-specific Treg in autoimmunity has been to isolate nTreg from patients 
with autoimmune disease and expand these in vitro with the aim of addressing the imbalance 
between effector and regulatory cells that has been described491. This may be problematic 
though due to the impaired function of nTreg in autoimmune disease that has been 
reported493.  
In the final chapter it was demonstrated that allograft rejection in the bm12.Kd.IE to C57BL/6 
model can be abrogated by iTreg specific for single alloantigens expressed by the allograft, 
despite expression of additional alloantigens, suggesting that linked-suppression occurs. This 
raises the possibility that iTreg targeted against one tissue-specific autoantigen may be 
effective at attenuating disease progression even if it is not the main target of the autoimmune 
response – therefore avoiding the need to define the precise specificity of pathogenic 
autoreactive T cells in each patient. In support of this, a study revealed that generating iTreg 
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specific to an antigen expressed in synovial joints, in a model of autoimmune arthritis, 
significantly attenuated disease progression even though the model was engineered such that 
pathogenic T cells were targeted against a different antigen505. This may be due to Treg 
accumulation in the target organ permitting the linked-suppression of pathogenic T cells 
irrespective of their antigen specificity. 
Several outstanding questions must be answered before Treg immunotherapy becomes a 
clinical reality in both transplantation and autoimmunity. There remains the real concern that 
antigen-specific iTreg may revert to an effector phenotype following transfer into a pro-
inflammatory environment and exacerbate the disease they are designed to prevent. Much 
work is underway attempting to define the optimal in vitro culture conditions and attempting 
to identify markers of Treg phenotype stability – such as methylation status of the ‘Treg 
specific demethylated region’472. Furthermore, the effective human ‘dose’ of Treg is not yet 
appreciated. There may be many problems with simply extrapolating from murine studies due 
to differences between murine and human immune systems254. Nevertheless, significant in 
vitro expansion will be required with the inherent concern that Treg phenotype may be altered 
during this process. Additionally, whilst single administrations of Treg are often effective in 
murine models, it is not clear that this is necessarily the case in human patients. These 
questions are the focus of much on-going research throughout the world that will be 
informative to the development of regulatory immunotherapy in both transplantation and 
autoimmunity.  
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